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Extracellular vesicles (EVs) are small, membrane delimited particles which are released from 
cells of all types and disease status. When EVs were first discovered they were thought to be 
a mechanism to remove waste from cells, but it has since been shown that EVs are important 
intercellular messengers. EVs contain biomolecules such as proteins and nucleic acids, 
including mRNA and miRNA, which reflect the status of the parental cell. EVs can be found in 
almost every bodily fluid, including blood, urine, saliva, and ascites. They are released into 
the extracellular milieu where they can be endocytosed by neighbouring cells. As EVs are 
enclosed with a lipid membrane their cargo is protected from degradation in circulation, so 
they can also travel to distal parts of the body and retain activity. Because of this EVs have 
been implicated in the pathogenesis of many diseases by transferral of biomolecules from 
diseased cells to healthy cells, for example transfer of oncogenes to induce oncogenic 
transformation in healthy cells. EVs have the potential to be used as non-invasive disease 
biomarkers, if suitable detection and characterisation methods were available. 
Currently, the gold standard method of EV isolation is a process of differential centrifugation 
followed by ultracentrifugation. There is no current gold standard method of EV 
characterisation. Quantification and size determination of EVs can be done by methods such 
as nanoparticle tracking analysis (NTA), tunable resistive pulse sensing (TRPS), or dynamic 
light scattering (DLS). Size and morphology can be analysed by electron microscopy. Flow 
cytometry, invaluable for cell phenotyping, cannot be used on EVs because their small 
diameter does not sufficiently scatter the laser light in order to be detected. Protein analysis 
can be done by Western blot; however, this is a bulk technique and cannot distinguish rare 
subpopulations. Similarly, proteomic studies have been carried out on EV populations, but 
this is also a bulk technique and requires a large, highly purified sample and the results are 
not inherently quantitative. New methods of EV characterisation are required which are 
sensitive, high-throughput, and can analyse individual EVs. 
In this work, EVs were isolated from Burkitt lymphoma (BL) cells, a type of high-grade non-
Hodgkin lymphoma. In vivo these tumours have a high rate of constitutive apoptosis, which 
promotes the accumulation and activation of tumour associated macrophages (TAMs). TAMs 
have been shown to have pro-tumour phenotype, including the promoting tumour cell 
growth and angiogenesis, and may even play a role in metastasis due to their ability to 
remodel the extracellular matrix. It could be that the EVs released from the apoptotic tumour 
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cells (apoEVs) are impacting the microenvironment to promote the growth of the tumour. 
To determine if this could be the case, apoEVs and EVs derived from viable cancer cells were 
analysed to determine if there are any distinguishable biochemical differences between 
these EV groups which may imply a functional difference. 
Raman spectroscopy was used to characterise both apoEVs and EVs released from viable 
tumour cells. This is a vibrational spectroscopy technique which can produce a molecular 
fingerprint of the analyte. By comparing the spectra of EVs and apoEVs using principal 
component analysis (PCA), a difference could be seen between the apoEVs and EVs. 
Differences could also be seen between EVs derived from cells of different lineages (HeLa 
cervical epithelial cells and BL cells). This implies that EVs derived from different sources have 
different chemical constituents, and Raman spectroscopy could be a useful tool for 
characterising and distinguishing different types of EVs. 
A more targeted approach of detecting EVs would be to use surface enhanced Raman 
spectroscopy (SERS). Incubating EVs with gold nanoparticles functionalised with Raman 
reporter molecules and antibodies would allow for sensitive detection of EV subpopulations. 
In order to identify target proteins for SERS analysis, a non-biased bioinformatic approach 
was carried out. First, gene expression profile data were obtained from the online repository 
gene expression omnibus (GEO). Gene expression levels in B cell samples were compared to 
levels in lymphoma samples. Genes with a higher expression in lymphoma samples were 
identified, with the view that these would preferentially identify lymphoma EVs in a blood 
sample, which would contain a mixed population of EVs deriving from both lymphoma and 
healthy B cells, as well as epithelial cells and other sources. The proteins identified by this 
analysis did not appear to be transferred onto the EV surface. Proteomics had been carried 
out on the BL apoEVs and viable BL cell EVs, so the results from this analysis were used to 
identify membrane proteins which were common to both EV subgroups, and proteins which 
were only found on the apoEVs in order to selectively detect this population. The pan-B cell 
marker CD20 was identified in both populations, while the lymphocyte receptor CD53 was 
found only on the apoEVs, so these proteins were used as targets for detection with SERS. 
A nitrocellulose membrane was used to non-specifically capture EVs by hydrophobic 
interactions with proteins. A pilot study with BL cells showed that SERS signal of anti-CD20 
functionalised gold nanoparticles increased with an increasing number of cells captured, with 
low levels of non-specific binding. However, when the assay was repeated with apoEVs and 
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EVs, the signals obtained from both anti-CD20 functionalised nanoparticles and anti-CD53 
functionalised nanoparticles were at a similar level or lower than the signal obtained from 
the EV-free controls. Western blots of the EV populations showed that there was no 
detectable CD20 or CD53 in either population, despite showing up in the proteomic analysis. 
This work shows that Raman spectroscopy can be used to differentiate between EVs of 
different types. SERS also has great potential in detecting EV sub-populations, however the 
target proteins chosen for this study were not present on the surface of the EV. Other 
markers could be used as targets for EV detection by SERS, such as proteins identified by 
proteomics which have been experimentally validated to be present on the EV surface, or 





Extracellular vesicles are small particles which can be released from all cell types throughout 
the body. They are many times smaller than the cells from which they come, which makes 
them extremely difficult to study. However, in the past few decades research has shown that 
these tiny cell fragments can have some profound effects. They can carry messages all around 
the body and are found in every bodily fluid, from blood, to saliva, to tears, and even milk. 
These tiny messengers are often found to play a role in diseases. In particular, cancer cells 
release a lot of these particles, which can be taken up by nearby healthy cells to transform 
them into cancer cells, or travel to distant parts of the body to sow the seeds for cancer to 
spread. 
In many types of cancer, a lot of cells dying within the tumour can actually release messages 
the cause the tumour to grow faster. These messages may be packaged up into the 
extracellular vesicles, as dying cells release many of these particles. 
In my work, I have been studying the particles released from dying cancer cells to see 
whether they contain different messages to the particles from cancer cells which are not 
dying. To do this, I have used lasers to cause the atoms in the extracellular vesicles to vibrate. 
The vibrations of the atoms can change the colour of the light being shone on them, and the 
colour of the light emitted can indicate the type of atoms that are present. Using tiny particles 
of gold can make the light emitted brighter and easier for the instruments to see. This method 
has shown that the extracellular vesicles being released from dying cancer cells do appear to 
be different to the particles being released from cancer cells which are not dying. Finding out 
exactly what these vesicles have inside them could indicate why these dying cancer cells are 
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1.1 Non-Hodgkin’s Lymphoma 
Lymphoma is a cancer occurring in the lymph system. There are two main types of 
lymphoma: Hodgkin’s lymphoma which makes up 10% of lymphoma cases, and non-
Hodgkin’s lymphoma (NHL) which accounts for the remaining 90% of cases. NHL has many 
different subclassifications, but taken together NHL is the fifth most commonly occurring 
cancer in the UK.1 However, the survival rates for NHL have greatly increased since the 1970s 
with the development of new treatment methods. 
The diagnosis of lymphoma is carried out by obtaining a tissue biopsy from the tumour, with 
analysis by both flow cytometry and immunohistochemistry on formalin-fixed paraffin-
embedded tissue sections. Each NHL subtype has a specific set of markers used to identify it 
defined by WHO guidelines,2 and some of these are outlined in Table 1.1. 
Table 1.1: Diagnostic classifications of non-Hodgkin’s lymphoma subtypes, according to 
WHO guidelines 
Lymphoma type Immunophenotype 
Follicular lymphoma CD19+, CD20+, IgM ± IgD, CD10+, Bcl-6+, Bcl-2±, 
Diffuse large B cell lymphoma CD19+, CD20+, Bcl-2±, Myc+ 
Burkitt’s lymphoma CD19+, CD20+, CD10+, Bcl-6+, Bcl-2-, CD5-, Myc+, 
Ki67>95%, (monotypic sIg+, MUM1-) 
 
NHL can be fast-growing and aggressive, such as diffuse large B cell lymphoma (DLBCL), or a 
slow-growing indolent form such as follicular lymphoma (FL). 
1.1.1 Burkitt’s lymphoma 
Burkitt’s lymphoma (BL) was first reported as an aggressive sarcoma of the jaw observed in 
children in Uganda.3 Along with the facial tumours, patients presented with tumours in the 
kidneys, liver, the thyroid, testis, heart, stomach, pancreas, salivary gland, cranium, and 
femur, with no tumours observed in  the liver or spleen3,4 and only minor involvement of the 
lymph nodes.5 This lymphoma was the dominant form of childhood cancer in Uganda, 
accounting for 50% of cases compared to 6-10% of childhood cancer cases in other parts of 
the world.4 However, incidence elsewhere did not occur with the jaw infiltration, only the 
abdominal tumours.5 The high incidence of this lymphoma in certain geographic locations 
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implied an environmental factor. A herpes virus was found to be present in these BL cases, 
called the Epstein-Barr virus (EBV),6 which was found to transfer to peripheral blood 
lymphocytes and promoted the growth of these cells.7 High levels of antibody against EBV 
were found in both African and American patients.8 The cases found predominantly in 
children in subequatorial Africa with presentation in the jaw, as described by Burkitt, are 
almost always EBV-positive and are known as endemic BL. Cases in the rest of the world 
rarely display EBV involvement and are called sporadic BL, and cases may also be associated 
with immunodeficiency or immunosuppression.9  
Although only 5% of adult cases of NHL are BL, this is the most common form of lymphoma 
in children, accounting for 40% of childhood NHL.10 BL is also the most aggressive form of 
lymphoma, displaying high rates of both proliferation and cell death which in turn promotes 
the accumulation and proliferation of macrophages, giving the tumours the characteristic 
‘starry-sky’ appearance in haematoxylin and eosin (H&E) stained tissue sections.3,5,11  
BL malignancies are derived from the highly proliferative germinal centre (GC) B cells and are 
positive for the GC markers CD10 and CD77.12 BL is BCL-6+ but negative for BCL-2 (B cell 
lymphoma 2). However, analysis of BCL-6 for the diagnosis of BL does not improve 
classification above using CD10. The characteristic genetic mutation in BL is the 
t(8;14)(q24;q32) translocation of c-MYC from its locus on chromosome 8 to the 
immunoglobulin heavy chain in chromosome 14.13–15 Translocations of t(8;22) and t(2;8) 
were also observed, corresponding to translocations with the κ- and λ-immunoglobulin light 
chain loci.14 MYC is a transcription factor which can promote transition from the G0 to S phase 
of proliferation by controlling pathways such as protein synthesis, DNA replication, and 
metabolism. High grade lymphomas such as BL showed c-MYC translocations from 
chromosome 8, whereas indolent lymphoma showed translocations of BCL-2 from 
chromosome 18.15 This translocation of MYC is not an oncogenic event in itself, although cells 
appeared to remain proliferative rather than differentiating. Transgenic mice engineered 
with this mutation formed monoclonal tumours only after a latency period of 5 months, 
indicating other oncogenic factors are required in addition to the Myc translocation.16 Many 
cases of BL are described as ‘MYC-simple’, where there are no BCL2 translocations or 
breakpoints in the BCL6 gene occurring alongside the IGH-MYC translocation.17 The ‘MYC-
simple’ genetic status is associated with favourable outcome for patients. 
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Treatment of BL involves high-intensity chemotherapy. The lymphoma malignancy B 
treatment protocol involves systemic high-dose methotrexate and high-dose cytarabine and 
has shown high survival rates (>90%) in children. A modified version in adults resulted in a 
mean 2-year survival of 70%, with 65% rate of 2-year event-free survival.10 Treatment is also 
successful using cyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) 
combined with methotrexate.18 
Distinguishing between BL and DLBCL can be difficult, as DLBCL can also carry c-MYC 
translocation. Although only 5-10% of DLBCL cases have this translocation, the higher 
incidence of DLBCL means that this characteristic alone cannot identify a case of BL. 
Determining the correct diagnosis is important, as the course of treatment for BL and DLBCL 
is different, however only 53% of hematopathologists reach an agreement on the 
pathological diagnosis of BL, Burkitt’s-like lymphoma (which has some morphological 
features of BL and some features resembling DLBCL), and DLBCL.19 Gene expression analysis 
has been used to identify a molecular signature of BL, and many of these cases had been 
incorrectly diagnosed by pathologists as atypical BL or DLBCL based on morphological 
features. The signature includes many c-Myc target genes and genes associated with GC B 
cells.17,20 Mutations in either TCF3, a transcription factor which is involved in regulation of 
genes associated with normal B cell development, and ID3 a negative regulator of TCF3, have 
been found in many cases of BL.21,22 Inactivating mutations of ID3, resulting in the 
upregulation of genes promoting transition from G1 to S phase of proliferation and higher 
expression of MYC target genes, were more common than mutations in TCF3, indicating a 
potential tumour suppressor function for this gene. 
1.1.2 Follicular lymphoma 
20% of cases of NHL are follicular lymphoma (FL), found predominantly in women with a 
median age of 60 years old. The disease typically presents as a slow progressing 
lymphadenopathy. There is some variability, with some patients undergoing transformation 
to a high-grade disease. 37% of patients with FL show disease transformation to DLBCL 
histologically within 15 years.23 Although the median survival is 9 years, only 25% of patients 
remain disease free during this period, the rest experience several incidences of relapse and 
remission, whether the treatment approach is intensive or conservative.24 Advanced FL 
appears relatively incurable, although the indolent nature means that many patients survive 
for long periods despite the incomplete treatment response. The median survival after first 
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round of treatment is 4.5 years, with the response rate and duration of remission decreasing 
with each subsequent round of treatment. There was a 48% response rate to the fourth 
round of treatment, showing the value of repeated, non-toxic therapy.24 
The addition of the anti-CD20 antibody Rituximab to CHOP (R-CHOP), which is the standard 
treatment for difficult cases of FL, of showed an increase in the duration of remission.25 The 
prognostic value of some biological markers may depend on the course of treatment, with 
the addition of rituximab overcoming the effects of some markers which had previously been 
poor prognostic indicators.26 
FL phenotype is similar to a germinal centre B cell, with positive expression of BCL6, CD10, 
LMO2, and HGAL. Clonal and subclonal analysis showed that BCL2 translocation to the IGH 
locus, t(14;18)(q32;21), was the primary event observed in 60% of FL cases.27 However, the 
frequency of BCL2 translocations decreases with increasing disease stage. Mutation of 
histone methyltransferases was also observed, with mutation of CREBBP observed in 32% of 
cases thought to be a disease-driving mutation and mutation of MLL2 in 89% an accelerator 
mutation. 
Mutations in genes which play a role in transcriptional regulation and somatic mutations 
have been found to be enriched in NHL. A study of germinal centre B cell lymphomas (FL, BL, 
and GCB-DLBCL) showed gain-of-function mutations in the histone methyltransferase gene 
EZH2, which leads to enhanced methylation of histone H3, in 22% of FL samples.28 Another 
gene encoding a histone methyltransferase, MLL2, was found to be frequently mutated with 
loss-of-function modifications indicating that this gene acts as a tumour suppressor. 
Mutation were observed in 89% of FL samples, the same frequency as the t(14;18)(q32;q21) 
BCL2 translocation, as well as 32% of DLBCL samples.29 
1.1.3 Diffuse large B cell lymphoma 
Diffuse large B cell lymphoma (DLBCL) is the most common NHL, accounting for 30-40% of 
NHL cases. Tumours are mainly found in lymph nodes; however, they can occur anywhere in 
the body and are also commonly observed in the GI tract and skin.  
WHO classification has delineated DLBCL into a number of different subtypes, the two main 
subtypes defined by the ‘cell-of-origin’ immunophenotype. The germinal centre B cell type, 
GCB, retains the profile of GC B cells such as CD10, CD38, and BCL-6 and commonly has BCL2 
and MYC translocations, while the other type shows expression of genes associated with 
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activated B cells (ABC) and is observed more often with translocations of BCL6 and expression 
of MUM1 and BCL-2.30,31 These subtypes have different clinical responses, as the ABC type 
has been shown to have a poorer outcome than GCB type following R-CHOP therapy.30–33 
High levels of MYC translocation and expression levels in GCB DLBCL have also been 
associated with poor prognosis,34 particularly with co-expression of BCL2.35 The MYC/BCL-2 
co-expressed cases had poorer progression-free survival (32%) and 5-year survival (36%) 
compared to those without co-expression (65% and 71%, respectively).36 
Genes such as EZH2, SGK1, BCL2, CD79B, and MYD88 are often observed to have mutations 
in DLBCL.21,28 
1.2 Apoptosis 
Apoptosis is an immune silent form of programmed cell death. Although the term 
‘programmed cell death’ is often used interchangeably with apoptosis, there are other forms 
of programmed cell death such as autophagy, pyroptosis, and necroptosis.  
1.2.1 Hallmarks of apoptosis 
A number of morphological changes are evident in cells undergoing apoptosis, as described 
by Kerr et al.37 Both the nucleus and the cell shrink in size, followed by fragmentation of the 
nucleus, membrane blebbing, finishing with the formation of apoptotic bodies. Many of 
these apoptotic bodies were seen in the cytoplasm of surrounding healthy cells, indicating 
that they are rapidly engulfed with no inflammation.37 
Degradation of the nucleus was observed to yield double stranded fragments which were 
multiples of 180 bp, indicating that these fragments occur due to internucleosomal cleavage 
by an endonuclease.38–40  
Apoptosis also causes the activation of ROCK I, a serine/threonine kinase which regulates Rho 
GTPases. This activation results in stabilisation of actin filaments and coupling of actin-myosin 
filaments to the plasma membrane, causing the characteristic morphology of membrane 
blebbing seen in apoptotic cells.41 
An early event in apoptosis is the loss of plasma membrane lipid asymmetry, exposing 
phosphatidylserine (PS) on the outer membrane surface. This is caused by apoptosis-induced 
inactivation of flippase enzymes ATP11C and CDC50A, which internalise aminophospholipid 
molecules to the internal membrane leaflet,42,43 and activation of scramblase enzyme Xkr8, 
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which can translocate both aminophospholipids and neutral moieties such as 
phosphatidylcholine (PC).44 This provides a means of apoptotic cell detection. Annexin V 
(AxV) is a protein which shows preferential binding to PS over other membrane lipids, in a 
Ca2+-dependent manner.45 By labelling AxV with a fluorescent molecules such as FITC, a flow 
cytometric assay to detect apoptotic cells was developed.46 Addition of propidium iodide, a 
membrane-impermeable dye which binds to DNA, can indicate whether the plasma 
membrane integrity has been lost.46 Apoptosis in tissue sections can be studied by the 
detection of DNA fragmentation. The 3’-OH DNA strand breaks can be labelled with 
biotinylated deoxyuridine using terminal deoxynucleotidyl transferase (TdT). The signal is 
then detected and amplified using avidin-peroxidase. This technique is called TdT-mediated 
dUTP-biotin nick end labeling (TUNEL).47 
1.2.2 Mechanisms of apoptosis 
There are broadly two different means by which cells are activated to undergo apoptosis. 
Both of these pathways involve cysteine aspartyl proteases known as caspases. There are 12 
members of the caspase protein family found in humans, each with different substrate 
specificity and functions, many of which are involved in apoptosis. Initiator caspases, such as 
caspase-8 and caspase-9, function to activate effector caspases, whereas effector caspases 
such as caspase-3 and caspase-7 cleave vital cell proteins in order to bring about the 
morphological changes observed in apoptosis. Caspases are proenzymes which are activated 
by cleavage of a prodomain from the N-terminus to form the active enzyme. Both pathways 
ultimately result in the activation of effector caspase-3 causing the morphological changes 
as described above. 
1.2.2.1 Intrinsic pathway 
The intrinsic apoptosis pathway is initiated by an internal stressor signal such as DNA damage, 
lack of growth factor, or infection. This pathway is regulated by the BCL-2 family of proteins. 
These proteins share BCL-2 homology (BH) domains BH1, BH2, or BH3 and can interact with 
each other via the BH3 domain. BCL2 was first identified in B cell lymphoma, translocated to 
the immunoglobulin heavy chain locus. It was shown to have a protective effect against 
apoptosis in IL-3 dependent myeloid cells which had been deprived of the growth factor.48 
The suppression of apoptosis was shown to be due to blockage of release of cytochrome c 
from the mitochondria.49–51 
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BCL-2 and BCL-XL pro-survival proteins are found primarily on the outer mitochondrial 
membrane, with some found on the perinuclear membrane.52,53 Other members of the BCL-
2 proteins, including BAX, BAK, and the BH3-only proteins such as BID, BIM, and BAD, are 
pro-apoptotic. The structures of these proteins are similar to pore-forming proteins found in 
bacteria,54 indicating the interaction they may have with the mitochondria during apoptosis. 
An apoptotic stimulus causes activation of the pro-apoptotic BAX and BAK, causing BAX to 
oligomerise and form a pore in the mitochondrial membrane. This pore causes the release of 
cytochrome c from the mitochondria. These pro-apoptotic proteins may exist as dimers with 
the anti-apoptotic proteins in viable cells. BAD displays preferential binding to BCL-XL and 
BCL-2, thereby displacing BAX from the BCL-XL/BCL-2 dimer to form mitochondrial membrane 
pores and release cytochrome c.55 The release of cytochrome c from the mitochondria during 
apoptosis occurs before depolarisation of mitochondria,49,50,53 and mitochondrial 
depolarisation itself does not cause cytochrome c release.53 
The cytochrome c released from the mitochondria binds to APAF-1 in the presence of dATP, 
which undergoes a conformational change allowing formation of a heptamer.56 The APAF-1 
heptamer can then recruit pro-caspase 9, which oligomerises and is activated, forming the 
apoptosome. Cytochrome c does not remain associated with the apoptosome, but caspase-
3 is tethered to the apoptosome.57 The apoptosome can then cause activation of the 
executioner caspases, such as caspase-3 and caspase-7. Caspase-3 cleaves proteins such as 
flippases ATP11A and ATP11C, which inactivates them,43,45 and also activates a scramblase 
Xkr8,44 causing loss of plasma membrane lipid asymmetry and the exposure of PS on the 
outer membrane leaflet. The endonuclease responsible for internucleosomal cleavage, 
caspase-activated deoxyribonuclease (CAD), is released from its inhibitor protein ICAD by 
caspase-3 activity,58 and cleavage of ROCK I increases the activity of this protein causing 
membrane blebbing.41 
1.2.2.2 Extrinsic pathway 
The extrinsic apoptosis pathway is a receptor mediated pathway governed by the tumour 
necrosis factor (TNF) family of proteins. Transmembrane receptors such as FAS and TNFR1 
contain death domains on the cytoplasmic region. The corresponding ligands for these 
receptors, death factors such as FASL, TNF-α, and TRAIL, are homotrimeric membrane 
proteins. The binding of FASL to FAS causes oligomerisation of the receptor which induces a 
conformational change in the Fas death domain, which can then bind FAS-associated death 
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domain (FADD) which recruits procaspase-8, forming a complex known as DISC (death-
inducing signal complex), which then activates caspase-8 by auto-catalysis.59,60 Activated 
caspase-8 acts in the same way as caspase-9, as an initiator caspase in order to activate 
caspase-3 which results in the biochemical and morphologic features of apoptosis. 
Death factor proteins can be cleaved by metalloproteinase enzymes to release a soluble form 
of the ligand. While Fas is expressed in many cell types, FasL is mainly expressed in activated 
T cells and NK cells. The membrane-bound form of FasL is the active form and does not enter 
the cell to activate apoptosis, remaining bound to Fas at the membrane.61 However, soluble 
FasL is actually protective against FasL-induced apoptosis,61–63 possibly because soluble FasL 
binding to Fas causes internalisation and subsequent degradation of Fas receptor. Rapid 
degradation of Fas limits the amount of procaspase-8 which can be activated by DISC, while 
membrane-bound FasL binding to Fas retains Fas at the membrane and prolongs the DISC 
activity to release active caspase 8. 
1.2.3 Apoptotic cell clearance 
Apoptotic cells are rapidly cleared by phagocytes in a process known as efferocytosis. If cells 
are not cleared efficiently secondary necrosis occurs, where the integrity of the plasma 
membrane is lost, releasing danger associated molecular patterns and inducing an immune 
response. In order for phagocytes such as macrophages to efficiently clear apoptotic cells, 
they must be able to recognise which cells are apoptotic.  
Apoptotic cells can release signals which recruit phagocytes to the site of apoptosis. These 
molecules include CXCL1,64 lysophosphatidylcholine,65 and sphingosine-1-phosphate,66 and 
nucleotides.67 The exposure of PS early in the process of apoptosis acts as an ‘eat-me’ signal 
to identify cells for efferocytosis.68 Annexin I has also been shown to act as ‘eat-me’ signal 
after caspase-mediated recruitment from the cytosol to the outer leaflet of the plasma 
membrane.69 Calreticulin has also been identified as an ‘eat-me’ signal.70 
Different types of macrophages display surface receptors for different ‘eat-me’ signals, 
however PS is recognised by all types of macrophages.71 Milk fat globule-EGF-factor 8 (MFG-
E8) is a secreted glycoprotein which acts as a bridging molecule between the phagocyte 
receptor and the apoptotic cell. The factor 8-homologous domains recognise and bind PS, 
while the EGF domain contains an RGD motif to bind αvβ3 integrin on phagocytes.72 Other 
bridging molecules include Protein S (PROS)73 and GAS6,74 which display Ca2+-dependent 
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binding to PS and Tyro 3/Axl/MERTK receptor kinases on macrophages.75,76 Recognition of 
apoptotic cells by these receptors is followed by the release of anti-inflammatory factors like 
TGF-β, IL-10, and PGE2, and decrease in production of IL-6 and TNF-α pro-inflammatory 
cytokines.77–79 Once the apoptotic cells have been recognised and bound to the phagocyte, 
the cells are engulfed by the phagocytes via the formation of phagosomes, which are 
transported to lysosomes to degrade the engulfed material.80,81  
1.2.4 Oncoregenerative niche 
The balance between cell proliferation and cell death is important. 10x109 cells undergo 
apoptosis every day in the body,82 in tight homeostatic balance with cell generation from 
stem cells. In cancer, this balance is tipped so that cell proliferation exceeds cell death, 
forming neoplasms. This occurs by mutations in the cancer cells resisting cell death, 
experiencing sustained proliferative signalling, evading growth suppressors, and cell 
immortality.83 However, many types of aggressive tumours display high rates of spontaneous 
cell death within the tumour which is an indicator of poor prognosis.  
It is known that, in order to maintain homeostatic balance, cells undergoing apoptosis can 
induce replication of surrounding cells, termed compensatory proliferation.84,85 This process 
appears to be hijacked in some types of cancer, where apoptotic tumour cells induce 
proliferation of the surrounding cells. After exposure to radiotherapy, tumour cells in vitro 
have been observed to undergo a rapid repopulation, reaching pre-treatment levels after 2 
days.86 Co-injection of lethally irradiated cancer cells with untreated cells showed a higher 
rate of tumour growth in a xenograft model than injection of untreated cells alone, and this 
has been shown for glioblastoma,87 breast cancer,88 melanoma,89 and stromal cells such as 
fibroblasts88 and endothelial cells.90 When caspase-3 is inhibited in these cells, the effect is 
abrogated.88 The presence of active caspase-3 in tumours has been shown to be an indicator 




Figure 1.1: Apoptosis in BL, showing the typical starry sky morphology in the BL2 H&E section 
which is lost upon transfection with Bcl-2 in the BL2-Bcl-2 stained section. The apoptotic BL2 
tumours also display positive staining for CD68 macrophage marker and TUNEL, indicating 
apoptosis, which is reduced in the BL2-Bcl-2 sections. Reproduced from C. A. Ford et al., Curr. 
Biol., 2015, 25, 577–588. 
BL tumours have reasonably high rates of spontaneous apoptosis which causes the activation 
and accumulation of tumour-associated macrophages (TAMs). When BL cells transfected 
with BCL2 were injected into mice, tumour growth was suppressed and the tumours which 
did result had reduced proliferation and TAM recruitment compared with tumours from BL 
cells not transfected with BCL2 (Figure 1.1).89 Gene expression analysis of TAMs isolated from 
BL tumour sections by laser capture microdissection showed an anti-inflammatory signature, 
with pro-angiogenic and tissue remodelling genes such as those encoding MMP2, MMP3, 
MMP12, CD13, galectin-3, and GPNMB, and growth factors IGF-1 and PDGF-CC. Thus, 
apoptosis in aggressive lymphoma drives the accumulation of pro-tumour TAMs, which in 
turn promote tumour cell proliferation.89 The tissue repair mechanism has been termed the 
‘onco-regenerative niche’.92 High levels of TAMs have also been correlated with poor 
prognosis in follicular lymphoma,93 breast cancer,94 prostate cancer,95 and glioma.96 As 
therapy-induced  apoptosis has also been show to promote TAM accumulation, this effect 
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must be studied in order for effective therapies to be developed to counteract the onco-
regenerative niche. 
1.3 Extracellular vesicles 
1.3.1 Definition and characteristics 
In 1946, Chargaff and West discovered that there was a clotting factor present in blood which 
could be removed at high speed centrifugation (31,000 g) but not removed in low speed 
centrifugation (5000 g), and suggested that it may be associated with fragments of red blood 
cells.97 Further study of these ‘membrane fragments’ by electron microscopy revealed a 
vesicular morphology with a triple membrane layer containing cytoplasm.98 These vesicles 
were shown to transfer plasma membrane proteins off the cell surface, such as the 
transferrin receptor which is shed from reticulocytes during maturation.99 Using gold 
nanoparticles (AuNPs) to track the loss of the receptor, it was observed that direct budding 
of the plasma membrane was not the mechanism of release. The membrane receptor was 
internalised, first to the limiting membrane of multivesicular bodies (MVB), followed by 
formation of small vesicles within the MVB of average size 30-50 nm by internal budding of 
the MVB membrane, with the receptor on the external surface.100 These small vesicles were 
released from the cells by fusion of the MVB membrane with the plasma membrane, and 
were termed ‘exosomes’ (Figure 1.2).101 Exosome formation and release was shown to be an 
active process which was dependent on protein and RNA synthesis, and glycolysis.102 MHC 
class II-enriched compartments (MIICs) of antigen presenting cells, which have lysosomal 
characteristics such as LAMP1 and CD63, were shown to contain internal membrane 
structures, some of which release MHCII on exosomes which could act as antigen presenting 
molecules for T cells.103 This study was the first to show exocytosis of extracellular vesicles 




Figure 1.2: Biogenesis of EVs. Exosomes are formed via multivesicular bodies and released 
from the cell by exocytosis, microvesicles bud directly from the plasma membrane, and 
apoptotic bodies form as a result of apoptosis 
Although the field of EV research is well established, and it is generally accepted that there 
are at least 3 different types of EVs (exosomes, microvesicles, and apoptotic bodies; Figure 
1.2), there is still little consensus amongst researchers about important aspects such as 
nomenclature, categorisation, isolation techniques, and analysis. Exosomes, the smallest 
class of EVs, are defined by some researchers by the mode of biogenesis from endosomal 
compartments, others define exosomes as a secreted vesicle which “may serve a physiologic 
function”, and others defining exosomes as the EV fraction that sediments at 100,000 g. 
Similarly, microvesicles (MVs, also called membrane vesicles, membrane particles, 
microparticles, ectosomes, etc.) can be defined as EVs which bud from the plasma membrane 
(Figure 1.2), EVs which sediment at 10,000 g, or some use this as a general term for EVs. A 
panel at the first annual meeting of the International Society for Extracellular Vesicles (ISEV) 
was unable to come to a consensus with the attendees, and instead has implemented some 
guidelines as to the nomenclature, as well as isolation and characterisation techniques for 
EVs, which should be kept in mind.104 The generic term ‘extracellular vesicle’ is to be used to 
describe particles naturally released from the cell which are delimited by a lipid bilayer and 
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do not replicate. Assigning an EV to a particular subtype based on biogenesis should be 
avoided unless the EV is imaged while being released. Terms instead should be used which 
refer to the physical characteristics of the EVs (e.g. size with ranges, or density), biochemical 
composition (e.g. phenotype), or descriptions of the isolation conditions or parental cells.105 
1.3.2 EV separation methods 
Achieving a complete purification or isolation of EVs is unrealistic. The position of the ISEV, 
as set out in the minimal information for studies of extracellular vesicles 2018 
(MISEV2018),105 is that the appropriate terminology is separation of EVs from non-EV 
components, separation of EV subtypes, concentration of EVs by increasing the number of 
EVs per volume, or enrichment of EVs or EV markers relative to another metric. The most 
appropriate method of separation or concentration depends on the desired downstream 
study. Different techniques have different recovery/specificity e.g. high recovery, low 
specificity (precipitation); intermediate recovery, intermediate specificity (size exclusion 
chromatography (SEC), ultracentrifugation (UC) with intermediate speed/time), low 
recovery, high specificity (filtration combined with SEC, density flotation, immunoaffinity), or 
high recovery, high specificity (not currently achievable).  
As there is no standard method for EV separation, the major focus of the ISEV guidelines is 
on transparency of reporting. For this, EV-TRACK was developed as a repository for detailed 
experimental protocols of published EV studies.106 A checklist of 115 parameters, based on 
the MISEV recommendations, was established and used to develop EV-METRIC, a score of 
the methodology and reporting of 1226 EV publications. 30% of studies failed in all EV-
METRIC components, 81% of these studies could have improved their metric by more 
detailed reporting without any additional experiments, this highlighting the importance of 
transparency and reproducibility in the field.106 
A survey of EV researchers show that the most commonly used method for separation of EVs 
is differential centrifugation and UC, with more than half of respondents saying that they use 
a combination of different techniques for EV separation.107 Other commonly used methods 
include density gradient centrifugation, filtration, and SEC. 
The lack of specificity in the use of UC for the separation of EV subpopulations is highlighted 
in a study, where 2 distinct EV types are observed in the 100,000 g pellet from a mouse 
mammary carcinoma cell line.108 Treatment of the cells with shRNA to inhibit Rab27a, a small 
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GTPase involved in the trafficking and release of exosomes, showed an expected decrease in 
the levels of four typical exosome markers in the pellet: Cd63, Tsg101, Alix, and Hsc70. 
However, the levels of Cd9 and Mfge8 were not reduced, indicating a population of Cd9+ EVs 
which are not formed in the endosomal pathway. There was a slight separation of the 
Rab27a-dependent Cd9+ EVs from the Rab27a-independent EVs by density gradient 
centrifugation, highlighting the importance of multiple separation and analysis techniques.108 
Centrifuges can have either swinging bucket rotors or fixed angle rotors, which have different 
sedimentation path lengths, and have been shown to pellet different populations of EVs 
using typical conditions of 100,000 g for 70 minutes. Thus, the rotor type used for separation 
and the k-factor should be reported for transparency and reproducibility.109 The high 
sedimentation speeds may also damage the membrane structures of EVs.110 
Density gradient centrifugation can be used in order to separate contaminants from an EV 
preparation which would co-sediment under ultracentrifugation but have different density. 
EVs separated using density gradient centrifugation have shown to be enriched in EV-
associated proteins compared to EVs prepared by UC alone,111,112 indicating a higher purity 
of the density gradient centrifugation sample. Sucrose-density gradient UC has been used to 
confirm the membranous nature of EVs.103 However, the solution is hyperosmotic this can 
result in dehydration of the particles being isolated and slow sedimentation rates, as well as 
co-isolating particles with similar densities such as high density lipoproteins (HDL)113 or virus 
particles.114 Iodixanol has also been used as a reagent for establishing a velocity gradient, 
which has been shown to have better resolving power of EVs from viral particles.114 
SEC has been used to separate ‘membrane fragments’ since the early days of EV research.98,99 
SEC to separate EVs typically uses Sepharose CL-2B which has a pore size of 75 nm, thus EVs 
smaller than 70 nm are expected to elute from the SEC with the protein fraction while larger 
EVs elute in the void volume.115 This technique has been successful in the separation of EVs 
from lipoprotein contaminants in blood samples, with good recovery rates from 72% to 85% 
reported.113,115 SEC has also been done using a methacrylate gel column, with analysis of 
eluent by dynamic light scattering (DLS) using a flow through cuvette coupled directly to the 
HPLC.116 EVs have been separated by a commercially available SEC, qEV, to remove 




Immunoaffinity capture is a good method for the specific separation of subpopulation of EVs 
based on expected surface markers. This technique is useful when the volume is low. 
Although this method shows reduction in the concentration of EVs isolated, the purity of the 
preparation has been found to be higher than UC or density gradient separation of EVs.112  
1.3.3 EV analysis techniques 
MISEV2018 guidelines state that multiple complementary techniques should be employed 
for the analysis of EV preparations, including quantitative analysis based on particle number 
or concentration of protein or lipid in the EV sample, and qualitative analysis for the presence 
of EV-associated components as well as the absence or reduction of non-EV contaminant 
components.105 
1.3.3.1 Electron microscopy 
Electron microscopy (EM) has been used for the analysis of membrane structures for many 
years. Transmission electron microscopy (TEM) analysis can yield information on the size and 
the morphology of EVs simultaneously. TEM has shown that apoptotic bodies contain 
condensed chromatin structures.117 TEM showed 12% reduction in EV size due to sample 
preparation compared with other methods, with a recovery of 21% of EVs from the 
separation procedure.118  
As opposed to TEM, where drying of the sample causes collapse of the structure of EVs, cryo-
EM samples remain hydrated and retain their structure. This gives a more realistic picture of 
the morphology of the sample. However, the contrast of cryo-EM is reduced because of the 
lack of staining. In one cryo-EM study of plasma, most of the particles observed were 
identified as lipoprotein contaminants, seen as small, electron dense particles which did not 
have a lipid bilayer.119 
1.3.3.2 Atomic force microscopy 
Atomic force microscopy (AFM) is a method of imaging that analyses nanoscale structural 
features of a sample. A cantilever tip is passed over the sample by raster scanning. The tip is 
oscillated during the scanning such that the tip is only in direct contact with the sample when 
it is at the lowest height of the oscillation. The frequency or amplitude of the oscillation and 
contact with the sample changes the height of the cantilever, and this height adjustment is 
measured to generate an image of the surface topology. This ‘tapping mode’ AFM is useful 
for biological samples as it minimises the mechanical perturbation of the sample. Non-
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contact modes of AFM, such as amplitude modulated, where tip height is adjusted based on 
the amplitude of oscillation, or phase modulated, where the amplitude of oscillation is 
constant and the phase difference between oscillation and excitation is measured, have also 
been used for EV preparations.  
Substrates for AFM must be very flat, with roughness less than 0.5 nm. Muscovite mica is 
often used as a substrate for AFM, as it is easily cleaved to generate an atomically flat surface 
with a negative charge to form an electrostatic interaction with EVs. EVs tend to form 
flattened structures,120,121 or dome-like structures,120 when adsorbed onto the mica surface.  
To further stabilise the EV immobilisation, the substrate can be coated with antibodies 
specific for molecules expected to be on the EV surface. This also allows specific detection of 
EV subtypes, such as CD41-positive platelet-derived EVs.122 This study also examined the 
freeze-thaw effect on EVs, and although there was no difference in the size distribution of 
the EVs, there were fewer CD41-positive EVs in the samples which had been previously 
frozen. 
AFM can be carried out in air mode, where the sample has been dried onto the mica 
substrate, or in liquid mode. Air dried EVs can show an underestimation of particle size due 
to sample dehydration,123,124 and can exhibit a cup-shaped morphology due to dehydration 
effects and force exerted on the EV surface by the AFM tip.121,124 Measurements of EV 
diameter by AFM are comparable to those obtained by DLS.120 As well as the size, AFM can 
also measure the surface topology of EVs, indicating the presence of biomolecular cargo 
within the EV or detecting the binding of antibody-coated AuNPs on the surface.121 The 
mechanical stiffness can also be measured: cancer-derived EVs have been found to have 
reduced stiffness compared to EVs derived from healthy cells,125 and hepatocyte-derived EVs 
were softer than EVs derived from hepatocyte progenitor cells.126 
1.3.3.3 Dynamic light scattering 
DLS is a well-established technique to analyse the size distribution of particle suspensions. 
Light scattered from the bulk solution is used to calculate the mean particle size. While this 
is useful for the analysis of monodisperse samples, results are not as accurate for 
heterogeneous sample populations such as EVs. The size profile is biased towards larger 
particles, as larger particles scatter light with greater intensity. Light is also scattered from 
large particles at lower angles, so instruments with options for the detection angle may be 
more suitable for analysis of the size distribution of EVs.127 
30 
 
Despite this drawback, DLS has been used in many studies to determine the size profile of EV 
samples. DLS is a high-throughput analysis technique requiring minimal sample preparation 
compared to techniques such as EM. Many comparative studies have shown that the results 
obtained from DLS analysis are not dissimilar to results obtained from techniques analysing 
particles individually.116,120,128 
1.3.3.4 NTA 
Nanoparticle tracking analysis (NTA) is a method which measures the size distribution of 
particles based on their velocity by Brownian motion. A sample is introduced into the 0.3 mL 
sample chamber and illuminated using a laser (Figure 1.3). The scattered light is detected by 
a camera which records a video of the particles moving under Brownian motion at a rate of 
30 frames per second. The particles in each frame are then tracked individually to determine 
the mean square displacement of each particle, which is related to particle size via the 
Stokes-Einstein equation (1).129 Particles larger than 1 µm cannot accurately be measured by 
NTA due to the slow diffusion rate of these particles.130 NTA overcomes the limitations of DLS 
by monitoring particles on an individual basis rather than bulk solution and calculates an 
accurate size distribution of the particles for hydrodynamic radii between 30 nm and 1 µm. 
Sources of error with NTA are external vibration of the instrument, as well as inaccurate 
measures of sample viscosity and temperature, as these affect the Brownian motion of 
particles.131 Larger particles scatter the laser light at greater intensity, so settings which are 
optimal for the detection of larger particles in the sample may not be sensitive enough to 
pick up on smaller particles and thus bias the size distribution towards larger particles. 
 
 





where <  𝑥, 𝑦  >2 is mean squared displacement, KB is Boltzmann’s constant, T is the 
temperature of the sample medium in Kelvin, ts is the sampling time, η is the viscosity of 





Figure 1.3: Schematic of NanoSight instrumentation for small particle analysis. Reprinted 
from Materials Today, 14, Andrew Malloy, Count, size and visualize nanoparticles, 170-173., 
Copyright (2011), with permission from Elsevier 
Analysis of EV populations with NTA has proven to be useful for both size distribution and 
concentration studies. Estimates of EV concentration by NTA give much higher results than 
counting by flow cytometry, by two orders of magnitude.130,131 Concentrations obtained are 
accurate for samples within the range 1 x 108 – 8 x 108 mL−1, with size distribution comparable 
to electron microscopy.130  
Different laser wavelengths are available for sample illumination, and bandpass filters can be 
added to the instrumentation to detect fluorescently-labelled particles. Comparing the 
profiles obtained by light scatter and fluorescent measurements can give an indication of 
population heterogeneity or could indicate the presence of non-EV contamination. For 
example, plasma samples labelled with quantum dot-labelled cell tracker peptide showed 
greatly reduced particle concentrations measured with the fluorescence filter than by light 
scatter, due to the presence of contaminating lipid particles.130 The ability of NTA to measure 
proteins on EVs using fluorescence is a promising, high-throughput alternative to Western 
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blot analysis with reduced sample pre-processing, especially for samples obtained in small 
volumes, such as blood or urine from mice.132  
NTA has also been useful to assess the separation efficiency and storage conditions of EV 
samples by measuring the changes in particle concentration and size distribution. No 
difference was found in the size or stability of EV samples after multiple centrifugation steps 
at 110,000 g for 2 hours.133 The optimal conditions for storage of unprocessed urine was -
80°C with protease inhibitors. This results in some particle loss compared to fresh samples, 
but the loss was reduced when compared to other storage temperatures (-20°C, 4°C, and 
room temperature) and when compared to samples without protease inhibitors. Isolated EV 
samples were found to be stable in storage at 4°C for up to 48 hours, and multiple freeze-
thaw cycles had no effect on the size distribution.133 
1.3.3.5 Tunable resistive pulse sensing 
Tunable resistive pulse sensing (TRPS) calculates the size of particles based on the Coulter 
principle, which measures the resistive pulse generated by the particle moving through a 
pore. A membrane with a cylindrical or conical pore separates two chambers, one containing 
sample and the other with an electrolyte solution.134 The resistance of the pore is determined 
by application of a voltage across the pore and measurement of the electric current. EVs 
move through the pore by a combination of convective and electrophoretic flow caused by 
the application of external pressure and voltage, respectively. Diffusion rates of EVs are 
negligible. When a particle moves through the pore, the resistance across the pore increases, 
measured as a drop in the current, termed ‘blockade height’. The decrease in current is used 
to calculate the resistive pulse, which is proportional to the volume of the particle.134,135 In 
TRPS, the lower detection limit is based on the pore size, stability of the current, and 
conductivity of the sample medium. Tunable resistive pulse sensing systems allow for the 
pore diameter to be changed by stretching of the membrane.136  
The rate of particle flow across the membrane is determined by pressure and is not 
influenced by electro-osmosis or electrophoresis and diffusion rates of EVs are negligible, so 
difference in the zeta potential of samples and calibration beads is not a source of error, 
meaning concentration can be calibrated accurately.118 Non-specific binding of sample 
constituents to the pore can cause blockages, leading to drops in current and unstable and 
reduced reproducibility of measurements. Application of a coating solution to the membrane 
can prevent this non-specific binding.115  
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The minimum detection size can be improved using high currents and low pore stretching, 
which causes increased blockade height. However, limiting pore stretching can cause 
clogging. Blockade height is reduced by an increase in pressure, however low sample 
concentrations require high pressures. Using a fixed blockade height strategy, the 
reproducibility of the minimum detectable size and concentration determination were 
improved.137 Maximum detection size is also limited by the pore size. Clogging of the pore 
can occur for larger particles, and unclogging, which is fixed by reversing the pressure or 
applying a temporary high pressure using a plunger, may change the pore dimensions. 
Sample volumes required for TRPS are small, approximately 40 µL. Measurement time for a 
sample is on the order of 30 minutes, consisting of 3 calibration measurements, sample 
measurement at 3 different pressures, with 3 replicate sample measurements.115 Some 
instruments can give measurements of size distribution, concentration, and zeta potential of 
particles. 
In a comparison to EV analysis by other methods, TRPS had the lowest observed error for 
determining concentration of an EV sample.118 Dedicated small-particle flow cytometry 
showed the lowest error in the calculation of EV size, however it underestimates the particle 
concentration 15-fold. Thus, TRPS was determined to show the highest reproducibility for EV 
analysis. Measurements of EV size and concentration obtained by TRPS are comparable to 
TEM, NTA, DLS, and SAXS.116 
1.3.3.6 Flow cytometry 
The intensity of scattering of particles with diameters smaller than the wavelength of light, 
such as EVs, is inversely proportional to the sixth-power of particle size, meaning the 
scattering detection limits of many flow cytometers is 300-500 nm; reducing the detection 
limit from 200 nm to 100 nm would require 60-fold increase of signal to noise. However, virus 
particles down to 60 nm diameter have been detected by flow cytometry.138 The refractive 
index of particles being measured is also important as sub-micron particles with higher 
refractive indices have greater forward scatter intensity in flow cytometry, which is used as 
an estimate of particle size. 0.4 µm polystyrene beads have the same light scattering intensity 
as 1 µm cellular particles, which is 36-times higher forward scattered light intensity than 0.4 
µm synthetic lipid vesicles. Platelets have the same scatter profile as 0.9 µm polystyrene 
beads.139 The resolving power of flow cytometers is instrument dependent, with older 
models unable to resolve 0.5 µm polystyrene beads and others resolving 0.2 µm beads.139 
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Analysis of EVs by flow cytometry can be misleading due to the presence of contaminants 
with similar biophysical properties such as size and scatter profiles. Immune complexes have 
been detected in the EV gate of flow cytometry.128 Incubation of the sample with detergent, 
such as 0.05% Triton X-100, can cause EV-lysis, thereby estimating the EV contribution to the 
observed signal.128 Platelet free plasma analysed by flow cytometry show continuous 
distribution of particles in the 1-2 µm gate down to the resolution limit of 0.4 µm, indicating 
that platelet-sized particles remain in the preparation.139 The light scattering intensity of sub-
cellular particles decreases non-linearly with size, and the angle of scatter also changes to 
larger angles for smaller particles. Cells typically scatter at angles <2°, so setting the minimum 
forward scatter detection angle to 14° increases the signal to noise ratio for smaller particles 
to be detected.138,140 Using fluorescent threshold to trigger data acquisition rather than light 
scattering profiles allows the detection of particles which are too small to pass the light 
scatter threshold, and may help reduce spurious results due to coincident particles.141 
Equipping the instrument with a higher-powered laser, such as 200 mW rather than 25 mW, 
increases the sensitivity of the fluorescence triggering.142 EVs can be analysed by dual staining 
with a lipid membrane dye for fluorescent triggering and general EV detection, alongside 
antibodies for analysis of surface markers.140 BODIPY-maleimide, or bio-maleimide, can also 
be used to non-specifically stain EVs by binding of the maleimide to thiols of cysteine residues 
and thiols on membrane proteins,143 and the lipid membrane intercalator PKH67 is also 
efficient at labelling EVs.142 EVs should be quantified prior to staining for flow cytometric 
analysis to ensure optimal staining conditions are used.144 Removal of unbound fluorescent 
labels from the EV sample is important, as dye aggregates may occur which could be mistaken 
for EVs. Separation of unbound dye by density gradient floatation is more effective than 
ultracentrifugation.142  
The ImageStream imaging cytometer can be used to detect EVs. This instrument uses a CCD 
rather than photo multiplier tubes, and records 12 images in 10 fluorescent channels as the 
sample passes though the flow cell. EVs as small as 20 nm have been detected.145 
1.3.3.7 EV clearance 
EVs are released from many cell types in health and disease, and can be taken up by recipient 
cells. There has been a growing interest in the application of EVs in therapy, by using synthetic 
EVs to carry therapeutic agents directed against the target cells, or EVs from mesenchymal 
stem cells which may have regenerative properties. In order to make full use of this potential 
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application, the distribution and clearance of EVs has been studied. EVs can be taken up by 
Kupffer cells, which are specialised phagocytes in the liver, and phagocytes in the spleen, as 
well as undergoing endocytosis by dendritic cells and processed for antigen presentation.146 
EVs injected intravenously into mice were found to have a half-life of 2 minutes,147 and 
localised mainly in the liver and spleen where they were taken up by Kupffer cells and 
macrophages,147–152 similar to synthetic liposomes and other nanoparticles. EVs may also be 
trafficked to specific sites. For example, EVs derived from B16-BL6 melanoma cells, which has 
a tendency to form lung metastases, were observed to localise to the lung 4 hours after 
injection.147,148 CD169 on macrophages in the subcapsular sinus and medulla of lymph nodes 
and marginal zone of the spleen has been shown to be important for the capture and 
clearance of EVs derived from B cells by binding with α2,3-sialic acid present on the EV 
surface.153  
1.3.3.8 EVs in cancer 
One of the major areas of study with regards to EV function is the role these particles play in 
cancer. The number of EVs present in the blood of cancer patients is often higher than that 
found in healthy controls,154 however the concentrations observed depend on the pre-
analytical variables and separation techniques used. The concentration of disease-specific 
EVs has been shown to decrease after treatment, such as surgical resection155,156 or 
chemotherapy.157,158 Most of the EVs found in the blood of healthy volunteers are derived 
from platelets.154  
EVs retain markers of the tumour from which they are derived and can be used as a cancer 
biomarker. EVs from B cell lymphomas have been shown to express CD19154 and CD20,159 
hepatocellular carcinoma EVs can be differentiated based on CD147,155 CD138 is present on 
multiple myeloma EVs,154,160 and a panel of protein markers has been used to identify EVs 
associated with prostate cancer.161 EVs may carry copies of oncogenic mutations, such as 
KRAS mutants in pancreatic ductal adenocarcinoma,162 the c-MYC oncogene,163 or the 
oncogenic form of EGFRvIII in glioma,164 as well as specific miRNA species156,158 and functional 
mRNA which can activate translation to increase the metastatic potential of recipient 
cells.165,166 The presence of these cargoes in EVs can be used as liquid biopsies to detect these 
specific disease subtypes in patients. EVs termed ‘large oncosomes’ have also been studied, 
which are cancer cell derived EVs larger than 1 µm. Organelles such as lysosomes and 
mitochondria have been observed in these large EVs.167  
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EVs in cancer have been shown to induce endothelial cell tube formation and 
angiogenesis.168–170 EVs may also contribute to immunotherapy resistance by carrying on 
their surface the protein targets against which therapeutic antibodies are directed. For 
example, EVs derived from B cell malignancies can act as decoys of anti-CD19167 or anti-
CD20159,171 immunotherapy, and HER2 expression on EVs can inhibit the anti-HER2 antibody 
Trastuzumab used in breast cancer therapy.172 Breast cancer EVs have also been shown to 
display a larger form of VEGF which has reduced affinity for the anti-VEGF antibody 
Bevacizumab, thereby reducing the effects of this therapy.168 EVs have also been shown to 
supress anti-tumour immune responses, by inactivating NK cells or CD4+ T cells,173 activating 
regulatory T cells,174 or induction of T cell apoptosis via FasL.175,176  
Cancer derived EVs have been shown to alter the stromal cells within the tumour, such as 
chronic lymphocytic leukaemia EVs activating stromal cells to a cancer-associated fibroblast 
phenotype,170,171 enhanced monocyte survival resulting from the transfer of CCR6 and CD44 
after EV phagocytosis,177 or inducing a metabolic switch from oxidative phosphorylation to 
aerobic glycolysis.157 EVs released from pro-tumour stromal cells have also been shown to 
contribute to disease pathogenesis, such as cancer-associated fibroblast EVs conferring 
resistance to gemcitabine therapy in pancreatic ductal adenocarcinoma,178 and TAM EVs 
conferring cisplatin resistance in gastric cancer.179  
A number of studies have linked cancer-derived EVs with priming the pre-metastatic niche 
by travelling to sites such as lymph nodes, lungs, and liver, resulting in the recruitment of 
tumour cells to these distal sites.180–183  
The concentration of EVs has been correlated with disease stage in a number of cancer types, 
including haematological malignancies,154,160 ovarian cancer,184 and prostate cancer.166 
Phenotypic associations have also been observed, such as the correlation between proteases 
carried within EVs and tumour malignancy and invasion,184 the levels of transient receptor 
potential channel TRPC5 on EVs associated with chemoresistance in breast cancer,185 IL-31 
and IL-31R expression correlated with stage in FL patients,186 and a panel of five proteins 
which can distinguish between high-grade and low-grade disease in prostate cancer 
patients.161 
1.3.3.9 ApoEVs 
EVs derived from apoptotic cells (apoEVs) appear to have different characteristics to EVs 
derived from their viable counterparts. Apoptotic cells release more EVs than non-apoptotic 
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counterparts.187–190 Apoptotic cells also released larger EVs than untreated controls.87,188 
ApoEVs have been found to contain DNA which had undergone internucleosomal 
cleavage.144,188,189,191 However, other studies have not detected histone proteins in 
apoEVs.87,192 Apoptotic cells can release EVs which have autoantigens exposed on the surface, 
inducing dendritic cells to a pro-inflammatory phenotype thereby contributing to 
autoimmune disorders such as Sjögren’s syndrome193 and systemic lupus erythematosus.194  
Apoptotic cells have been observed to shed the chemokine CX3CL1,64 and the ‘eat-me’ signal 
ICAM3,195 from the cell surface through apoEVs, and these apoEVs showed chemotactic 
recruitment of macrophages. IgM promotes the clearance of apoEVs and apoptotic bodies of 
< 2 µm by macrophages.196 ApoEVs have been shown to exhibit desialylated glycoepitopes, 
an ‘eat-me’ signal caused by caspase activity during apoptosis, which can enhance 
macrophage clearance of apoEVs.191 
Uptake of apoEVs by cancer cells increased cell motility and invasion properties both in vitro 
and in vivo.87,197 Glioblastoma cells also showed increased resistance to apoptosis from 
different stimuli likely caused by spliceosomal proteins in the apoEVs affecting genes 
responsible for DNA damage repair and stress response.87 
1.4 Raman spectroscopy 
When light interacts with a molecule, the light can be absorbed or scattered. Absorption of 
light requires that the energy of the incident light is the same as the difference in energy 
between the ground electronic state (E0) and an excited state (E1), whereby the energy of the 
light is used to promote an electron to the higher energy orbital (Figure 1.4). Scattering of 
the incident radiation does not require a photon with a specific energy. The incident light 
interacts with the molecule by causing a distortion of the electron cloud due to polarisation, 
forming a short-lived ‘virtual’ energy state. This virtual state is not stable and so the light is 
released immediately as scattered radiation. If the electron polarisation occurs without any 
nuclear movement in the molecule, there is no change in the energy of the scattered light 
compared to the incident light and this is said to be an elastic process (Figure 1.4). This is 




Figure 1.4: Jablonski diagram showing energy transfer in absorption and scattering. E0 and E1 
represent the ground state and excited state orbitals, respectively. Upward arrows represent 
the incident radiation interacting with electrons of the molecule and downward arrows 
represent the scattered light. 
However, if nuclear motion occurs when the molecule is in the virtual state, the photon will 
transfer energy to or from the molecule and the energy of the scattered light will no longer 
be the same as the incident radiation.198  This is known as Raman scattering and occurs for 
every 106-108 incident photons. If the molecule originates in the ground state, then it will 
return to the first excited vibrational state and the scattered light will be of lower energy 
than the incident light, this is known as Stokes scattering. If the molecule interacts with the 
incident radiation when in a vibrationally excited state, then the scattered radiation is of 
higher energy and is known as anti-Stokes scattering (Figure 1.4). Stokes scattering is the 
dominant form of Raman scattering. 
The amount of energy lost from the incident radiation during Raman scattering is equal to 
the frequency of the molecular vibrations. Bonds consisting of lighter atoms (e.g. C-H) vibrate 
with higher frequencies than bonds consisting of heavier atoms (e.g. C-S).198 Bond strength 
also plays a factor in the vibration frequency, with stronger bonds having a higher 
















about the molecular bonds present in the sample can be inferred. In this way, Raman 
spectroscopy is a label-free spectroscopic technique which gives detailed information about 
the functional groups present in a sample. 
1.4.1 Application of Raman spectroscopy in biological analysis 
The label-free nature of Raman spectroscopy makes it useful for the analysis and 
characterisation of biological systems. Traditional biochemical assays acquire measurements 
from bulk samples, such as ELISA and Western blots, and probe for only one analyte at a time, 
often requiring multiple complex sample preparation steps. Other single cell analytical 
techniques can be based on the use of fluorescent markers, such as flow cytometry or 
fluorescent microscopy, but the number of markers which can be analysed at one time is 
limited by the number of excitation wavelengths available and the number of fluorophores 
which can be resolved at those wavelengths. Raman spectra have narrow bands which allow 
the identification of multiple biomolecules in a single spectrum without any labelling 
required. Raman spectra also inherently contain a large amount of information about the 
sample, and multivariate analysis techniques can use this information to identify very small 
changes between samples of similar biochemical composition. 
Raman spectroscopy has been used to distinguish between different modes of cell 
death,199,200 differentiate cancerous cells from healthy cells201,202 and tissue obtained from 
different anatomical sites,203 determine the distribution of biomolecules within cells,204–206 
and the response of cells to toxins.207 Raman spectroscopy can also be a useful tool when 
combined with biosensors.  
1.4.1.1 Parameters for Raman data acquisition in biological systems 
The development of Raman microscopes has allowed the simultaneous visualisation of 
sample and data acquisition. In this way, spectral data can be related back to the cellular 
localisation. Raman microspectroscopy has great potential for clinical applications but it is a 
low throughput technique. A Raman flow cytometer has been developed to try to overcome 
this issue.208 Raman spectra were acquired from a sample moving through a flow cell, 
analogous to a conventional fluorescent flow cytometer. The collection of Raman spectra is 
triggered by a change in the forward scattered light. Signal intensity can be improved by 
reducing the flow rate of the sample to increase the integration time, using higher powered 
lasers, or using surface enhanced Raman spectroscopy nanoparticles for detection. This has 
the potential for sensitive multiplexed detection. 
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Thurn and Kiefer described the first use of optical trapping in combination with Raman 
spectroscopy in 1983.209 The levitation of micron-sized particles resulted in the avoidance of 
background signal from a supporting substrate and the optimal focus of the particle within 
the laser beam. Optical levitation is caused by the exertion of forces of a continuous wave 
Gaussian-mode laser. Vertical forces act against gravity to support the weight of the particle, 
and deflection of laser light causes the transverse motion of the particle into the centre of 
the beam, creating an optical potential well. The particle will be suspended at a point above 
the beam waist, where the laser force acting upwards is equal to the gravitational force acting 
downwards, and any displacement from this position will cause restoring forces to bring the 
particle back to this position.209 If the instrumentation is set up such that this optical potential 
well is at the sample focal position point of a spectrometer, simultaneous trapping and 
Raman measurements can be carried out. Using a 514.5 nm laser with 500 mW power, Thurn 
and Kiefer measured Raman spectra from 30 µm glass spheres and non-spherical quartz 
microcrystals. Optical levitation, or laser tweezers Raman spectroscopy (LTRS) was used for 
the first time on red blood cells in 2002.210 The device was set up using a lower laser power 
to trap the cells and a higher power to acquire the Raman spectra, to reduce damage to the 
cells. Since then LTRS has been applied successfully for the study of individual cells many 
times.210–215  
The excitation wavelength chosen for analysis is very important. The Raman scattering effect 
is inversely proportional to the fourth power of the wavelength, meaning that shorter 
wavelengths generate higher intensity scattering.198 This is important to maximise the signal 
to noise ratio of the inherently weak Raman effect. However, shorter wavelengths are not 
compatible with biological systems; the damaging effects of UV and shorter visible 
wavelengths on cells are well documented.216 Some studies have shown that photodamage 
and bleaching of samples can occur at wavelengths such as 457.9 nm, 488 nm, and 514.5 nm, 
but not 632.8 nm or 660 nm.217 Fixed peripheral blood lymphocytes (PBLs) were observed to 
be resistant to photodamage using 647 nm laser excitation at 70 mW for up to 100 seconds 
exposure time,205 but this wavelength can also cause photodamage of carotenoid protein 
after repeated spectral acquisition of the same cell.218 Exposure of red blood cells to 785 nm 
excitation at 20 mW of power for 15 minutes also caused degradation of the Raman 
spectrum, which was not observed with 2 mW.210 The overall energy dose of the irradiating 
light is the limiting factor rather than the laser power itself, and in general near IR 
wavelengths induce less damage than shorter wavelengths.217 
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1.4.1.2 Fixation of biological samples for Raman spectroscopy 
Chemical fixation methods are often employed in biological analysis to preserve cells and 
tissues from damage which may occur in the time between sample preparation and analysis. 
However, these processing methods can alter the structure of the tissue and generate 
contaminating peaks derived from the fixative, impacting the Raman spectrum. Tissue 
sections are formalin-fixed paraffin preserved (FFPP) by embedding in a block of wax which 
allows easy cutting of tissue sections, however wax peaks can be present in the Raman 
spectra of these samples.219 Often for immunohistochemical staining, a dewaxing procedure 
is carried out. Dewaxing using xylene is not always efficient and can leave some residual wax 
peaks in the spectrum.219 Dewaxing can also remove lipids from the tissue, as these have a 
similar fatty acid chain structure to the wax.203,220 This removal of lipids can have a profound 
impact on the Raman analysis of the tissue, as seen when tissue samples from the back of 
the hand and the thigh were analysed.203 Analysis of unprocessed tissue samples showed 
discrimination between tissue obtained from the hand and the thigh, but this distinction 
between anatomical sites was removed after FFPP and dewaxing of the samples due to the 
loss of extracellular lipids. Structural alterations were also seen in the same study, where the 
thickness of the epidermal layers changed after processing. Freezing tissue is also used as a 
method to aid in cutting of tissue sections. However, freezing conditions are known to disrupt 
cytoskeletal proteins, and this can be observed as a decrease in some protein bands in 
cryosectioned tissue.219 Tissue fixation with formalin caused a reduction in the amide I band 
at 1637 cm−1 due to the cross-linking of proteins in the sample. Treatment with xylene after 
formalin fixation can cause contaminating peaks due to the presence of xylene but can also 
reverse some of the cross-linking caused by formalin, restoring the amide I band.219  
Studies have also been carried out on fixation methods used for single cells and the effects 
these can have on the resulting Raman spectra. It appears that different methods of fixation 
affect the spectra to varying degrees and may be dependent on the cell type used. HaCaT 
keratinocyte cells subjected to air-drying, desiccation, or formalin fixation showed that 
formalin fixation had the greatest impact on the cell spectra, showing greatly reduced peak 
intensities.221 However, when principal component analysis (PCA) was carried out on the 
data, the formalin fixed cells had the tightest cluster of the three groups indicating high levels 
of sample consistency using this fixation method. The opposite was true for the macrophage 
line MM6, which had higher signal intensity observed in the formalin group, but PCA 
identified air-drying to generate the most reproduceable results for these cells. Another 
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study using formalin, Carnoy’s fixative, and methanol-glacial acetic acid (Meth-Ac) to fix 
HaCaT keratinocytes, BEAS2B bronchial epithelial cells, and A549 adenocarcinoma cell lines 
gave mixed results.222 Meth-Ac appeared to result in better preservation of lipid moieties in 
A549 cells, and Carnoy’s fixative resulted in protein peaks having a greater similarity to 
unfixed cells in the BEAS2B line. However, PCA results showed that the formalin fixed cells 
were most similar to the unfixed cell of each type. A study in which B and T lymphoblastic 
cancer cell lines were fixed with either paraformaldehyde or -20°C methanol found that the 
duration of fixation was important, as the magnitude of the spectral changes were greater in 
the methanol fixed cells, but increasing the formalin incubation time increased the 
magnitude of the changes seen with this method.212 Formalin fixed cancer cells could be 
distinguished from normal peripheral blood lymphocytes, while the methanol treatment 
impaired the delineation between these groups, indicating that formalin is the better fixative 
for these cells.212 Thus the choice of fixative must be carefully considered before carrying out 
a Raman experiment. 
1.4.1.3 Reproducibility of biological Raman data acquisition 
Intracellular variation is one of the main challenges of obtaining representative Raman 
spectra of cells. Different organelles will have different spectral signals depending on their 
biomolecular composition, and features which are indicative of cell state, such as cell cycle, 
viability, or cell type, may be localised to a single organelle. This intracellular variability, 
combined with intercellular variability, requires a large number of cells to be sampled in 
order to develop an accurate model for the identification of different cell types and states. 
Intracellular variability may be overcome by acquiring Raman ‘images’ or ‘maps’ of the entire 
cell. A sample area is marked out for analysis and multiple Raman spectra are obtained at 
defined step sizes across this area to create a hyperspectral data cube. These data can then 
be used to generate a mean spectrum for the cell as a whole or measure the distribution of 
biomolecules across the cell by representing peak intensities for specific biomolecules as a 
false colour image. However, cell mapping can be time consuming and is not suited to high 
throughput applications. On the other hand, Raman spectra acquired from a small number 
of locations within a cell may not be representative of the cell as a whole. One study showed 
that, although individual spectra appeared to show that protein and lipid levels remained the 
same and nucleic acid content decreased after doxorubicin treatment of Jurkat T cells, 
analysis of whole cell data showed that the size of the treated cells had increased.223 Thus, 
the nucleic acid concentration had not changed, and the amount of protein and lipid had 
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actually increased, but this was not represented by point spectra. Some studies have looked 
to find the minimum number of individual cell spectra which are needed to accurately 
represent the mean cell spectrum derived from a map. One study found that just 30 
randomly selected spectra from a cell map could accurately replicate the total biomolecular 
content of cells which had been calculated using whole cell data.224 When creating 
classification models, it was found that between 84 and 104 spectra from cell maps were 
needed to train the model in order to yield a sensitivity of greater than 90%, dependent on 
cell type. When a single point spectrum was used rather than mapping data, many more 
training spectra were required (164 in one cell type, >250 in the other two).225  
1.4.1.4 Biochemical analysis using Raman spectroscopy 
Raman microspectroscopy can be used to monitor the change in cells over time. Time-lapse 
imaging of PBLs was carried out to generate Raman maps of entire cells in under 2 minutes.218 
Successive maps could be acquired of the same cell until the cell either moved away from 
the acquisition area or the membrane started blebbing indicating cell death had occurred.  
Raman maps of cells have been used to show the variation in intensity of a certain 
biomolecular peak over the cell area, to give an indication of the distribution of this group 
intracellularly. For example, the DNA signal in PBL nuclei was found to have much greater 
intensity than that found in the nuclei of lens epithelial cells.204 The nuclei of the epithelial 
cells are larger in diameter than those of PBLs, and transcriptional activation in the epithelial 
cells causes decondensation of the chromatin, both of which lead to lower intensity Raman 
bands. Raman DNA peak intensities may also be able to distinguish between cells in different 
stages of the cell cycle.226 
Different methods of data analysis of Raman spectra can give meaningful results. While 
univariate analysis, in which changes in individual peaks between samples are compared, 
may be useful in some situations, there are many methods of multivariate analysis of Raman 
spectral data that can take into account changes across the entire spectrum. PCA is a method 
of data reduction which can be used to infer the biochemical differences between different 
groups of cells. One study found that when a group of samples analysed by PCA had fewer 
contributing spectra than other groups in the analysis, the contribution of the spectra from 
the smaller group to the PC loading was decreased, resulting in the reduction of the relative 
scores of the smaller group for that PC.227 Thus, the number of datapoints in each group for 
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PCA analysis should be equal when attempting to distinguish between different cell types or 
treatment effects.  
Comparison of colorectal cancer cell lines derived from a primary and secondary tumour 
showed separation by PCA, suggesting that the secondary tumour had higher levels of β-
sheet proteins and porphyrins while the primary tumour had higher levels of α-helix proteins 
and lipids.228 PCA was able to distinguish melanoma cell lines from melanocytes, and separate 
melanoma cell lines with different mutations from the wild-type cells.201  
Separation of different types of cells can be done by PCA in combination with linear 
discriminant analysis (LDA) to build a classification model. For LDA the number of input 
variables must be smaller than the number of samples, so the entire Raman spectrum cannot 
be analysed as the number of wavenumbers analysed is usually larger than the sample size.229 
In PCA-LDA, the PCs generated in PCA are used as the variables for LDA. PCA-LDA has been 
used many times to create classification models for cancer diagnosis. A classification accuracy 
of 98% was achieved in distinguishing the two colorectal cancer cell lines SW480, a primary 
colon adenocarcinoma, and SW620, a lymph node metastasis derived from the same 
patient.230 A classification accuracy of 100% was obtained in distinguishing four different lung 
cancer cell lines and a normal lung epithelial cell line.202 PCA-LDA has also been used to 
analyse serum samples from patients with colon cancer, rectal cancer, and healthy controls, 
with an identification accuracy of 88%.231 
Support vector machine (SVM) models have also been using for classification. One group has 
carried out repeated studies to distinguish cancer cells from leukocytes and erythrocytes 
using SVM, with the goal of identifying circulating tumour cells in blood.213,232,233 An acute 
myeloid leukaemia cell line (OCI-AML3) and two different breast cancer cell lines (BT-20 and 
MCF7) were used in these studies. The model was first tested using data from cell maps of 
dried samples, and the classification of a mixed sample of the cells was verified by staining 
the epithelial cells with an anti-EpCAM fluorescent antibody.232 Using LTRS, the cells were 
analysed in suspension resulting in a prediction accuracy of 99.54% for leukocytes and 
erythrocytes and 99.74% accuracy in the cancer cell lines identification.233  
K-means clustering is a technique where spectra can be clustered together based on their 
spectral similarity, identifying common biochemical signatures for groups of spectra. False-
coloured maps can be produced identifying the clusters, along with the mean spectrum for 
each region. This has been successful for the analysis of tissue samples to detect different 
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layers of skin,203 or different structural features of a tissue biopsy such as fibrosis or adipose 
cells.220  
In classical least squares (CLS) analysis, a linear combination of reference spectra is used to 
estimate the percentage of pure components which make up the observed Raman spectrum 
of a sample, which allows quantitative analysis of spectral changes of cells under different 
conditions. This technique has been used to show that RNA levels decrease in embryonic 
stem cells undergoing differentiation.229 Mouse embryonic stem cells showed a reduction of 
38% in the amount of RNA present, while foetal osteoblasts displayed a 20% reduction in 
RNA after 7 days of differentiation and 45% reduction after 14 days, without changes to any 
other biomolecular components.  
1.4.1.5 Analysis of cell death by Raman spectroscopy 
There are many methods available to establish the viability of a cell population. As mentioned 
in Section 1.2.1, flow cytometry is often used to measure the exposure of PS and integrity of 
the membrane using fluorescently labelled AxV and propidium iodide. Caspase-3/7 
substrates are also available which become fluorescent when cleaved by these enzymes and 
can be used in microscopy to detect apoptotic cells. However, these methods require 
exogenous labelling with fluorescent markers. Many studies have used Raman spectroscopy 
to distinguish between viable and apoptotic cells in a label-free manner, which can allow the 
same cells to be measured many times in a time lapse study234 or even be used in further 
assays. 
Cytochrome c, which is released form the mitochondria during apoptosis, shows absorbance 
at 413 nm, 520.8 nm, and 530.9 nm. Thus, cytochrome c is resonant at 532 nm laser excitation 
which is often used for Raman spectroscopy, resulting in enhancement of depolarised and 
amorphously polarised bonds due to π-π* Q transitions of the porphyrin ring.235 Peaks due 
to resonant cytochrome c vibrations are observed at 714 cm−1 (symmetric pyrrole folding), 
747 cm−1 (pyrrole breathing), 1127 cm−1, 1314 cm−1, and 1583 cm−1.202,235 Distribution of 
cytochrome c in apoptotic HeLa cells was analysed after treatment with Actinomycin D and 
the 750 cm−1 peak decreased, indicating release from the mitochondria causing loss of 
localised concentration and a drop in peak intensity (Figure 1.5).206 Labelling the cells with 
the fluorescent mitochondrial stain Mitotracker confirmed that the cytochrome c signal was 
no longer in the mitochondria after treatment. Another study showed a decrease in the 
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cytochrome c peaks at 745 cm−1, 1127 cm−1, and 1314 cm−1 in Jurkat cells stored in PBS at 4°C 
for 3.5 hours using LTRS.211  
 
Figure 1.5: Distribution of cytochrome c (A,E), protein (B,F), and lipid (C,G) seen in apoptotic 
(A-D) and non-apoptotic control (E-H) HeLa cells shown as false coloured images generated 
from Raman spectral data. (D) was created through merging images A-C, and H was 
generated from merging images E-G. Reproduced from M. Okada et al., Proc. Natl. Acad. Sci., 
2012, 109, 28–32. 
Raman studies of apoptotic cells show changes in a number of peaks associated with nucleic 
acids. The 780-800 cm−1 band, which includes contributions from the phosphodiester DNA 
backbone, has been shown to decrease in apoptotic cells, 199,207,215,223,226,236–238 likely caused 
by internucleosomal cleavage.236 Other nucleic acid peaks shown to be decreased in 
apoptotic cells include 1095 cm−1,215,223,226,239,240 1322 cm−1 and 1342 cm−1,215,226,238 and the 
1338 cm−1 adenine and 1578 cm−1 guanine bands.215,223,240 CLS analysis has also showed a 
decrease in the contribution from DNA and RNA signals in apoptotic cells.223,237,239 The 788 
cm−1 phosphodiester band appears to be the most sensitive to change during apoptosis, and 
although the 1095 cm−1 phosphodioxy band is less sensitive, it has been shown to shift to 
1090 cm−1.238 
Other studies have shown an increase in nucleic acid peaks in apoptotic cells, including an 
increase in the 788 cm−1 to 1005 cm−1 peak ratio in breast cancer cell lines treated with 
etoposide,234 an increase in the 831 cm−1 phosphodiester peak in BL cells treated with 
paclitaxel,240 and 4-fold increase in the DNA signals in apoptotic HeLa cells compared to viable 
counterparts.205 It may be that these studies are detecting changes occurring at an earlier 
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stage of apoptosis, where the nucleus has condensed but not yet fragmented, thereby 
increasing the local nucleic acid concentration resulting in higher peak intensities. 
Protein signals have also been observed to decrease in apoptotic cells, including bands at  
623 cm−1 (phenylalanine, Phe),236 645 cm−1 (tyrosine, Tyr),236 938 cm−1 (α-helices),236              
1005 cm−1 (Phe),207,226,236,238,240 1052 cm−1,199,236 1210 cm−1,240 1231 cm−1 (random coil),226 and 
a decrease in width of 1660 cm−1 amide I band indicating a change in protein conformation.226 
However, CLS analysis of proteins in apoptotic cells has yielded mixed results, with some 
reports showing a slight increase in protein concentration,223,224 one study showed no change 
in overall protein concentration,237 and one report showed a decrease in the contribution of 
protein.239 
Lipid peaks have been reported to increase in apoptotic cells, including those at 720 cm−1 
corresponding to phosphatidylcholine,237,238 1158 cm−1,237 1303 cm−1,207,214,236 1649 cm−1 to 
1005 cm−1 ratio,234 and 1743 cm−1.214,236 An increase in lipid concentration was seen by 
CLS223,224,237,239 and distribution of the lipid signals have shown the formation of lipid 
droplets.205,234 Lipids can also be monitored in the high wavenumber region. After loss of 
membrane integrity in Jurkat cells, a decrease in the peaks at 2850 cm−1 and 2875 cm−1 were 
observed. These peaks have been associated with the packing and conformation of lipids, 
indicating that the membrane environment in these cells has been disrupted.241 
Analysis of necrotic cells showed an increase in protein peaks and a shift in the 1658 cm−1 
amide I band,199 with a decrease in nucleic acid and lipid peaks.239 The relative percentage of 
protein content in necrotic cells was seen to increase by CLS analysis, although the absolute 
protein concentration in these cells is lower than that of viable cells.239  
Multivariate analysis has also been carried out on Raman data from cells at different stages 
of death to investigate the biochemical changes. PCA of Jurkat T cells exposed to different 
concentrations of doxorubicin for different amounts of time show differing biochemical 
groupings of cells based on the concentration and time, with the cells exposed to the higher 
concentrations showing spectral changes faster than the lower concentrations.214 The 
treated cells were grouped into three clusters. Group 1, containing spectra from 24-hour 0.1 
µM doxorubicin treatment, showed increases in lipid signals. Group 2, containing spectra 
from 48-hour 0.1 µM doxorubicin treatment and 24-hour 0.5 µM doxorubicin treatment, 
showed increases in DNA signals over control, possibly indicating nuclear condensation. 
Group 3, containing 48-hour and 72-hour spectra from the 0.5 µM doxorubicin treatment, 
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showed reduction in the nucleic acid bands compared to control, suggesting that nuclear 
fragmentation had occurred in this group. This suggests that the apoptotic process can be 
followed by Raman spectroscopy to identify different biochemical changes at the different 
stages. Other groups have also shown a separation of apoptotic cells from viable cells by 
PCA.199,215,223,237,240 PCA of Raman spectra of melanoma cells which had been treated with 
either staurosporine to induce apoptosis, 3-bromopyruvate to induce necrosis, or resveratrol 
to induce autophagy, showed some slight separation of the three groups of treated cells and 
viable controls, although the autophagic cells were similar to viable.201  
SVM models have also been used to distinguish between cell viability states. One study 
generated a model which had 100% accuracy for viable, 94% accuracy for early apoptotic, 
92% accuracy for late apoptotic and 97% accuracy for necrotic cells.199 Another study trained 
an SVM model using data from untreated, etoposide treated (apoptotic), and Triton X-100 
(necrotic) A549 cells, which was then used to predict mode of death for cell exposed to mild 
heat (45°C). The etoposide, Triton X-100, and viable cells were all correctly classified, and the 
heat treatment was also correctly classified as apoptotic.200  
PCA-LDA has also been used to classify apoptotic and necrotic cells. K562 leukaemia cells 
were classified as viable, apoptotic, or necrotic with 100% accuracy.239 PCA-LDA was able to 
differentiate not only untreated from treated cells, but also distinguished between ricin and 
sulfur mustard treatment in A549 cells with a sensitivity of 71% and 88%, respectively, and 
could distinguish between the concentration of sulfur mustard used with an accuracy of 93%, 
as lower concentrations induce apoptosis and higher concentrations induces necrosis.207 
PCA-LDA of paclitaxel treated BL cells showed a classification specificity of 75%, 85%, 95%, 
and 100% for the 0.05 µg/mL, 0.5 µg/mL, 1 µg/mL, and 5 µg/mL treatment concentrations, 
respectively, when compared pair-wise with untreated control cells, with a sensitivity of 
100% for each group.240 Thus, Raman spectroscopy gives accurate representations of the 
biochemical changes occurring in cells undergoing cell death. 
1.5 Surface-enhanced Raman spectroscopy 
Surface-enhanced Raman spectroscopy (SERS) is a variant of Raman spectroscopy in which 
the Raman scattering intensity is increased due to plasmonic interactions. The phenomenon 
was first observed in 1974, when Fleischmann et al. recorded Raman spectra of pyridine at a 
silver electrode.242 It had been proposed that the stronger signal intensity came from the 
increased surface area of the probe caused by the oxidation-reduction cycles, however 
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further study showed that the surface area was only increased by 10-20% whereas the signal 
intensity of the ring-stretching bands were 5-fold higher than for pyridine in solution.243 As 
the spectra in solution were obtained as a result of light scattering from 4 x 105 times more 
molecules than were adsorbed on the sample area of the electrode, it was implied that the 
silver electrode increased the scattering cross-section of pyridine with an enhancement 
factor roughly of the magnitude 105. It was already known that electromagnetic fields applied 
to roughened metal surfaces could cause oscillations of the metallic conduction electrons, 
generating a plasmon resonance effect which localised the strength of the electromagnetic 
field about the particle (Figure 1.6), and it had even been proposed that monolayers of 
molecules on these metals could interact with the surface plasmon to cause Raman 
transitions.244  
 
Figure 1.6: Schematic of the localised surface plasmon resonance of a noble metal 
nanoparticle in an electromagnetic field showing oscillation of the electron cloud of the metal 
to cause enhancement of Raman signals. 
It is now generally accepted that the SERS effect is caused by two factors: the 
electromagnetic enhancement due to the surface plasmon resonance, and a chemical 
enhancement due to coupling of a molecule with the metallic surface. The electromagnetic 
enhancement is the dominating effect, which can cause enhancements of molecules not 
directly attached to the metal up to nanometre distances from the surface. The chemical 
enhancement effect can contribute enhancements factors of up to 104 due to charge transfer 
from the metallic surface to the molecule, or from the molecule to the metallic surface.245 
The observed enhancement factor of a SERS system is dependent on a number of 
parameters, such as the wavelength of incident light, dielectric constant of metal used, the 







size increases. Larger NPs absorb less light and scatter more due to scaling differences 
between absorption and scattering.  The surface plasmons of metal NPs in close proximity 
can couple with each other to form ‘hot spots’, generating enhancement factors of up to 
1012.246 These coupled NPs show red-shifting of the plasmon resonant wavelength compared 
with isolated particles. The magnitude of the red-shift is dependent on the NP size and the 
distance between the NPs.247 Large enhancement factors are also seen for non-spherical 
particles which have sharp protrusions.246  
As SERS enhancement is strongly distance-dependent, dye molecules are often used to coat 
the surface of the SERS NPs for use as SERS reporter molecules. Reporters can be effective 
by adsorption onto the NP by electrostatic interaction, however choosing reporters which 
can chemisorb to the metallic surface can make use of the chemical enhancement effect to 
yield stronger signals. For example, malachite green (MG) is a dye molecule which has been 
used as a SERS reporter, and adsorbs onto the surface of gold nanoparticles (AuNPs) via a 
dimethylamino group (Figure 1.7A). However, modification with an isothiocyanate (ITC) 
group to MG (MGITC) adds a sulfur atom (Figure 1.7B), which has a strong affinity for gold 
and can thus chemically attach to the surface.  Spectral analysis shows that MGITC has 200-
fold higher enhancement factor than MG, due to the chemical coupling effect.248 If the 
reporter has an absorption band at the wavelength used for SERS excitation, this gives a 
further enhancement factor, termed surface enhanced resonance Raman scattering (SERRS). 
Many different reporter molecules have been synthesised to optimise the chemical and 
resonant enhancement effects for sensitive SERS detection.249–251 DNA also has a strong 
intrinsic Raman spectrum dominated by Stokes scattering of adenine giving a sharp peak at 
736 cm−1 which could be useful as a SERS reporter.252 
 




Interest in the SERS effect became more widespread when the sensitivity of the technique 
was demonstrated by detection of single molecules. Typical scattering cross-sections of 
Raman-active molecules are 10-30 cm2/molecule and require signal enhancement by a factor 
of 1014 to achieve single molecule detection. This was achieved by two groups in 1997, using 
silver nanoparticles (AgNPs) to detect the reporter molecules crystal violet253 and rhodamine 
6G (R6G).254 
1.5.1 Applications of SERS 
SERS has proven to be useful for a number of applications requiring the sensitive detection 
of different molecules, such as explosives,255 drugs,256 pH sensing,257 and reactive oxygen 
species sensing.258 As the spectral resolution of SERS is much greater than analogous 
techniques such as fluorescence, where the full width at half maximum (FWHM) of Raman 
spectral features can be as small as 2 nm, SERS has great potential for multiplexed analysis 
for the detection of multiple analytes in a single sample. This is very useful in biological 
systems, where complex biochemical information requires multiple measurement 
parameters to accurately reflect the conditions of the biological environment. 
1.5.1.1 In vitro biochemical SERS sensing 
The sensitive nature and rapid sample preparation and analysis times of SERS mean that it 
has great potential for use in the clinic. For example, rapid and accurate detection of different 
types and species of bacteria is important clinically in order to reduce the overuse of 
antibiotics to prevent the generation of antibiotic resistance. Multiplexed SERS analysis has 
been shown to be able to distinguish between different types of bacteria with a LOD of 102 
CFU/mL,259 and was even successful in distinguishing between different strains of E. coli.260 
Gold is more biocompatible than silver for incorporation into cells, and the enhancement 
factors for AgNPs and AuNPs are similar when using NIR wavelengths.261 Incubation of 
unlabelled AuNPs with HT29 epithelial cells showed enhancement of the biochemical Raman 
signals of the cells, showing peaks attributed to the DNA phosphate backbone at 1120 cm−1, 
Phe at 1004 cm−1, and other nucleic acid and protein signals.261 The characteristic biochemical 
bands found in Raman spectra due to CH stretching at 1450 cm−1 and the amide I band at 
1650 cm−1 are not seen in the SERS spectra.  
Confocal mapping of the distribution of carbohydrates could be useful for the detection of 
cancer cells, as cancer cells show different glycan profiles to heathy counterparts.262 Using 
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SERS nanotags conjugated with lectins to detect cell surface carbohydrates was found to have 
better discriminating power for distinguishing prostate cancer cells from prostate epithelial 
cells than using fluorescently-labelled lectins.  
By combining Raman spectra with SERS detection of nanotags, 3D volume mapping of a cell 
can give detailed cellular localisation information of nanoparticle uptake. Multiplexed 
detection of a mixture of AgNPs with three different reporter molecules were observed 
within the cell volume, and showed that the AgNPs do not localise to the nucleus and are 
contained mainly in the cytoplasm.263 Triplex detection has also been carried out on chronic 
lymphocytic leukaemia cells to detect CD20, CD19, and CD45 on the cell surface.264 However, 
these mapping studies are not high throughput, with 3D volume maps taking between 3 and 
5 hours to analyse a single cell.263 
Flow cytometry is a standard high throughput biochemical analysis technique which uses 
fluorescently-labelled molecules for analysis of single cells. The broad spectral features of 
fluorophores limit the number of molecules which can be detected simultaneously. Many 
groups have adapted flow cytometers to be able to detect signals from SERS NPs, either by 
exchanging a fluorescent filter in the instrument with a narrow bandpass filter matching a 
peak in the SERS spectrum of the SERS reporter molecule,264 or enabling the detection of a 
full spectrum of the reporter with just 10 µs acquisition time by transmitting Raman scattered 
light through an optical fibre for dispersion by spectrograph onto a CCD.265 This ‘flow 
spectroscopy’ technique can detect single SERS NPs in order to determine interparticle signal 
variability within batches which are not detectable in bulk spectroscopic analysis or by 
analysis of a narrow spectral band.266,267 A microfluidic chip has also been used for the 
detection of SERS NPs on cells.268 In this study, cells were incubated with NPs against a 
cancer-specific protein target or a general cell targeting molecule in order to distinguish 
between cancer and normal cell populations. Cells were individually flowed through the 
device with an integration time of 5-8 ms, allowing the analysis of approximately 1700 events 
in an overall run time of 8 minutes. 
SERS techniques have also been used to examine the biochemical changes in cells caused by 
apoptosis. SERS NPs with different reporter molecules were conjugated with antibodies 
against either BAX or BAD, two pro-apoptotic members of the BCL-2 family of proteins, and 
used to stain mouse lung tissue.269 By mapping the distribution of the characteristic peaks for 
each reporter, colocalization of BAX and BAD were seen using a single tissue sample. Cellular 
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uptake of AuNPs labelled with nuclear localisation signal were used to monitor nuclear 
changes in response to apoptosis.  SERS signals increased over the course of progression of 
apoptosis, with the distribution of signal becoming more widespread throughout the cell as 
the nucleus fragmented.270 Silicon wafers decorated with AgNPs have also been used to 
monitor the nuclear changes in cells grown on the wafer after exposure to an apoptotic 
stimulus. The SERS signal intensity of the 788 cm−1 DNA peak increased up to 24-hours post-
incubation with low concentrations of Triton X-100, indicting nuclear condensation. 
Fragmentation and internucleosomal cleavage was then seen by the decrease in SERS signal 
at 48 and 72-hour time points.271 AgNPs have also been formed in situ on apoptotic cells using 
negatively-charged PS as the nucleation centre for Ag+ reduction. Cells treated with 
staurosporine showed formation of AgNPs on the membrane surface and generation of SERS 
signals from membrane components such as proteins and lipids.272 A combination SERS-
fluorescence resonance energy transfer (SERS-FRET) assay making use of the quenching 
effect of AuNPs has been used to quantitatively detect cytochrome c release in apoptotic 
cells, with accuracy similar to ELISA.273 
1.5.1.2 In vivo biochemical sensing 
SERS can also be used for in vivo biochemical sensing. The biodistribution of NPs is dependent 
on the NP size, charge, and hydrophobicity. Smaller NPs show increased permeability and 
diffusion coefficients through tissue than larger particles.274 15 nm AuNPs have been found 
to traverse the blood brain barrier after intravenous injection,275 and were also found in the 
lungs and circulation. Increasing the particle size reduces the accumulation of NPs in lungs, 
brain, and blood and increases the distribution in sites such as liver and spleen.275 Studies of 
biodistribution of NPs after intravenous injection has found that that particles are rapidly 
taken up by cells of the reticuloendothelial system (RES) and can be found in Kupffer cells 
and macrophages in the spleen.276 Alteration of the nanoparticle surface by coating with 
hydrophilic polymers such as polyvinylpyrrolidone (PVP)276 or polyethylene glycol (PEG)277 
results in reduced uptake by the RES and longer half-life in circulation. 
Multiplexed detection of SERS NPs has been shown in in vivo systems. The accumulation of a 
mixture of four different non-targeted nanotags in the liver of mice was detected, with a 
correlation observed between the concentration of each reporter and the signal obtained.278 
Targeting of SERS NPs has also been achieved, where AuNPs conjugated with anti-EGFR 
antibody localised to an oral squamous cell carcinoma in a mouse xenograft model after 
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intravenous injection; AuNPs without the targeting antibody were only detected in the 
liver.279 The signal was stably detected in the tumour up to 8 days post-injection, whereas 
the signal in the liver was cleared after 48 hours. Targeted detection of three nanotags in a 
breast cancer xenograft in mice has also been successful.280 Multi-modal NPs have also been 
used in vivo. Lanthanide-based upconversion fluorescent nanoparticles conjugated with SERS 
AgNPs subcutaneously injected into mice could be detected using both fluorescence and 
SERS.281  
These multiplexed detection experiments require high-resolution maps of the target area, 
which can take many hours and is not suitable for clinical applications. One group has 
developed a widefield imaging system using bandpass filters at varying angles, which changes 
the centre wavelength of transmission to correspond to a particular peak in a reporter 
molecule.282 This system has a spatial resolution of 50 µm and 1 cm2 illumination spot, for an 
acquisition time of less than 5 seconds per bandpass image using 785 nm laser excitation at 
a power within the American National Standards Institute (ANSI) exposure limit for skin and 
tissue penetration depth of 5 mm. Using this system, a mixture of four SERS nanotags injected 
subcutaneously into mice was deconvoluted, with a linear response achieved between each 
tags concentration in the mixture and the signal intensity of a characteristic peak of the 
nanotag (Figure 1.8).282 A fibre-optic device has been designed for the acquisition of SERS 
spectra during endoscopy. The fibre bundle can fit through the instrument channel of a 
clinical endoscope and detect Raman signals with working distances of 1-10 mm.283 
Multiplexed detection of four nanotags was achieved with this system after topical 
application to ex vivo human colon tissue with 300 ms integration time. The device has been 
further adapted to allow signal detection by circumferential scanning, scanning the entire 
area of 2 feet of colon in just 10 minutes which can be carried out in parallel with the white 




Figure 1.8: Multiplexed in vivo delineation of SERS nanotags using a widefield imaging 
technique. A single injection site into a mouse (A) was used, containing four different 
reporters (B-E) was used, and the detection algorithm could distinguish between each 
reporter and a linear response was observed between concentration and signal intensity of 
a characteristic peak of the reporter molecule (F). Image reproduced from P. Z. Mcveigh, R. 
J. Mallia, I. Veilleux and B. C. Wilson, J. Biomed. Opt., 2013, 18, 046011. 
Although SERS AuNPs and AgNPs show little cytotoxicity, and the biocompatible coatings 
used prevent leaching of the reporter molecules from the NP surface, FDA approval is 
required before SERS NPs can be injected and studied in human trials. 
1.6 Aims 
It is well established that certain cancer types, such as Burkitt’s lymphoma (BL), have high 
rates of ‘constitutive’ apoptosis occurring within the growing tumour before any cytotoxic 
treatment is administered. In these tumours, apoptosis is correlated with poor prognosis, as 
the tumours also display rapid proliferation and pro-tumour survival pathways. It is also 
known that, while EVs are released from all cells to varying extents depending on disease 
status or conditions of environmental stress, apoptotic cells can release more EVs and larger 
EVs than their viable counterparts which may contribute to the conditioning of the tumour 
microenvironment to promote tumour growth and survival mechanisms. 
The central hypothesis of this work is that comparison of Raman spectral data obtained from 
EVs derived from apoptotic and control BL cells could be used as a label-free technique to 
determine whether there are biochemical differences between cargo of apoEVs and EVs 
which are not derived from apoptotic cells which could underlie distinct functional 
behaviours for these particles. 
Sensitive analyte detection can be achieved using SERS, which can also identify 
subpopulations within a sample by using targeting molecules attached to the surface of the 
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SERS nanoparticles. In order to identify targets for the preferential detection of lymphoma-
derived EVs over those derived from healthy B cells, gene expression profile data will be used. 
This is an unbiased, bioinformatic method to identify genes which are upregulated in 
lymphoma samples when compared to normal B cell counterparts, with the hypothesis that 
genes which are overexpressed in lymphoma would be suitable targets for the preferential 
detection of lymphoma-derived EVs in the peripheral blood of patients. Proteomic analysis 
of BL apoEVs and viable EVs will also be used to identify potential targets which can 




2 Materials and Methods 
A full list of consumables and equipment used can be found at the end of the chapter (Section 
2.11). 
2.1 Cell line maintenance 
All cell lines were kept at 37°C in 5% CO2 humidified atmosphere. 
2.1.1 BL2 and BL2-bcl2 
BL2 and the apoptosis-resistant stable transfection of BL2 cells with BCL2285 (BL2-bcl2) cell 
lines were grown in serum-free conditions, using a 1:1 mixture of RPMI 1640 and X-VIVO 
20.286 Cells were kept at a density below 1 x 106 mL−1 by passaging with fresh medium every 
2-3 days. 
2.1.2 HeLa 
HeLa cells were grown in 75 cm2 tissue culture flasks in Minimum Essential Medium Eagle 
(MEM) supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine, 100 U/mL 
penicillin, 100 µg/mL streptomycin, and 1% non-essential amino acids (100 X). When cells 
reached 80% confluency, the culture medium was removed, and the monolayer was washed 
with 20 mL Hank’s balanced salt solution (HBSS) without calcium or magnesium. 5 mL of 
0.05% trypsin/EDTA was added and incubated at room temperature for 1 minute, then the 
excess trypsin/EDTA was removed and the flask incubated at 37°C for 5 minutes or until the 
cells had detached from the culture flask. 6 mL of culture medium was then added to 
neutralise the trypsin. 1 mL of this cell suspension was added to a fresh 75 cm2 tissue culture 
flask and 20 mL of culture medium added. 
2.2 Bioinformatic analysis of gene expression profiles 
2.2.1 Selection of datasets 
Gene expression microarray datasets were downloaded from the online database Gene 
Expression Omnibus (GEO; http://www.ncbi.nlm.nih.gov/geo/). The database was accessed 
in February 2015. The datasets chosen were all from human samples and had all been carried 
out on the Affymetrix Human Genome U133 Plus 2.0 Array chip (Platform GPL570). 
B cell samples were found by searching GEO Datasets for the term “healthy B cells”. Data 
series were examined to find experiments which had used untreated B cell samples from 
healthy donors, and these CEL files were downloaded. The combined files contained samples 
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from peripheral blood mononuclear cells in which the B cells had not been isolated, as well 
as B cells which had been isolated based on specific cell surface antigens (e.g. CD19+ CD27+; 
CD20+ CD10- CD27+) and samples derived from tonsillar tissue and bone marrow. 
Lymphoma samples were found by searching for “Burkitt lymphoma” or “non-Hodgkin 
lymphoma” and choosing samples from untreated cell lines or from fresh biopsy tissue. 
2.2.2 Data pre-processing 
The downloaded CEL files were combined into one folder for data pre-processing in the R 
environment (version 3.1.2) using packages from BioConductor version 3.0 
(http://www.bioconductor.org).  
The arrayQualityMetrics package287 (version 3.22.1) was used to quality control the raw data. 
Samples were assessed for outliers using six different outlier detection metrics: distances 
between arrays, boxplots, relative log expression, normalised unscaled standard error, MA 
plots, and spatial distribution of M. If any sample was identified as an outlier by more than 
one metric, this sample was not used in further analysis. The data were normalised using the 
fRMA package288 (version 1.18.0). The samples were annotated with Probe ID, Entrez ID, and 
HGNC symbol using hgu133plus2.db Affymetrix Human Genome U133 Plus 2.0 Array 
annotation data (version 3.0.0). The data were arranged into a table such that each row 
corresponded to a single probe sequence from the array, and the columns represented the 
expression levels of each probe sequence in a particular sample. The annotation data were 
used to generate a unique identifier for each row by concatenating the Probe ID, Entrez ID, 
and HGNC symbol. 
2.2.3 Network generation and analysis 
The expression table was imported into BioLayout Express3D Version 3.3.289,290 The Pearson 
correlation was set to 0.85 and Markov Cluster (MCL) analysis carried out with an inflation 
value of 2.2. This generated a 3D network graph consisting of over 1200 clusters. The mean 
expression pattern for each cluster was viewed, with the sample information available as 
coloured blocks annotating each sample. The expression levels of the genes for healthy B cell 
data, which were grouped together, was visually compared to the expression level in the 
lymphoma samples. When the expression level was considered to be higher in the lymphoma 
samples, the genes in that cluster were investigated for cellular localisation. Gene products 
that showed localisation to the plasma membrane were investigated further, cross-
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referencing against gene expression profile data for the BL2 cell line which had been 
generated previously in the group (unpublished data), and a brief literature review of the 
protein function was carried out to determine whether the protein localised to the cortical 
membrane or had an external portion which could be used as an imaging target. 
2.3 EV generation and separation 
Extracellular vesicles (EVs) were generated from BL2 cells, BL2-bcl2 cells, and HeLa cells. BL2 
cells and BL2-bcl2 cells were both UV-irradiated to generate apoptotic cell derived EVs 
(apoEVs) and EVs, respectively. For HeLa cells, apoEVs were generated from UV-irradiated 
cells and EVs were separated from HeLa cells under the same conditions but with no 
exposure to UV-B radiation. 
2.3.1 Induction of apoptosis in cells 
2.3.1.1 UV treatment of BL2 and BL2-bcl2 cells 
BL2 and BL2-bcl2 cells were taken from culture and centrifuged at 300 g for 5 minutes at 
room temperature. The cells were resuspended in a small amount of 0.1 µm filtered RPMI/X-
VIVO culture medium. 10 µL of this cell suspension was diluted with 990 µL of 0.1 µm filtered 
RPMI/X-VIVO and counted by flow cytometry. The acquisition volume was set to 150 µL with 
a flow rate of 100 µL per minute. 50 µL of the suspension was allowed to run through the 
cytometer before data was recorded. 10,000 events were recorded in the cell gate, and the 
concentration of cells (events/µL) in the viable cell gate was used to calculate the number of 
viable cells in the sample. The cell suspensions were then diluted accordingly to give a final 
density of cells of 20 x 106 mL−1. The cell suspension was then placed in either a 25 cm2 tissue 
culture flask (12.5 mL) or in the well of a 12-well tissue culture plate (1.5 mL per well). The 
cells were then exposed to 300 mJ/cm2 UVB radiation in the form of six 50 mJ/cm2 doses, 
with swirling of the flask between each exposure. The flasks were then incubated at 37°C in 
a humidified atmosphere with 5% CO2 and progression of apoptosis was monitored every 
hour by dual staining samples with Annexin V (AxV) and Sytox Blue (SB) (2.5.1). 
2.3.1.2 UV treatment of HeLa cells 
1.5 x 106 mL−1 HeLa cells were seeded in a 25 cm2 tissue culture flask in 5 mL of HeLa culture 
medium and incubated for 24 hours. Each flask was washed with 5 mL of 0.1 µm filtered HBSS 
before adding 5 mL of 0.1 µm filtered HeLa culture medium, made up without any FCS. Flasks 
were exposed to a single dose of 600 mJ/cm2 UVB radiation. Control cells were seeded in the 
same manner but not exposed to UVB. The flasks were then incubated at 37°C in a humidified 
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atmosphere with 5% CO2. The progress of apoptosis was not monitored, as the dose of UVB 
and appropriate incubation time to achieve apoptosis was optimised as described in Section 
2.3.1.2.1 
2.3.1.2.1 IncuCyte analysis of apoptosis progression in HeLa cells after UVB irradiation 
HeLa cells were seeded in 100 µL of complete HeLa medium at 6000 cells per well in a 96-
well tissue culture plate overnight. The culture medium was then removed and replaced with 
100 µL of fresh medium. Each 96-well plate was exposed to a different dose of UVB radiation 
(0 mJ/cm2, 450 mJ/cm2, 600 mJ/cm2, and 900 mJ/cm2). After irradiation, 50 µL of the culture 
medium was removed and replaced with a 2x concentration of fluorescent reagents for 
measuring apoptosis (15 µM CellEvent, 6 µM DRAQ7). The plates were then placed into the 
tray of an IncuCyte ZOOM imaging plate reader. Plates were imaged using a 10x objective, 
with 4 images per well taken every hour for 17 hours using phase contrast, red fluorescent 
channel (DRAQ7) and green fluorescent channel (CellEvent). Three wells were imaged for 
each UVB dose, one well containing both CellEvent and DRAQ7, one well containing DRAQ7 
only (as a control for the DMSO solvent for the CellEvent stock solution), and one well 
containing no fluorescent reagents. The number of fluorescent events was calculated using 
the IncuCyte ZOOM 2016B software. The number of green events per well was used to 
indicate CellEvent positive apoptotic cells, red events indicates DRAQ7 positive cells which 
are necrotic, and the number of cells showing overlap of green and red giving the dual 
positive cells which are secondarily necrotic. 
To calculate the percentage apoptotic cells, the phase contrast images were used to count 
the total number of cells imaged using the Cell Counter plugin for ImageJ (version 1.51k). The 
number of red/green events per image was multiplied by 4 to find the total number of 
fluorescent events identified in the four acquired images. The percentage of CellEvent or 
DRAQ7 positive events was calculated as the total number of events divided by number of 
cells. The percentage viable (unstained) cells was calculated as 100-[(% CellEvent positive) + 
(% DRAQ7 positive) – (% Overlap)]. 
In order to find the optimum UV dose and incubation time, the ratio of CellEvent-positive 
events to DRAQ7-positive events was used to find the sample which had the highest number 
of apoptotic cells with the least amount of secondary necrosis. 
2.3.2 Separation procedure for EVs 
EVs were separated from cells which had been UVB-irradiated (Sections 2.3.1.1 and 2.3.1.2). 
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2.3.2.1 BL2 and BL2-bcl2 
When the UVB-irradiated BL2 cells had reached approximately 70% AxV+ SB- as measured by 
flow cytometry dual staining (typically 5-6 hours post-UVB), the process of EV separation was 
initiated. 
2 mL of the cell suspension was made up to 5 mL with 0.1 µm filtered PBS and centrifuged at 
25 g for 60 minutes at 4°C in a 15 mL tube to remove the cells from the suspension. The top 
4 mL of supernatant was removed and passed through a 5 µm mesh filter under gravity. This 
filtrate was then passed through a 1.2 µm syringe filter, where the plunger of the syringe had 
been removed to allow the suspension to filter under gravitational pressure. This 1.2 µm 
filtrate was used as the final EV suspension. 
Where necessary, EVs in this 1.2 µm filtrate were pelleted by centrifugation at 20,000 g at 
4°C for 60 minutes and resuspended in 0.1 µm filtered PBS. 
2.3.2.2 HeLa 
For the study of the kinetics of EV release from HeLa cells, cells were seeded and irradiated 
as described in Section 2.3.1.2. Six 25 cm2 tissue culture flasks were irradiated, and six flasks 
were used as non-irradiated controls. At two-hour time points, beginning immediately after 
irradiation, both an irradiated and non-irradiated culture flask were removed from the 
incubator, the contents of the flask were swirled and the entire culture supernatant (5 mL) 
was removed. This supernatant was centrifuged at 250 g for 5 minutes to remove any cells 
which had detached from the culture flask. The supernatant was then filtered through a 5 
µm mesh filter under gravity, and then a 1.2 µm syringe filter under gravity, as described in 
Section 2.3.2.1. 
For comparison of UVHeLa EV and HeLa EV, the 1.2 µm filtrate of the 8-hour post-UV HeLa 
and UVHeLa samples was used. Where necessary, EVs in this 1.2 µm filtrate were pelleted by 
centrifugation at 20,000 g at 4°C for 60 minutes and resuspended in 0.1 µm filtered PBS. 
2.3.3 Characterisation of EVs 
The number of EVs present in each sample and the size profile of the EVs was determine by 
nanoparticle tracking analysis (NTA) using a NanoSight. 
2.3.3.1 NanoSight analysis 
EVs, as 1.2 µm filtrate or as resuspended 20,000 g pellet, were diluted 1 in 5 with 0.1 µm 
filtered PBS. The sample was loaded into the chamber of the NanoSight using a 1 mL syringe. 
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The camera level was set to 14, the low particle threshold was set at zero and the high particle 
threshold was set to 1495, and the instrument was calibrated to 187 nm/pixel. For each 
sample, 3-5 60 second videos were recorded at a rate of 30 frames per second, with the 
sample in the chamber being advanced by depression of the syringe plunger between each 
recording. For analysis of the videos, the detection threshold was set to 12 and the minimum 
expected particle size set to the minimum of 30 nm. 
If the total particle concentration of the sample was outside of the 108-109 range advised by 
the manufacturer, the dilution of the sample was adjusted accordingly, and the sample was 
analysed again. 
2.4 Western blot 
2.4.1.1 Cell lysis 
3x106 cells were pelleted and stored at -80°C. Samples were thawed on ice and lysed using 
50 µL of cell lysis buffer (10 mM HEPES, 1 mM EDTA, and 1% Triton X-100) with 3.3 µL of 
protease inhibitor cocktail for 30 minutes.291 The lysate was cleared by centrifugation at 
14,000 g for 10 minutes at 4°C and the supernatant retained. 
2.4.1.2 EV lysis 
50 x 108 EVs, as quantified by NTA (Section 2.3.3.1), were pelleted by centrifugation at 20,000 
g at 4°C for 60 minutes, and stored at -80°C. Samples were thawed on ice and lysed using 60 
µL of cell lysis buffer with 6 µL of protease inhibitor cocktail for 20 minutes before syringing 
ten times with a 23G needle and syringe. Samples were left for a further 30 minutes on ice.  
Lysates were not cleared. 
2.4.1.3 Bradford assay 
The concentration of protein in the cell lysates was determined using a Bradford’s protein 
assay.292 The cell lysates were diluted 1 in 30 with water. Human IgG was used as a standard. 
A stock solution of 1 mg/mL was used, and six serial dilutions were performed. 10 µL of each 
sample, including a control sample containing only water, was added to a well of a 96-well 
plate and 190 µL of Bradford reagent diluted 1 in 5 with water was then added. Each sample 
was set up in triplicate. The absorbance at 595 nm was acquired using a Varioskan Flash plate 
reader. The mean absorbance of each sample was calculated, the absorbance of the control 
sample was subtracted, and the human IgG sample absorbances were used to draw a 
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standard curve of protein concentration against absorbance. The equation of this line was 
used to calculate the protein concentration in the cell lysate. 
2.4.1.4 SDS-PAGE 
For cell lysate samples, 10 µg of protein was made up to 6.5 µL with water. To this, 1 µL of 
10x reducing agent and 2.5 µL of 4x sample buffer were added. 
For EV lysate samples, to each 60 µL of EV lysate, 9 µL of 10x reducing agent and 22 µL of 4x 
sample buffer were added. 
Samples were heated at 70°C for 10 minutes. 10 µL of cell lysate sample (10 µg protein) and 
40 µL of EV lysate (equivalent to 25 x 108 EVs) were loaded into the wells of a pre-cast 4-12% 
Bis-Tris, 1.5 mm, 10-well protein gel. Gels were run in MOPS running buffer with the addition 
of 0.5 mL of NuPage Antioxidant at a constant voltage of 170 V for 70 minutes. 
2.4.1.5 Protein transfer and membrane staining 
The SDS-PAGE gel was equilibrated in transfer buffer for 5-30 minutes, then transferred onto 
a polyvinylidene difluoride (PVDF) membrane which had been pre-wet with methanol and 
equilibrated for 10 minutes in transfer buffer with 10% methanol at a constant voltage of 30 
V for 90 minutes.291 The membrane was washed in water for 10 minutes, then PBS + 0.1% 
Tween 20 (PBST) for 10 minutes. The membrane was blocked with 5% goat serum in PBST for 
1 hour at room temperature, then incubated with 1-in-1000 dilution of primary antibody 
(anti-CD20 or anti-CD53) in 5 mL of 5% goat serum in PBS for 1 hour at room temperature, 
or at 4°C overnight. The membrane was washed with 5 mL of PBST three times for 10 minutes 
each, then incubated with a 1-in-5000 dilution of goat anti-mouse HRP secondary antibody 
in 5 mL of 5% goat serum in PBS for 1 hour at room temperature. The membrane was washed 
with 25 mL of PBST eight times for 10 minutes each, the developed with Amersham ECL Prime 
Western blotting detection reagent for 5 minutes. The membrane was then exposed to x-ray 
film in the dark and developed using Photon Imaging Systems Ecomax Automatic X-ray film 
processor. 
For detection of β-actin, the membrane was incubated with a 1-in-5000 dilution of mouse 
anti-β-actin primary antibody, washed, and incubated with secondary antibody as above. The 
membrane was developed with Pierce ECL Western blotting substrate, exposed to x-ray film 
for 30 seconds and developed as above.  
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2.5 Flow cytometry 
2.5.1 Cells – evaluation of apoptosis 
For cell suspensions at a density of 20 x 106 mL−1, 10 µL of cell suspension was diluted with 
90 µL of cold Annexin V binding buffer (AxVBB; 10 mM HEPES, 2.5 mM CaCl2, 140 mM NaCl, 
pH 7.4).293 For other suspensions, 0.2-0.3x106 cells were pelleted in a FACS tube, the 
supernatant was removed, and the cells resuspended in 100 µL AxVBB. 
1 µL of AxV488 was added to the tube and incubated for 15 minutes at 4°C in the dark. 400 
µL of AxVBB was then added, followed by 0.5 µL of Sytox Blue (SB), which was allowed to 
incubate with the cells for 1 minute before analysis. 
2.5.2 Cell phenotyping 
BL2 cells were taken from cell culture and counted using a haemocytometer. Enough 
quadrants were counted in order to ensure the total number of cells counted exceeded 100, 
and the count was carried out in duplicate. Cells were pelleted at 300 g for 5 minutes and 
resuspended in cold PBS with 5% goat serum at a density of 1 x 106 mL−1. 100 µL of this cell 
suspension was incubated in a FACS tube with the appropriate volume of antibody, or isotype 
control. Samples were incubated for 40 minutes at 4°C. The cells were washed three times 
with 3 mL of 5% goat serum in PBS, the cells were then resuspended in 500 µL of 5% goat 
serum in PBS and run on the flow cytometer with a stop point of 10,000 events recorded in 
the cell gate. 
2.5.3 EV phenotyping 
2.5.3.1 EV staining 
80 µL of 1.2 µm EV filtrate, generated as described in Section 2.3.2.1, was diluted with 20 µL 
of 0.1 µm filtered 5% goat serum in PBS, to give a final concentration of 1% goat serum. The 
appropriate volume of antibody or isotype control was added, and 0.1 µm filtered PBS to give 
a total sample volume of 120 µL. The samples were incubated for 30 minutes at 4°C. 1.2 µL 
of 10 µM ATTO390-maleimide membrane dye was added and the samples incubated for a 
further 15 minutes at 4°C. 880 µL of 0.1 µm filtered PBS was then added. A no EV diluent 
control was made by adding 400 µL of RPMI/X-VIVO to 1.6 mL of PBS and 400 µL of 5% goat 
serum in PBS (all 0.1 µm filtered). The appropriate volume of ATTO390-maleimide dye or 
antibodies were added to 100 µL of this diluent and made up to 1 mL with 0.1 µm filtered 
PBS and analysed on the flow cytometer to optimise the settings as no EV controls. 
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2.5.3.2 Instrument set-up and EV analysis 
For the flow cytometric analysis of EVs, the side scatter (SSC) filter of the instrument, an OD2-
488/10 single-pass bandpass filter off of the 488 nm laser, was replaced with a custom filter 
which had a lower OD to allow more SSC light to pass through, making the instrument more 
sensitive in order to detect the small EVs. Fluorescence thresholding using the ATTO390-
maleimide membrane dye (VL1 channel) was employed to further increase the sensitivity of 
detection for small particles. The acquisition volume was set to 500 µL, and flow rate was set 
to 12.5 µL/minute. Plots of SSC-H vs VL1-H and SSC-H vs FSC-H with axes set to log scale were 
used to detect EVs. 0.1 µm-filtered PBS was run in order to optimise the voltage settings. The 
VL1 threshold was adjusted so that background events were just visible in the SSC-H vs VL1-
H plot with an event rate of 1-10 per second. The SSC voltage was adjusted to 50-500, and 
the FSC voltage set to 10,000. Unstained EVs were used to adjust the fluorescent voltages, 
so that the unstained particles had fluorescent values of 102-103. When samples were 
analysed, at least 25 µL of the sample was run through the cytometer before recording to 
allow the particles to focus. If the event rate was >500 events per second, the sample was 
diluted to achieve <500 events per second to avoid swarming artefacts. Samples were 
recorded with a time stop option of two minutes, to allow >10,000 events to be recorded. 
2.6 Raman spectroscopy of EVs and cells 
All Raman spectra were acquired using a Renishaw inVia spectrometer, with 532 nm laser 
excitation wavelength using a point illumination beam configuration, 2400 l/mm grating, slit 
opening of 65 µm, Renishaw CCD camera with dimension 1040x256 pixels, and 60x water 
immersion objective (NA 1.00). Samples were prepared and analysed on a CaF2 window 
under PBS. At least 200 µL of each sample was used in order to have enough liquid on the 1 
cm diameter CaF2 window for the focal length of the objective to be achieved. Non-adherent 
samples were attached to the surface of the CaF2 window using CellTak. 0.85 µL of 1 mg/mL 
Cell-Tak was diluted with 75 µL of 0.1 M NaCO3 buffer pH 8 and placed on the CaF2 window 
for at least 30 minutes. The CaF2 window was then washed with 2 x 100 µL sterile water and 
allowed to dry. 
2.6.1 Acquisition of Raman spectra from cells 
2.6.1.1 BL2 and BL2-bcl2 cells 
UV-treated BL2 and BL2-bcl2 cells were obtained from EV preparations as described in 
Sections 2.3.1.1 and 2.3.2.1. The remaining supernatant above the 25 g cell pellet was 
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removed and the cells were resuspended in PBS and fixed in 4% neutral buffered formalin 
(NBF) at a density of 1 x 106 mL−1 for 20 minutes at room temperature. The fixed cells were 
washed with PBS and resuspended in PBS at a density of 1 x 106 mL−1. 
Viable BL2 and BL2-bcl2 cells were taken directly from cell culture without any treatment. 
The viability was assessed by dual staining with AxV and SB as described in Section 2.5.1. The 
cells were fixed in the same manner as the UV-treated cells. 
100 µL of these fixed BL2 and BL2-bcl2 cell suspensions (1 x 105 cells) were incubated on a 
Cell-Tak coated CaF2 window for at least 1 hour in order to settle under gravity onto the Cell-
Tak coating and allow the cells to adhere to the surface. An additional 200-300 µL of PBS was 
then applied to the window. 
Viable and UV-treated BL2 and BL2-bcl2 cells were mapped in a single plane with a step size 
of 0.7 µm in both the x- and y-axis. Each spectrum of the map was acquired with an exposure 
time of 1 second and a laser power of approximately 35 mW with the spectrum centred at 
1250 cm−1. 10 cells were mapped for each experiment, and three independent experiments 
were carried out for a total of 30 cell maps for each condition. 
Each map was pre-processed using the Noise filter function on the WiRE 4.2 Renishaw 
software to remove the noise components from the acquired map spectra. 
2.6.1.2 HeLa and UVHeLa cells 
1 x 105 HeLa cells were seeded onto a CaF2 window which was placed in a 6-well tissue culture 
plate with 3 mL of complete HeLa culture medium for 48 hours. 
For viable HeLa cells, the cells were washed with 3 mL of PBS and fixed with 4% NBF for 20 
minutes. The cells were then washed with 2 x 3 mL of PBS. 
For UV-treated HeLa cells (UVHeLa), cells on the CaF2 window were washed with 3 mL of PBS 
before 3 mL of fresh culture medium was added. The cells were irradiated with one dose of 
600 mJ/cm2 of UVB radiation and incubated for 8 hours at 37°C in a 5% CO2 humidified 
atmosphere. The cells were then washed gently with 3 mL PBS and fixed with 4% NBF for 20 
minutes. The cells were then washed with 2 x 3 mL of PBS. 
HeLa and UVHeLa cells were Raman mapped in a single plane with a step size of 1 µm in both 
the x- and y-axis. Each spectrum of the map was acquired with an exposure time of 1 second 
and a laser power of approximately 35 mW with the spectrum centred at 1250 cm−1. 10 cells 
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were mapped for each experiment, and three independent experiments were carried out for 
a total of 30 cell maps for each condition. 
Each map was pre-processed using the Noise filter function on the WiRE 4.2 Renishaw 
software to remove the noise components from the acquired map spectra. 
2.6.2 Acquisition of Raman spectra from EVs 
EVs from UV-treated BL2 and BL2-bcl2 cells, and HeLa and UVHeLa cells were prepared as 
described in Section 2.3. EVs from each cell condition were analysed by the same method. 
200 µL of 1.2 µm filtrate EV suspension was incubated overnight at room temperature on the 
surface of a Cell-Tak coated CaF2 window. The bulk of the remaining liquid was removed from 
the CaF2 window with a pipette, and the window was washed gently with 2 x 100 µL of 0.1 
µm filtered PBS before adding 200-300 µL of PBS. EVs were visualised using the white light 
source of the spectrometer. Two spectra were acquired for each EV at different spectral 
regions, one centred at 1250 cm−1 and one centred at 2850 cm−1, with an exposure time of 
10 seconds at a laser power of approximately 35 mW. The spectra of 50 EVs were acquired 
for each sample, with three independent replicate experiments, for a total of 150 EV spectra 
per sample. 
2.6.3 Data-processing of Raman spectra 
All spectra were converted to .spc files using the Renishaw inVia software WiRE 4.1 for import 
into MATLAB for data processing and analysis. 
2.6.3.1 Data processing of Raman cell maps 
Non-cellular background spectra of the Raman maps were removed by thresholding on the 
Phe peak at 1004 cm−1 to create a mask of the area of the cell and removing the spectra 
outside of the cell mask. The mean and standard deviation (SD) of the remaining spectra were 
calculated and any spectra lying outside the range of ±1 SD from the mean were removed as 
a quality control step. The mean spectrum for each of these cell maps was then found. The 
mean cell spectra were baseline corrected using the baseline_correction function from the 
cluster-toolbox-v2.0 on https://github.com/Biospec which employs an asymmetric least 
squares algorithm. The data were then scaled so the peak with the highest intensity was 
given an arbitrary intensity value of 1, so the different spectra could be easily compared. The 
spectra were converted to the first derivative and principal component analysis (PCA) was 
carried out on the data. 
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2.6.3.2 Data processing of EV spectra 
The EV spectra were imported into MATLAB as spc files. These spectra were baseline 
corrected using the baseline_correction function from the cluster-toolbox-v2.0 on 
https://github.com/Biospec, which employs an asymmetric least squares algorithm. The data 
were then scaled so the peak with the highest intensity had an arbitrary intensity value of 1, 
so the different spectra could be easily compared. The spectra were converted to the first-
order derivative and principal component analysis (PCA) was carried out on the data. 
2.7 Synthesis of nanoparticles for surface enhanced Raman spectroscopy 
2.7.1 Gold nanoparticle synthesis 
Gold nanoparticles (AuNPs) were prepared using a modified version of the Turkevich, 
Stevenson, and Hillier citrate reduction method for preparation of gold colloid.294 
All glassware was thoroughly cleaned and soaked overnight in aqua regia (3:1 v/v HCl:HNO3). 
The clean glassware was rinsed with water until the washings were of neutral pH. 60.5 mg of 
sodium tetrachloroaurate was dissolved in 500 mL of deionised water and brought to boiling 
point with continuous stirring. A solution of 57.5 mg sodium citrate dissolved in 7.5 mL of 
deionised water was added rapidly and the solution was boiled for 15 minutes. The solution 
was cooled with stirring, and the AuNPs were analysed for LSPR by UV-vis spectrometry and 
for size and zeta potential using a Malvern Zetasizer. 
2.7.2 Functionalisation of AuNPs with Raman reporter 
A 100 mM stock solution of malachite green isothiocyanate (MGITC) was prepared in 
deionised water. 1 mL of AuNPs (0.2 nM) was placed in a 1.5 mL Eppendorf tube with the 
appropriate volume of MGITC stock to yield final MGITC concentrations ranging from 0.1-1 
mM. The tube was placed on a shaker for 30 minutes, then the AuNPs were pelleted by 
centrifugation at 2320 g for 20 minutes. The supernatant was carefully removed and the 
AuNP pellet was resuspended in 1 mL of water. 
2.7.3 Conjugation of antibodies to nanoparticles 
A 1 mg/mL stock solution of N-Hydroxysuccinimide (NHS), and a 1 mg/mL stock solution of 
1-ethyl-3-(3-dimethylaminopropyl) carbodiimide HCL (EDC) were made with deionised 
water. 74 µL of the EDC solution was added to 40 µL of 12.5 µM polyethylene glycol 
(CT(PEG)110, MW 5000) solution, or to 40 µL of 1mM CT(PEG)12 (MW 635). To 217 µL of NHS 
solution, 10 µL of anti-CD20 or anti-CD53 monoclonal antibody (mAb) (both at a 
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concentration of 1 mg/mL) was added. These NHS/mAb and EDC/PEG solutions were then 
combined in a 1.5 mL Eppendorf tube to which 709 µL of 10 mM HEPES buffer pH 7 was 
added and the solution was stirred overnight to generate PEG-functionalised mAb. 
The PEG-functionalised mAb was added to the MGITC-functionalised AuNP (Section 2.7.2) 
split across two 1.5 mL Eppendorf tubes and placed on a shaker for 2.5 hours. The AuNPs 
were pelleted by centrifugation at 2320 g for 20 minutes. The supernatant was carefully 
removed and the mAb- and MGITC-functionalised AuNP pellet was resuspended in either 1 
mL of water, for UV-Vis and Zetasizer analysis, or in 100 µL of 0.1% bovine serum albumin 
(BSA) in 10 mM phosphate buffer (PB; 7.54 mM sodium phosphate dibasic, 2.46 mM sodium 
phosphate monobasic) pH 7 for surface enhanced Raman spectroscopy (SERS). 
2.8 SERS of MGITC- and antibody-functionalised AuNPs 
2.8.1 SERS of functionalised AuNPs in solution 
The MGITC-AuNPs, as prepared by the method in Section 2.7.2, were placed in a clear glass 
vial. The SERS spectrum of each concentration of MGITC-AuNP was acquired using a Snowy 
Range Sierra spectrometer using a 785 nm laser excitation with 45 mW laser power and 
integration time of 1 second. 
2.8.2 SERS of MGITC-AuNPs on nitrocellulose 
10 µL of MGITC-AuNPs as prepared by the method in Section 2.7.2 were dropped onto raw 
nitrocellulose and allowed to dry. SERS measurements were acquired using a Renishaw inVia 
Raman microscope, with 785 nm diode laser excitation wavelength using the StreamLine line 
illumination beam configuration, 1200 l/mm grating, slit opening of 50 µm, Renishaw CCD 
camera with dimension 1040 x 256 pixels, and 20x objective (NA 0.4). Three replicate maps 
were acquired at different areas of the AuNP spot for each MGITC concentration, of size 200 
x 200 steps in x and y directions with 3.5 µm step size using 9 mW laser power with an 
integration time of 2 seconds. Maps were pre-processed using the cosmic ray removal wizard 
in WiRE version 4.4 and converted to spc files using WiRE version 4.1. The spc files were 
imported into MATLAB and the mean spectrum for each of the three maps was calculated 
individually, and the mean of these three mean spectra was then calculated as the 
representative SERS spectrum for that concentration of MGITC-functionalised AuNPs. 
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2.9 SERS MGITC-AuNP detection of biological samples 
All SERS spectra of biological samples on nitrocellulose were acquired as StreamLine maps 
on the Renishaw inVia configured as described in Section 2.8.2. For the biological samples, 
the map size was 500 x 500 steps in the x and y direction with a step size of 3.5 µm. Spectra 
were acquired with 785 nm laser excitation using 9 mW laser power with an integration time 
of 2 seconds. 
2.9.1 SERS measurements of cells 
8.5 mL of BL2 cell suspension was taken directly from culture, pelleted at 300 g for 5 minutes, 
resuspended in 8.5 mL of PBS and counted using a haemocytometer. 4 quadrants were 
counted in order to ensure the total number of cells counted exceeded 100, and the count 
was carried out in duplicate. The BL2 cells were pelleted again and resuspended in PBS at a 
cell concentration of 10 x 106 mL−1. The sample was further diluted so that six solutions with 
BL2 cell concentrations of 10 x 106 mL−1, 9 x 106 mL−1, 8 x 106 mL−1, 7 x 106 mL−1, 6 x 106 mL−1, 
and 5 x 106 mL−1 were obtained. 1 µL of these cell solutions were spotted onto 1 cm x 1cm 
squares of raw nitrocellulose, with care being taken not to touch the tip of the pipette to the 
nitrocellulose, and the edges of the spot were marked with a pencil. When the nitrocellulose 
squares were dry, each was placed into the well of a 24-well tissue culture plate and blocked 
with 5% BSA in phosphate buffer (PB) for 1 hour at room temperature. 20 µL of anti-CD20 
conjugated MGITC AuNP (0.84 nM), prepared as described in Section 2.7.3, was added to the 
nitrocellulose with 150 µL of 0.1% BSA/0.05% Tween 20 in 10 mM PB (BSA/PBT) and the 
samples were placed on a shaker for 1 hour at room temperature. The nitrocellulose squares 
were then washed with three 500 µL aliquots of BSA/PBT for 5 minutes each. SERS maps of 
the samples were then acquired as described in Section 2.9, with the area at the centre of 
the pencil marks chosen for analysis if there was not a visible AuNP spot. Maps were pre-
processed using the cosmic ray removal wizard in WiRE version 4.4 and converted to .spc files 
using WiRE version 4.1. The .spc files were imported into MATLAB. The peak intensity at 1171 
cm−1 was used to identify the presence of MGITC AuNPs, and to remove any false positive 
results due to high background, a signal-to-baseline peak intensity was generated by 
subtracting the intensity at 1140 cm−1 from the peak intensity at 1171 cm−1. A false-coloured 
map was generated of this signal and the thresh_tool function was then used to generate a 
mask of the false-coloured map keeping only the pixels with an intensity value of greater 
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than 100. The number of pixels in this mask was used as a measure of the number of MGITC 
AuNPs bound on the sample. 
2.9.2 SERS measurements of EVs 
BL2 and BL2-bcl2 EVs were prepared as described in Section 2.3.2.1. Two 500 µL aliquots of 
1.2 µm EV filtrate were pelleted at 20,000 g for 1 hour at 4°C. One pellet was resuspended in 
1 mL of 0.1 µm filtered PBS and the concentration of EVs were quantified on the NanoSight 
as described in Section 2.3.3.1. The other EV pellet was resuspended in 100 µL of 0.1 µm 
filtered PBS and the concentration of EVs in this suspension was assumed to be 10x that 
found in the 1 mL suspension. If the EV concentration was >40x108 mL−1 then the sample was 
diluted to this concentration. If the EV concentration in the sample was <40x108 mL−1 then 
the sample was diluted to either 20x108 mL−1 or 10x108 mL−1, as appropriate. Four EV 
suspension concentrations were investigated: 40x108 mL−1, 20x108 mL−1, 10x108 mL−1, and 
5x108 mL−1. 1 µL of EV suspension (multiple 1 µL drops where necessary to reach desired EV 
concentration) was placed onto 1 cm x 1cm squares of raw nitrocellulose, with care being 
taken not to touch the tip of the pipette to the nitrocellulose, and the edges of the spot were 
marked with pencil. When the nitrocellulose squares were dry, each was placed into the well 
of a 24-well tissue culture plate and blocked with 5% BSA in PB for 1 hour at room 
temperature. 20 µL of either anti-CD20 (0.84 nM) or anti-CD53 (0.81 nM) conjugated MGITC 
AuNP, prepared as described in Section 2.7.3, were added to the nitrocellulose with 150 µL 
of BSA/PBT and the samples were placed on a shaker for 1 hour at room temperature. The 
nitrocellulose squares were then washed with three 500 µL aliquots of BSA/PBT for 5 minutes 
each. SERS maps of the samples were then acquired as described in Section 2.9, with the area 
at the centre of the pencil marks chosen for analysis if there was not a visible AuNP spot. 
Maps were pre-processed using the cosmic ray removal wizard in WiRE version 4.4 and 
converted to spc files using WiRE version 4.1. The spc files were imported into MATLAB. The 
peak intensity at 1171 cm−1 was used to identify the presence of MGITC AuNPs, and to 
remove any false positive results due to high background, a signal-to-baseline peak intensity 
was generated by subtracting the intensity at 1140 cm−1 from the peak intensity at 1171 cm−1. 
A false-coloured map was generated of this signal and the thresh_tool function was then used 
to generate a mask of the false-coloured map keeping only the pixels with an intensity value 
of greater than 100. The number of pixels in this mask was used as a measure of the number 
of MGITC AuNPs bound on the sample. This experiment was carried out in triplicate, with 
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three independent EV preparations and the mean and standard deviation pixel number for 
each EV concentration was calculated. A control where no EVs were spotted on the 
nitrocellulose was also carried out, to identify background binding level of AuNP to 
nitrocellulose. 
2.10 Chemicals and reagents 
Reagent Supplier Catalogue number 
1-Ethyl-3-(3-dimethylaminopropyl) 
carbodiimide HCL (Pierce) 
ThermoFisher Scientific 22980 
Amersham ECL Prime Western blotting 
reagent 




Amersham Hybond blotting paper GE Healthcare RPN6101M 
Amersham Hybond P 0.45 PVDF 
Blotting Membrane 
GE Healthcare 10600023 
Amersham Hyperfilm ECL GE Healthcare 28906837 
Annexin V, Alexa Fluor 488 conjugate Life Technologies 
(ThermoFisher) 
A13201 
ATTO390-maleimide ATTO-TEC GmbH, 
Siegen, Germany 
AD 390-41 





Bradford reagent BioRad, Hercules, 
CA,USA 
500-0006 
Calcium chloride Sigma Aldrich, Poole, UK C4901-100G 
CellEvent Caspase 3/7 2 mM in DMSO Life Technologies 
(ThermoFisher) 
C10423 
Corning Cell-Tak ThermoFisher Scientific CB-40240 
CT(PEG)12 Carboxy-PEG-Thiol ThermoFisher Scientific 26133 
DRAQ7 0.3 mM abcam, Cambridge, UK ab109202 
Dulbecco’s Phosphate buffered saline Gibco, Paisley, UK 14190-094 





FCS-SA Biotech Lot 30401 
Goat serum Biosera, Ringmer, UK GO-605/500 (Lot 
10075) 
Hank’s Balanced Salt Solution Gibco 14175-053 
HEPES Sigma Aldrich H4034-100G 
L-Glutamine 200 mM (100 X) Gibco 25030-024 
Malachite green isothiocyanate ThermoFisher Scientific  
MEM NEAA (100 X) Gibco 11140050 
Methanol analytical grade ThermoFisher Scientific M/4000/17 
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Millex-VV Syringe Filter Unit 0.1 µm Merck Millipore, 
Hertfordshire, UK 
SLVV033RS 
Minimum Essential Medium Eagle Sigma Aldrich M2279-500ML 
N-Hydroxysuccinimide Sigma Aldrich 130672-5G 
Novex NuPAGE 4-12% Bis-Tris protein 
gels, 1.5 mm, 10-well 
Invitrogen, Paisley, UK NP0335BOX 
Novex NuPAGE MOPS SDS Running 









NuPAGE Antioxidant Invitrogen NP0005 
NuPAGE LDS Sample Buffer (4 X) Invitrogen NP0007 
NuPAGE Sample Reducing Agent (10 X) Invitrogen NP0009 
Pen/Strep Gibco 15140-122 
Pierce ECL Western blotting substrate ThermoFisher Scientific 32106 
pluriStrainer 5 µM pluriSelect 43-50005-01 
Poly(ethylene glycol) 2-mercaptoethyl 
ether acetic acid (average Mn 5000, 
n~110) 
Sigma Aldrich 757845-500MG 
Protease inhibitor cocktail Sigma Aldrich P8340 
Richard-Allan Scientific 10% Neutral 
buffered formalin 
ThermoFisher Scientific 9400-5 
RPMI 1640 Gibco 31870-025 
SeeBlue Plus2 Prestained Standard Invitrogen 1829199 
Sodium bicarbonate Honeywell S6014-500G 
Sodium chloride ThermoFisher Scientific S/3120/63 
Sodium citrate Sigma Aldrich  
Sodium phosphate dibasic ThermoFisher Scientific BP332-1 
Sodium phosphate monobasic ThermoFisher Scientific BP329-1 
Sodium tetrachloroaurate Sigma Aldrich  
Sterile Water for Irrigation Baxter, Zurich, 
Switzerland 
UKF7114 
SYTOX Blue dead cell stain Invitrogen S34857 
Triton X-100  Sigma 9002-93-1 
Trypsin-EDTA (0.05%), phenol red Gibco 25300054 
Tween 20 Sigma Aldrich P1379-250ML 
Whatman Protran BA 85 Nitrocellulose GE Healthcare 10 401 197 
Whatman Puradisc FP 30 Cellulose 
Acetate Syringe Filter 1.2 μm 
GE Healthcare  10462260 




2.11 Equipment and instrumentation 
2.11.1 UV-Vis  
Agilent Cary 60 UV-Vis Spectrophotometer, with Cary WinUV software.  
Spectral range recorded 400-800 nm 
2.11.2 DLS 
Malvern Zetasizer Nano ZS with Zetasizer µV and software APS 6.20, standard Malvern Dip 
Cell. 
2.11.3 Snowy 785 
Snowy Range Instruments, Sierra series reader, 785 nm excitation wavelength with 45 mW 
laser power 
2.11.4 InVia 
Renishaw InVia Raman microscope, WiRE software versions 4.1 and 4.4. 
2.11.4.1 Lasers 
785 nm diode laser, power at sample 175 mW 
532 nm diode laser, power at sample 74 mW 
2.11.4.2 InVia objectives 
60x water immersion objective – Olympus LUMPlanFL 60x/1.00 
20x – Leica N plan EP 20x/0.4 
Laser spot diameter = 1.22 λ / NA  
Diameter = (1.22)(532 nm) / 1 [60x] = 649 nm 
Diameter = (1.22)(785 nm) / 0.4 [20x] = 2394 nm 
2.11.5 MATLAB 
Version 2017a, The MathWorks, Natrick, MA, USA 
2.11.6 Flow cytometry 
Life Technologies Attune NxT acoustic focusing cytometer 
2.11.6.1 Custom SSC filter 
OD1-488/10 bandpass filter, Catalogue number LAS-026086, Laser 2000 Huntingdon, 
Cambridgeshire, UK 
2.11.7 Plate reader 




Malvern NanoSight NS14c/b 
2.11.9 UV light source 
UVP CL-1000 Ultraviolet Crosslinker 
2.11.10 IncuCyte 
Essen Bioscience IncuCyte ZOOM, IncuCyte ZOOM 2018A software, 10x Nikon objective, 
Dual Color Model 4459 filter 
2.11.11 ImageJ 
ImageJ 1.51k 
2.11.12 X-ray developer 
Photon Imaging Systems Ecomax Automatic X-ray film processor 
2.11.13 Centrifuge 
2.11.13.1 25 g spin 
Hettich Zentrifugen Rotina 420R 
2.11.13.2 20000g spin 
Hettich Zentrifugen Mikro 200R 
2.12 Tissue culture 
BD Plastipak syringes Various 
Corning 25 cm2 Cell Culture Flask Catalogue Number 430639 
Corning 75 cm2 Cell Culture Flask Catalogue Number 431464U 
Corning Costar 96 Well Cell Culture Cluster Flat Bottom 
with Low Evaporation Lid 
Catalogue Number 3595 
FACS tubes: Falcon 5 mL Polystyrene Round-Bottom Tube Catalogue number 352008 
Falcon 15 mL High-Clarity Polypropylene Conical Tube Catalogue Number 352096 
Falcon 50 mL Polypropylene Conical Tube Catalogue Number 352070 

























Mouse IgG2a E4.3 BD 
Pharmingen 
564252 50 µg/mL 
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Mouse IgG2a p282 BD Horizon 564329 100 µg/mL 
anti-human 
β-actin 





Goat  Polyclonal Sigma A3673-
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Mouse IgG1 X40 BD Horizon 562946 200 µg/mL 
Isotype 
control (PE) 
Mouse IgG2a G155-78 BD 
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3 Raman spectroscopy of cells and tumour cell-derived extracellular 
vesicles 
3.1 Introduction 
Many methods are currently used to analyse extracellular vesicles (EVs). Flow cytometry is 
often used, but the limit of spatial detection of these instruments is often 300 nm, 
overlapping with the size profile of EVs. Confocal imaging can be used, but the broad emission 
bands of fluorophores mean that a limited number of molecules can be investigated at any 
one time. 
3.1.1 Raman spectroscopy of EVs 
Raman spectroscopy, as it is inherently a label-free technique, has the potential to be a useful 
tool in the analysis of EVs. As the diameter of the laser is on the same order of magnitude as 
EVs, the entire particle can be analysed with a single point spectrum in order to analyse 
multiple biomolecules with a single measurement. However, to date only a limited number 
of studies have used Raman spectroscopy to explore the biochemistry of EVs. Initial studies 
examined synthetic lipid vesicles, and showed that Raman spectroscopy can be used to 
examine particles of this scale, and also that phase transitions of the vesicle membrane can 
be monitored.295 The eukaryotic cell model organism Dictyostelium discoideum constitutively 
release ‘nanovesicles’ during growth phase and under starvation conditions, and these have 
been analysed by Raman spectroscopy.296,297 Spectra of Dictyostelium discoideum EVs dried 
onto a CaF2 window were shown to contain many bands typically found in cells, such as the 
782 cm−1 nucleic acid peak, 1450 cm−1 CH2 vibration, amide I band at 1656 cm−1, and amide 
III band at 1257 cm−1.297 Some studies used laser trapping to capture EVs for Raman analysis. 
Differences in the spectra of EVs released during the growth phase and starvation conditions 
were observed.296  
EVs from cancer cell lines have also been differentiated from non-cancer derived EVs based 
on Raman spectral data.298 Amide I and amide III bands corresponding to α-helices were 
shifted and reduced in prostate cancer EV samples compared to benign prostate hyperplasia 
EVs, whereas the amide III 1240 cm−1 vibration corresponding to β-sheet conformation was 
increased in prostate cancer EVs. One drawback of Raman spectroscopy for the analysis of 
EVs is the long integration times needed to generate good signal-to-noise from the small 
particles. One study using laser tweezers Raman spectroscopy (LTRS) analysed each particle 
for a total of 5 minutes to generate spectral data.299 However, principal component analysis 
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(PCA) of the data was able to distinguish between microvesicles and exosomes separated 
from the same cancer cell line, further showing the potential for using Raman spectroscopy 
to distinguish between EV subpopulations. EVs derived from mesenchymal stromal cells 
(MSCs) have also been studied by Raman. MSC EVs from bone marrow and adipose tissue 
were distinguished based on their Raman spectra, and PCA combined with classical least 
squares (CLS) fitting showed that the difference between these populations was due to the 
different lipid moieties present.300 Raman spectroscopy could also be used as a rapid assay 
to determine purity of an EV sample, as EVs separated by methods with different efficiencies 
could be distinguished based on the higher signal to noise profiles of the higher purity 
samples.301 The more efficient separation methods also yielded Raman spectra with lower 
protein to lipid and nucleic acid to lipid ratios. Raman spectroscopy can also be used in 
conjunction with fluorescent microscopy, which showed that the CD9-positive population of 
EVs had lower Raman signals than the CD9-negative counterparts.302 This difference in signal 
intensity indicates that the CD9-positive population are smaller and less dense than the CD9-
negative EVs, and can be detected more easily in conjunction with a fluorescent assay. 
Thus, Raman spectroscopy has great potential to distinguish between subpopulations of EVs 
in a label-free manner. 
3.2 Aims of the chapter 
The aim of this chapter is to use Raman spectroscopy to investigate the changes in both 
tumour cells and EVs derived from the tumour cells after exposure to UVB radiation. 
The Burkitt’s lymphoma (BL) cell line BL2 was used since this cell line becomes apoptotic in 
response to UVB irradiation. The BL2-bcl2 transfectant cell line does not initiate cell death 
after an apoptotic stimulus such as UVB irradiation due to the expression of the anti-
apoptotic BCL2 gene.285 BCL-2 is a protein located in the membrane of mitochondria, and 
blocks cell death by preventing the formation of a mitochondrial pore and thus the release 
of cytochrome c. The BCL-2 protein was first discovered in B cell lymphoma, from which it 
derives its name, and is upregulated in a number of different lymphomas, however it is 
characteristically absent in BL. The BL2-bcl2 transfectant cell line was therefore generated as 
a non-apoptotic control for the BL2 line since, even when no stimulus is applied, BL2 cells 
have a level of constitutive apoptosis of approximately 10%. The BL2-bcl2 line has a higher 
level of viability, and when used as an experimental control, the same stimulus and 
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conditions can be applied to the BL2-bcl2 cells and these cells will remain viable and have a 
higher level of viability than untreated BL2 cells. 
HeLa cells were also used in the investigation as a cell line with a different lineage to that of 
the BL cells. A non-apoptotic genetic transfectant control for HeLa cells was not available as 
this line has a low level of constitutive apoptosis. For this cell line, the experimental control 
used was cells under the same conditions as the irradiated cells, but without exposure to 
UVB. 
When obtaining Raman spectral data for whole cells, the whole cell was mapped at high 
resolution, with 1 µm step sizes in both x and y directions. The cells were fixed with formalin 
and spectra were acquired with the cells in phosphate buffered saline (PBS). The non-cellular 
PBS background was removed, and the remaining spectra averaged to generate a single 
Raman spectrum representative of each cell in order to remove the intracellular variability. 
EVs were also separated from each of the different cell lines. The EVs from the UV-irradiated 
BL2 cells (apoEV) are a heterogeneous population, with EVs coming from both apoptotic cells 
and viable cells throughout the course of the incubation after the cells have been irradiated. 
However, the EVs from the BL2-bcl2 cells should be relatively homogenous as these cells do 
not undergo apoptosis and therefore will only release a single population of EVs. Raman 
spectroscopy was carried out on these EVs to ascertain if differences between EVs released 
from viable and apoptotic tumour cells could be observed spectroscopically using a label-free 
technique, combined with multivariate analysis. 
The Raman spectra of these EVs were acquired by attaching the EVs to the surface of a CaF2 
window. Because of the small size of EVs (<1.2 µm, mostly <500 nm), the entire EV could fit 
within the laser spot of the Raman microscope system, therefore only a single spectrum 
needed to be acquired for each EV. Therefore, the EVs characterised by Raman spectroscopy 
were limited to those which were large enough to be seen clearly under the white-light lamp 
of the microscope on the Raman spectrometer, meaning many of the smaller ‘exosome’-type 





3.3 Raman maps of whole cells 
3.3.1 Viable and apoptotic BL2 and BL2-bcl2 cells 
3.3.1.1 Induction of apoptosis and assessment of cellular viability 
BL2 cells and BL2-bcl2 cells at a density of 20x106 mL−1 were irradiated with 300 mJ/cm2 of 
UVB light and incubated at 37 °C for a period of 5-7 hours. A sample of cells was taken every 
hour to monitor the progression of apoptosis using flow cytometry by dual staining with 
Annexin V (AxV) and Sytox Blue (SB). AxV binds to phosphatidylserine (PS), which is a 
phospholipid normally localised to the cytosolic surface of the cell membrane. During 
apoptosis, PS is translocated to the outer surface of the membrane, where it is then free to 
bind AxV and is thus used as a marker of early apoptosis. SB is a membrane impermeable dye 
which is only fluorescent when bound to nucleic acids. During necrosis, the cell membrane 
loses its integrity, which allows SB to enter the cell and bind to DNA, becoming fluorescent. 
This dual staining technique identifies viable cells which are unstained (AxV- SB-), early 
apoptotic cells (AxV+ SB-), secondarily necrotic cells (AxV+ SB+), and necrotic cells (AxV- SB+). 
The progression of apoptosis of the UV-irradiated BL2 cells was used to determine the end 
point of the experiment (>70% AxV+ SB- with a minimal overall SB+ population). As shown in 
Figure 3.1A and Figure 3.1B, the population of AxV+ SB- BL2 cells (UVBL2) increases steadily 
over the course of the incubation. Immediately prior to UVB exposure the cells are 94% 
viable, not staining with either AxV or SB. The AxV+ population steadily increases at each 
timepoint post-irradiation, reaching 67% AxV+ SB- at the 6-hour post UV timepoint. The 
necrotic population does not increase, remaining at approximately 4% throughout the course 
of the experiment. The BL2-bcl2 cells remain >90% AxV- SB- over this time period 
(UVBL2bcl2). There is a slight increase in the population of apoptotic BL2-bcl2 cells after 
irradiation. This is most likely due to an incomplete transfection of the BCL2 gene, or varying 
levels of expression in the population causing some cells to be susceptible to apoptosis. 
The cells were isolated from the irradiated suspension after 5 hours, or when the cells 
reached at least 70% AxV+, by centrifugation at 25 g. The cell pellets were resuspended in a 
4% solution of neutral buffered formalin for 10-15 minutes at a concentration of 1x106 mL−1 
to fix the cells before Raman spectroscopy was carried out. Viable BL2 cells and BL2-bcl2 cells 
from culture, which were 90% and 93% AxV- SB-, respectively (Figure 3.2) were also fixed in 




Figure 3.1: Assessment of viability of BL2 cells (A) and BL2-bcl2 cells (B) after exposure to 300 
mJ/cm2 UVB radiation for Raman spectroscopy. Cells were irradiated at a concentration of 
20x106 mL−1 and incubated at 37 °C after UV exposure. Viability was assessed by dual staining 
with Annexin V (AxV) and Sytox Blue (SB), quantified by flow cytometry. Graph shows mean 
of 3 experiments, with the exception of BL2 6 hour post UV (2 experiments) and 7 hour (1 



















































Figure 3.2: Assessment of viability of BL2 and BL2-bcl2 cells from culture for Raman 
spectroscopy. Viability was assessed by dual staining with Annexin V (AxV) and Sytox Blue 
(SB), quantified by flow cytometry. Graph shows mean of 3 experiments. Error bars show one 
standard deviation. 
3.3.1.2 Raman spectroscopy of viable and apoptotic BL cells 
The fixed apoptotic and viable BL cells were then analysed by Raman spectroscopy to identify 
changes in the cells based on viability status. A CaF2 window was coated with Cell-Tak, a 
protein solution derived from marine mussels which allows cells and tissue sections to attach 
to surfaces. The cells to be analysed were applied in PBS to the window and allowed to settle 
under gravity in order to adhere to the window. Raman images of step size 0.7 µm of single 
cells were acquired using 532 nm excitation wavelength at 35 mW for 1 second acquisition 
time using a 60x water immersion objective. Three replicate experiments were carried out 
for each cell condition, with 10 cells mapped for each experiment, for a total of 30 cell maps 
per condition. The PBS background spectra were extracted from the cell spectra using 
MATLAB, and a mean spectrum for each cell generated. The spectra were baseline corrected 
and scaled so the highest intensity peak was scaled to unity. The mean spectra of the 30 cells 
for each condition is shown in Figure 3.3A and 3.3B, plotted with ± standard deviation (SD) 
shaded. The UVBL2 cells show higher intensities for a number of points in the spectrum, 
including 783 cm−1, 1004 cm−1, 1095 cm−1, 1255 cm−1, 1300-1320 cm−1, 1340 cm−1, and 1449 
cm−1. However, the SD of these peaks all overlap with those of the viable cells. The shoulders 
at 1606 cm−1 and 1620 cm−1, which have lower intensity in the UVBL2 cell spectrum, have a 
SD which does not overlap the SD of the other spectra, indicating that these peak changes 







AxV- SB- AxV+ SB-
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Figure 3.3C, where the UVBL2 cells can be seen to have a larger SD than the other cell 
conditions at a number of points, including those at 1004 cm−1, 1095cm−1, 1255cm−1, and 
1449cm−1. The SD at the other peaks in the spectrum are comparable for each condition. The 
larger variation in the UVBL2 is to be expected, as this cell population is more heterogeneous 
due to the application of UVB radiation and subsequent induction of apoptosis. The cells are 
undergoing programmed cell death in a relatively synchronous manner – as can be seen in 
the flow cytometry data (Figure 3.1) – and are mostly in early apoptosis (AxV+ SB-). However, 
the cells are not completely synchronised, and some may be further along in the apoptotic 
programme than others. As the BL2 cells are non-adherent, it is quite difficult to distinguish 
the viability of the cell by morphology alone. Thus, some of the cells analysed may be viable, 
and some may be secondarily necrotic. Similarly, for the non-apoptotic cell populations, the 
cells were not cell-cycle synchronised before analysis, so variation in the Raman spectra could 
be caused by differing cell-cycle stages, viability (as there is a low level of constitutive cell 
death in every cell population), and stress (as the UV-irradiated BL2-bcl2 cells were at quite 
a high cell density for irradiation which may have induced metabolic stress). 
The mean individual cell spectra were used to compare the conditions using the unsupervised 
multivariate analysis technique principal component analysis (PCA). PCA is a statistical 
method of data reduction which creates components which are orthogonal and have the 
maximum variability between them without any bias to the data groups. This makes it a 
useful method for reducing the dimensions of a Raman spectrum in a way that is easy to 
interpret back to the original spectrum in order to determine differences between groups of 
data. 
The baseline corrected spectra were converted to the first derivative for PCA, and the 
principal component (PC) scores plotted against each other. Figure 3.4A shows the score plot 
for PC1 vs PC2, where each data point represents the mean spectrum of a single cell. The 
apoptotic UVBL2 cells show some separation from the viable cell groups along PC1 axis, which 
corresponds to 24.7% of the total variance. The spectral loading of PC1 is shown in Figure 
3.4B. The main contributions to this PC are the phosphodiester peak at 785 cm−1,  the 





Figure 3.3: (A) The mean spectra of 30 cells for each condition, plotted offset with ± 1 SD 
(shaded) – viable BL2 cells (BL2), viable BL2-bcl2 cells (BL2bcl2), UV-irradiated BL2 cells 
(UVBL2) and UV-irradiated BL2-bcl2 cells (UVBL2bcl2). The spectra with SD are overlaid in (B), 
showing that the UVBL2 cells have higher intensity peaks at a number of points in the 
spectrum. The SD of the 30 spectra for each condition is plotted in (C). Data acquired with 







Figure 3.4: Principal component analysis (PCA) results of the first derivative Raman spectrum 
for the comparison of viable and apoptotic BL2 and BL2-bcl2 cells. (A) Plot of principal 
component (PC) scores PC1 vs PC2, showing a separation of the apoptotic UVBL2 cells from 
the rest of the viable cell populations along PC1. (B) Loading of PC1, showing the main peaks 
contributing to this PC are those at 785 cm−1, 1004 cm−1, and 1095 cm−1. 
Table 3.1: Peak assignments for PC1 loading 
Raman shift (cm−1) Assignment 
784 Phosphodiester; nucleic acid ring breathing 
1004 Phenylalanine 






The PC loading agrees with published literature, where the main changes in the spectra of 
apoptotic cells are seen in nucleic acid bands, such as the 784 cm−1 phosphodiester band and 
the 1095 cm−1 DNA band, due to the alterations of the nucleus during cell death. Some 
reports state that the nucleic acid peaks increase in intensity due to the nuclear condensation 
which causes a localised increase in nucleic acid concentration,205,234,240 while other reports 
state that the nucleic acid bands have reduced intensity due to nuclear fragmentation 
causing a decrease in DNA concentration.215,236 Based on the PC1 loading shown in Figure 
3.4B, and the mean cell spectra shown in Figure 3.1, it appears that in this study the nucleic 
acid bands have increased in intensity in the Raman spectra of the UVBL2 cells compared to 
the viable counterparts. This suggests that the cells are in early apoptosis, as the nucleus of 
the cells has condensed but not fragmented. This is in agreement with the flow cytometry 
assessment of viability indicating that the majority of UVBL2 cells are AxV+ SB-, while the 
UVBL2bcl2, BL2, and BL2bcl2 are mostly viable (AxV- SB-). 
3.3.2 Viable and apoptotic HeLa cells 
HeLa cells were chosen for comparison to the BL2 cell lines in this experiment as these two 
cell lines have different physiological lineages. BL2 cells are of haematopoietic origin, 
whereas HeLa cells are of epithelial origin. Therefore, it would be expected to observe 
differences seen between these two cell types by Raman spectroscopy. 
3.3.2.1 Induction of apoptosis and assessment of viability 
In order to induce the HeLa cells into apoptosis in a manner analogous to the BL2 cells, 
optimisation of the UVB dose and incubation period of the HeLa cells was carried out. The 
progression of apoptosis in the cells was monitored using the IncuCyte Zoom (Essen 
Bioscience), which is a fluorescent imaging plate reader housed inside an incubator, allowing 
images to be taken automatically at specified timepoints without removing the plate. HeLa 
cells were seeded into 96-well plates (6000 cells per well for 24 hours), exposed to various 
doses of UVB radiation (450 mJ/cm2, 600 mJ/cm2, 750 mJ/cm2, and 900 mJ/cm2), and 
incubated in the IncuCyte with images taken every hour to determine the progression of 
apoptosis (Figure 3.5). The viability was determined using CellEvent, a caspase-3/7 substrate 
which is fluorescent upon cleavage by active caspase-3 or caspase-7, indicating that the cell 
is apoptotic. The membrane impermeable dye DRAQ7 is used to identify necrotic populations 
in the same way as SB in flow cytometry assays described in Section 3.3.1.1. The number of 
cells in each well which had stained positively for CellEvent and DRAQ7 at each UV dose is 
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shown in Figure 3.5A. Cells that were not irradiated were included as a negative control. The 
ratio of CellEvent positive events to DRAQ7 positive events is shown in Figure 3.5Figure 3.6B, 
showing that the highest proportion of cells in early apoptosis with minimal secondarily 
necrosis is 8 hours after irradiation with 600 mJ/cm2 UVB. However, although this appears to 
be the optimal conditions with regards to the proportion of early apoptotic cells, by counting 
the total number of cells in the phase contrast images and comparing this to the number of 
fluorescent cells, only 31% of the cells were apoptotic (Figure 3.6). 68% remained unstained 
at this time point, indicating that the majority of the cells were still viable. Therefore, the 
levels of apoptosis reached with the HeLa cell assay are not analogous to those observed in 





Figure 3.5: Monitoring the response of HeLa cells to different doses of UVB radiation. (A) Plot 
of CellEvent positive cells and DRAQ7 positive cells as a function of time post UV exposure. 
Cells that had not been irradiated were used as a control. The ratio of CellEvent positive 
events to DRAQ7 positive events is shown in (B). The highest ratio is 8 hours post-irradiation 




Figure 3.6: Viability of HeLa cells after exposure to 600 mJ/cm2 UV. At 8 hours, only 31% of 
the cells stain positive for CellEvent. 6% are necrotic, staining with DRAQ7. Accounting for 
the cells which stain positively for both CellEvent and DRAQ7, this leaves 68% of the cells 
unstained with either CellEvent or DRAQ7, indicating that those cells are viable. 
3.3.2.2 Raman spectroscopy of viable and apoptotic HeLa cells 
HeLa cells were seeded onto CaF2 windows and allowed to attach and grow for 24 hours. The 
cells on the window were irradiated with 600 mJ/cm2 UVB and incubated at 37 °C for 8 hours 
before fixing with 4% NBF (UVHeLa). Cells which had been seeded onto the window without 
being irradiated were used as the viable control (HeLa). Raman images of step size 1 µm of 
single cells were acquired using 532 nm excitation wavelength at 35 mW for 1 second 
acquisition time using a 60x water immersion objective. Three replicate experiments were 
carried out, and 10 cells were Raman mapped under PBS for each experiment, with a total of 
30 cell maps obtained per condition. The cell spectra were extracted from the background 
spectra of PBS using MATLAB, and a mean spectrum for each cell was generated. The spectra 
were baseline corrected and scaled. The mean spectra of the 30 cells for each condition is 
plotted offset in Figure 3.7A and overlaid in Figure 3.7B, with ±1 SD shaded. The peaks and 
SD of the spectra overlap for many bands, but a difference is seen in the intensities of the 
peaks at 852 cm−1, 1004 cm−1, 1031 cm−1, and 1207 cm−1. The SD for the HeLa and UVHeLa 
cells are quite similar at most peak positions (Figure 3.7C). The main points of difference are 
the larger SD for the UVHeLa cells in the nucleic acid band region 783-792 cm−1, and the 























CellEvent- DRAQ7- 96% 95% 95% 95% 92% 89% 82% 75% 68% 61% 57%
CellEvent+ 4% 4% 4% 5% 7% 10% 17% 24% 31% 38% 42%










Figure 3.7: (A) The mean of 30 cells for each condition, plotted offset with ±1 SD (shaded) – 
viable HeLa cells (HeLa), and UV-irradiated HeLa cells (UVHeLa). The spectra with SD are 
overlaid in (B), showing that the spectra overlap at most points. The SD for each condition is 







One issue with the acquisition of the UVHeLa cell spectra is the low percentage of early 
apoptotic cells in the population (Figure 3.6). Thus, in order to be certain that the cells 
analysed were apoptotic, the morphology of the cells was taken into account when choosing 
which cells to analyse. Adherent cells which are apoptotic become detached from the surface 
of the CaF2 window and have a rounded appearance with some membrane blebbing. The 
cells with these morphological features may even have advanced from being early apoptotic 
to being secondarily necrotic, which would cause a large amount of variation in the spectra. 
However, the SD of the UVHeLa and HeLa cells are reasonably similar to one another, 
implying that this did not affect the data. 
PCA was then carried out on the first derivatives of the HeLa and UVHeLa cell data, the results 
of which are shown in Figure 3.8. As seen in Figure 3.8A, there is clear separation of the 
UVHeLa cells from the HeLa cells along PC1, which accounts for 56.9% of the variance in the 
spectra. The HeLa cells have a positive score for PC1, while the UVHeLa cells have a negative 
PC1 score. The loading on PC1 is shown in Figure 3.8B, indicating that the main variation 
contributing to this variation is the Phe peak at 1001 cm−1. As can be seen in Figure 3.7B, the 
main cause of variation at this peak between HeLa and UVHeLa is the shift of the peak from 
1004 cm−1 in the HeLa cells to 1001 cm−1 in the UVHeLa cells. This shift could be caused by a 
number of factors, such as a change in the secondary structure of the proteins in the cell, 
changes in hydrogen bonding or changes in pH.198 It may also be an artefact of batch 





Figure 3.8: PCA results of the first derivatives of the Raman spectra for the comparison of 
viable and apoptotic HeLa cells. (A) Plot of PC1 vs PC2 scores, showing a separation of the 
apoptotic UVHeLa cells from the viable HeLa cells along PC1. (B) Loading of PC1, showing the 
main peak contributing to this PC is that at 1001 cm−1. 
3.3.3  BL2 cells, BL2-bcl2 cells, and HeLa cells 
As outlined in Section 1.4.1.5, apoptotic cells and viable cells can be differentiated by Raman 
spectroscopy and different cell types can also be distinguished from one another. Published 
work by other groups has shown that different forms of cell death can be distinguished,239 
and cell death induced by different stimuli can also be distinguished.207 However, it is not yet 
known whether viable and apoptotic cells of more than one cell type can be distinguished 
based on their viability or cell type, since apoptotic and viable cells of more than one cell type 






The Raman data obtained from the viable and apoptotic BL2 and BL2-bcl2 cells were 
therefore compared against the viable and apoptotic HeLa cells, in order to distinguish 
whether these cells could be separated based on cell type as well as viability. The result from 
the PCA of the first derivatives of the Raman spectra of this group of cells is shown in Figure 
3.9. 
 
Figure 3.9: (A) PCA plot of the first derivative Raman spectrum of all cells (BL2, BL2bcl2, 
UVBL2, UVBL2bcl2, HeLa, UVHeLa). The HeLa cells and UVHeLa cells separate from the BL 
cells along PC1, with some separation of HeLa and UVHeLa along PC2. (B) Loading of PC1 
shows contributions from peaks at 1001 cm−1, 1489 cm−1, and 1660 cm−1. 
The scores plot of PC1 (43.8% of variance) vs PC2 (14.2% of variance), is shown in Figure 3.9A. 
This shows that the cells separate based on type rather than viability, with the HeLa and 
UVHeLa having positive scores for PC1, and the BL cells mainly having negative scores for 








where the UVHeLa and UVBL2 cells mostly have positive scores for PC2 and HeLa cells have 
negative scores, however there is no separation of the viable BL2 and BL2-bcl2 cells along 
this axis. The loadings of PC1 are shown in Figure 3.9B, with the main contributory peaks to 
this component found at 1001 cm−1, 1489 cm−1, and 1660 cm−1. The peak at 1489 cm−1 is most 
likely due to DNA or nucleic acid ring breathing modes, and this peak is absent in the spectra 
of the HeLa and UVHeLa cells when compared to the BL cells (Figure 3.10A and Figure 3.10B). 
This may be due to the relative size of these cells. BL2 cells, and B cells in general, are smaller 
than epithelial cells, with a relatively small volume of cytoplasm as the majority of the cell is 
taken up by the nucleus. The nuclear material is also more concentrated in lymphocytes 
because of their smaller size. Thus, the concentration of nucleic acids in the mean spectrum 
of the BL2 and BL2-bcl2 cells will be higher than that in the HeLa cells, as the nucleus makes 
up a smaller proportion of the HeLa cells. This difference in the nucleic acid concentrations 
of the two cell types can also be seen in the band at 782 cm−1, which also corresponds to DNA 
ring breathing modes. Although this peak has lower intensity in the HeLa and UVHeLa cells 
(Figure 3.10C), when plotted with ±1 standard deviation in Figure 3.10D, the standard 
deviations overlap, indicating that the variation in the intensity of this peak is not significant. 
However, the 1489 cm−1 peak, in Figure 3.10B, does show clear differences in the standard 





Figure 3.10: Plot of all cell spectra (BL2, BL2bcl2, UVBL2, UVBL2bcl2, HeLa, UVHeLa) showing 
nucleic acid bands. (A) Zoom in on the region 1400-1500 cm−1 region, showing the reduction 
of the 1489 cm−1 peak in the HeLa cells, and the same region plotted with ± 1 standard 
deviation in (B). The region from 700-850 cm−1 is shown in (C) showing the reduction in peak 
intensity at 782 cm−1, and the same region is plotted in (D) with ± 1 standard deviation, 
showing overlap of the standard deviations of the 782 cm−1 peak for all cell types. 
The contribution from the peak at 1660 cm−1, corresponding to the amide I vibration, could 
be due to differing secondary structure of the proteins within the cell types. However, as the 
spectra have been scaled so that the peak with the highest intensity in the spectrum is 1, the 
changes in this peak may be due to slight shifts in the peak maximum for this band in the 
different cells analysed. 
Therefore, it appears that in the analysis of spectral data from a mixed group of viable and 
apoptotic cells from different lineages, the lineages differences between the cells dominate 
over the viability status of the cells. However, the data from the HeLa cells were acquired at 
a much later time than BL2 group data. This may play a role in the differentiation of these 
groups, due to variation in the spectrometer over this time period. Another factor influencing 
this analysis is the growth medium of the cells. The BL2 and BL2-bcl2 cells were grown in a 







grown in MEM supplemented with 10% FCS. These differences in growth conditions may also 
influence the Raman data obtained from these cells, skewing the PCA of the data based on 
these factors rather than true biological differences. 
3.4 Separation of EVs from apoptotic and non-apoptotic cells 
EV-related research is a growing field; as the functions of these particles are revealed, the 
interest in these particles grows. EVs released during early apoptosis are of particular interest 
due to the observation that some tumours with high rates of apoptosis, and corresponding 
infiltration of tumour-associated macrophages (TAMs), have aggressive growth phenotypes. 
The hypothesis is that the EVs released from the apoptotic tumour cells (apoEV) play a role 
in the conditioning of the tumour microenvironment or the activation of macrophages to 
form the ‘onco-regenerative niche’. The reasons for avoiding secondary necrosis in the in 
vitro system is two-fold: these cells are not present in great numbers in vivo as they are 
phagocytosed by the TAMs in the tumour, and the presence of these cells with their 
disrupted cell membranes in the culture system could create artefacts due to the release of 
the intracellular contents into the extracellular milieu, and membranous EV artefacts. 
ApoEVs and EVs were separated from UV-irradiated BL2 and BL2-bcl2 cells respectively, in 
order to study them by Raman spectroscopy. A similar procedure was used for HeLa cells, 
either irradiated or not irradiated, in order to be able to compare the EVs from the two cell 
lines. Some changes to the protocol were necessary as the HeLa cells are adherent rather 
than suspension cells. 
3.4.1  Separation of EVs from BL2 and BL2-bcl2 cells 
BL2 and BL2-bcl2 cells were irradiated with UVB light as described in Section 3.3.1.1 and 
Figure 3.1. The cells were removed from suspension by low speed centrifugation at 25 g for 
60 minutes at 4°C. The low speed is to ensure that the delicate membranes of the early 
apoptotic cells are not disrupted by the shear force generated by centrifugation, which could 
create artefacts in the preparation. The supernatant was then passed through a 5 µm mesh 
filter, to remove any remaining cells from the suspension, followed by a 1.2 µm syringe filter, 
in order to remove any larger EVs and apoptotic bodies from the preparation. The filters used 
were chosen to limit the shear force exerted on the EV suspension – the mesh filter is 
normally used for pluripotent cells, which have plastic morphology, and the 1.2 µm syringe 
filter was used without the plunger applied to the syringe, instead allowing the suspension 
to pass through the filter aided only by gravitational force. 
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The size and concentration of the EVs were determined using a NanoSight (Malvern), which 
measures the EVs using nanoparticle tracking analysis. By recording the Brownian motion of 
particles and tracking this motion frame-by-frame, the hydrodynamic radius of the EVs can 
be determined, and the number of particles tracked in the analysis is used to determine the 
concentration of particles in the sample.  
Figure 3.11 shows the concentration and size distribution of the EVs released from UV-
irradiated BL2 and BL2-bcl2 cells. The BL2 cells release more EVs than BL2-bcl2 cells under 
the same conditions of cell concentration and stimulus (Figure 3.11A). The size distributions 
of these EV populations also differs, as the BL2 cells release a much more heterogeneous 
distribution of particle sizes than the BL2-bcl2 cells. Figure 3.11B shows that the BL2 EVs have 
a population of EVs between approximately 300 nm and 700 nm which are much lower in 
the BL2-bcl2 EVs. The BL2 cells also release more of the ‘exosome’-sized EVs with a diameter 
of <100 nm than released by the BL2-bcl2 cells. This size difference could indicate that the 
BL2 EVs, or apoEVs, can carry more functional cargo in order to affect the tumour 
microenvironment. 
 
Figure 3.11: NanoSight analysis of EVs released from UV-irradiated BL2 and BL2-bcl2 cells. (A) 
Total particle concentration of BL2 EVs and BL2-bcl2 EVs in the 1.2 µm filtrate from the EV 
preparation. (B) Size distribution of the EVs as determined by nanoparticle tracking analysis. 
BL2 cells release more EVs and larger EVs than BL2-bcl2 cells. 
3.4.2  Separation of EVs from HeLa cells 
A number of changes needed to be made to the EV separation protocol in order to adapt it 
for the HeLa cell line. The BL2 cells were irradiated with 300 mJ/cm2 UV at 20 x 106 mL−1. The 

































































they are adherent, they cannot reach the same cell concentrations as the non-adherent BL2 
cells. In order to yield an acceptable concentration of EVs for further analysis and 
quantification, a number of different cell densities of HeLa were examined in different culture 
vessels. 1.5 x 106 cells seeded for 24 hours in a 25 cm2 culture flask, with 5 mL of culture 
medium, was sufficient to yield an adequate concentration of EVs. 
The BL2 cells were grown in a chemically-defined medium without serum (RPMI/X-VIVO 
mixture). However, the HeLa cells are grown in a medium which does contain serum, and 
foetal bovine serum (FBS) is known to contain EVs just as serum from humans contains EVs. 
The HeLa cells, both UV-irradiated and the non-irradiated control cells, were washed with 
Hank’s balanced salt solution (HBSS) and transferred into 0.1 µm filtered serum-free medium 
immediately prior to UV-irradiation and incubation. 
A timecourse of the EV release from the UV-irradiated HeLa cells (UVHeLa) and the control 
cells (HeLa) was carried out to determine if the HeLa cells have the same pattern of EV release 
as the apoEVs from BL2 cells and BL2-bcl2 EVs. A different flask was used for each timepoint 
and the entire culture supernatant of 5 mL was used for EV separation. This was because the 
HeLa cells are adherent and taking a sample of the supernatant to analyse at different 
timepoints would artificially inflate the concentration of EVs in the later timepoints. The EVs 
were separated in the same manner as the BL2 EVs, a centrifugation step was used to remove 
any cells which may have detached from the culture flask due to apoptosis, followed by dual 
filtration through a 5 µm mesh filter and 1.2 µm syringe filter under gravity. 
The total number of EVs released from the UVHeLa and control HeLa cells can be seen in 
Figure 3.12A. The UVHeLa cells produced a higher concentration of EVs than the non-
irradiated control HeLa cells at each timepoint, including the sample which was taken 
immediately after UV-irradiation. This could indicate that the process of EV release occurs 
rapidly enough after a stimulus to be observable in the few minutes needed to retrieve the 
cell culture supernatant after irradiation. However, the optimum concentration of particles 
for the NanoSight to give an accurate quantification is between 108-109, so the difference 
seen between UVHeLa and HeLa cells at this timepoint may due to the lack of sensitivity of 




Figure 3.12: NanoSight analysis showing timecourse of EV release from UV-irradiated and 
control HeLa cells. (A) Total concentration of EVs released from HeLa cells at 2-hour intervals. 
Three independent experiments were carried out, the error bar shows standard deviation. 
Size distribution of UVHeLa (B) and HeLa (C) EV, showing only the 4-hour, 6-hour and 8-hour 
timepoints for clarity.  
The differences in the size profiles of the UVHeLa and HeLa EVs are not as striking as those 
of the BL2 and BL2-bcl2 EVs (Figure 3.12B and Figure 3.12C). The UVHeLa cells do seem to 
release a higher proportion of smaller <100 nm EVs, but the difference in concentration of 
the larger (>400 nm) population seems to be increased in the UVHeLa EVs only due to the 
increase in overall EV number, while the HeLa EV concentration remains rather static 
between the 6 and 8-hour timepoints. 
The increase in the number of EVs released from the UVHeLa cells is more striking when 



















































































is much lower than the proportion of BL2 cells which are apoptotic after UV irradiation (78.5% 
Figure 3.1). 
3.5 Raman spectroscopy of EVs 
As demonstrated in Figure 3.11B and Figure 3.12B and 3.13C, the EVs are < 1 µm in diameter, 
having been passed through a 1.2 µm filter. The majority of these EVs are < 400 nm. This 
small diameter means that the entire EV can be investigated by Raman spectroscopy using 
single point spectra, rather than mapping, of the EV adhered onto a CaF2 window in a label-
free manner. All EV Raman spectra were acquired in PBS with a 60x water immersion 
objective using a 532 nm laser excitation with a power of 35 mW for 10 seconds.  
3.5.1 Raman spectroscopy of BL2 and BL2-bcl2 EVs 
The EVs separated as described in Section 3.4.1 were incubated overnight on a CaF2 window 
which had been pre-coated with Cell-Tak. Cell-Tak is a protein solution derived from mussels 
used to adhere cells and tissues to surfaces. This allowed the EVs to adhere to the CaF2 
window in order to be visualised using the white light source on the instrument and to remain 
stationary while in the path of the laser for data acquisition. 
Spectra of 50 EVs were acquired for each experiment, and three independent experiments 
were carried out, giving a total of 150 EV spectra. The mean spectra for BL2 EVs and BL2-bcl2 
EVs are shown in Figure 3.13. As can be seen from the raw mean spectrum, the BL2 EVs have 
a much higher background than the BL2-bcl2 EVs. This could be due to the presence of 
fluorescent material such as cytochrome c, which is resonant at the visible wavelength used 
to obtain the Raman spectra.235 Cytochrome c is ordinarily found in the mitochondria, but is 
released into the cytoplasm during apoptosis. This cytoplasmic cytochrome c could then be 
packaged into the BL2 apoEVs as cargo, causing a fluorescent background effect. This is not 
observed in the apoptotic cells, as the dispersion of cytochrome c throughout the cytoplasm 
would decrease the local concentration, thereby reducing the contribution this molecule has 




Figure 3.13: Mean Raman spectra of 150 BL2 EVs (red) and 150 BL2-bcl2 EVs (blue) from three 
independent experiments. The BL2EV spectra have a much higher fluorescent Raman 
background than the spectra of BL2bcl2EV. Raman spectra were acquired in PBS with a 60x 
water immersion objective using a 532 nm laser excitation with a power of 35 mW for 10 
seconds. 
The peaks seen in the Raman spectra of the EVs are assigned in Table 3.2. These peaks include 
lipid peaks, such as the membrane phospholipid phosphatidylinositol at 514 cm−1 and lipid 
ester peak at 1736 cm−1; nucleic acid peaks, including ribose peaks at 916 cm−1 and 974 cm−1, 
DNA phosphate backbone at 1070-1090 cm−1, and guanine and cytosine peaks at 1369 cm−1 
and 1611 cm−1, respectively; and protein peaks, such as tyrosine at 643 cm−1 and 1161 cm−1, 
and the amide III peak at 1260 cm−1. On the basis of the peaks observed in the spectra, it can 
be inferred that the particles investigated are membrane enclosed structures containing both 
protein and nucleic acids and are thus likely to be EVs. 
These EV Raman spectra are very different to the parental cells from which they derive 
(Figure 3.7). One of the most prominent differences is the absence of the Phe peak at 1004 
cm−1 from the EVs spectra. This is also seen in a number of literature studies of Raman 
spectroscopic analysis of EVs.299–301 It may be that peaks associated with the molecular 
vibrations of proteins are diminished in the EV spectra. When considering the size and 
composition of EVs, the majority of the biomolecular components will be the phospholipids 
making up the plasma membrane. The small volume of the particle would not be able to 
contain a high concentration of soluble proteins or nucleic acids to balance the strong signal 
from the lipids in the membrane, thereby giving the Raman spectra of the EVs a drastically 
different relative composition to the Raman spectra of the cells. 
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Due to the high background of the BL2 EVs Raman spectra, the two types of EV could not be 
directly compared without performing baseline correction on the data, as the PCA separated 
them based on the different background of the BL2-bcl2 EVs. The spectra were scaled to 
unity. In the EV spectra, the peak with the greatest intensity is the 1736 cm−1 lipid peak, which 
would have a significant contribution from the lipid membrane which delimits the EVs. As 
EVs are spherical particles with a radius in the nanometre scale, the surface area of the 
particle will be relatively high with very little cytoplasm inside. Thus, by scaling to a lipid peak 
the spectra are essentially normalised to the size of each EV. 














The baseline corrected spectra, plotted with ±1 SD shaded, are shown in Figure 3.14A and 
Figure 3.14B. The mean spectra show differences between the BL2 and BL2-bcl2 EVs at a 
number of peak positions, including the presence of a small shoulder peak in the BL2 EV 
spectrum at 810 cm−1, the higher intensity of the DNA band at 1070-1090 cm−1 in the BL2-
bcl2 EVs, the higher peak intensity due to cytosine at 1161 cm−1 in the BL2 EVs, the higher 
intensity of the shoulder peak at 1365 cm−1 in the BL2 EVs, and the peak at 1611 cm−1 which 





916 Ribose (RNA) 
974 Ribose (RNA) 
1046 Glycogen 
1070-1090 PO2- of DNA 
1125 Acyl lipid backbone 
1161 Tyrosine 




1380 Lipid CH3 
1434 CH2 
1611 Cytosine 
1736 C=O ester (lipids) 
103 
 
is present in the BL2 EVs but absent in the BL2-bcl2 EVs. However, as can be seen in Figure 
3.14B, the SD of the spectra overlap at all points, indicating that these differences may be 
due to biological variability. This is particularly evident when plotting the SD itself, shown in 
Figure 3.14C. The SD of the BL2 EV mean spectrum has much higher peak intensities than the 
SD of the BL2-bcl2 EV spectrum. The main peak in the BL2-bcl2 EV SD is the band in the 1500-
1700 cm−1 region, with smaller contributions at 536 cm−1, 917 cm−1, 991 cm−1, 1173 cm−1, 
1279 cm−1, and 1354 cm−1. In contrast, the SD of the BL2 EV spectrum has significant peaks 
at many points, indicating that the BL2 EV population is more heterogeneous than the BL2-
bcl2 EV population. This is expected, since the BL2 EV population will contain some EVs 
released as a result of apoptosis, but there will also be some EVs released constitutively, or 
as a result of the nutritional stress that the cells are under by being at a high cell density of 
20 x 106 mL−1. The BL2-bcl2 cells are all viable over the course of the EV preparation, so no 
EVs are released as a result of apoptosis and only constitutive EVs are released, thereby 




Figure 3.14: Mean, baseline corrected spectrum of BL2 EV and BL2-bcl2 EV plotted with ±1 
SD shaded. (A) shows the mean spectrum for each EV type offset for clarity. The spectra are 
overlaid in (B), showing that, despite differences in the two spectra, the SD overlaps at all 
points for the mean spectra of the two EV types. (C) shows the SD for each condition plotted. 
The SD of the BL2 EVs spectra is much higher than that of the BL2-bcl2 EVs spectra, showing 
that the BL2 EVs are a more heterogeneous population than the BL2-bcl2 EVs. Raman spectra 
were acquired in PBS with a 60x water immersion objective using a 532 nm laser excitation 






The PCA results of the BL2 and BL2-bcl2 derived EVs are shown in Figure 3.15, where each 
point represents a single EV spectrum. The plot of scores for PC1 (41.4%) vs PC2 (3.2%) in 
Figure 3.15A shows that the BL2 EVs display some moderate separation from the BL2-bcl2 
EVs along the PC1 axis. The BL2-bcl2 EVs have a negative PC1 score, with some outliers having 
a positive score. The BL2 EVs have a wider distribution of scores, where more than half have 
a positive PC1 score but there are many BL2 EVs with a negative PC1 score. There is not a 
clear separation of these two groups, most likely due to the heterogeneity of the BL2 EVs 
population. 
 
Figure 3.15: PCA of the first derivative Raman spectrum of BL2 EV and BL2-bcl2 EV Raman 
spectra. (A) Plot of scores of PC1 vs PC2, showing separation of the BL2 EV along the axis of 
PC1. (B) The loading of PC1, showing contribution from peaks at 917 cm−1, 1172 cm−1, 1353 













Table 3.3: Assignment of peaks in PC1 loading for BL2 and BL2-bcl2 EVs 
Raman shift (cm−1) Assignment 





The loading of PC1 is shown in Figure 3.15B, and the peaks contributing to this loading are 
assigned in Table 3.3. The contributions of PC1 are made up mostly of nucleic acids, with 
peaks corresponding to ribose at 917 cm−1, guanine at 1353 cm−1, and cytosine at 1611 cm−1 
observed. This suggests that the BL2 EVs have a higher nucleic acid content than the EVs 
derived from the BL2-bcl2 cells. This agrees with the hypothesis that when the cells undergo 
apoptosis, the nucleus condenses and fragments, thus allowing the transport of nuclear 
material in the EVs.  
3.5.2 Raman spectroscopy of HeLa and UVHeLa EVs 
The EVs separated from HeLa cells were incubated on a CaF2 window overnight, in the same 
way as the BL2 and BL2-bcl2 EVs. Three independent experiments were carried out, and 50 
EV spectra were acquired in each experiment, giving a total of 150 spectra for both HeLa EVs 
and UVHeLa EVs.  
The mean spectra are shown in Figure 3.16. On first inspection, the spectra are very similar 
to those of the BL2 and BL2-bcl2 EVs (Figure 3.14), showing the same pattern of peaks. 
The background in the mean Raman spectra of the HeLa EV and UVHeLa EV are similar, with 
the UVHeLa EV spectrum having a slightly higher background. Both types of EV show a higher 
background than observed in the BL2-bcl2 EVs spectra, but lower than the BL2 EVs (Figure 
3.13). Although the background for both types of HeLa-derived EVs was comparable, the 
spectra were baseline corrected and scaled in the same manner as the EVs from the BL2 and 




Figure 3.16: Mean Raman spectra of 150 HeLa EVs (yellow) and 150 UVHeLa EVs (green) from 
three independent experiments. Raman spectra were acquired in PBS with a 60x water 
immersion objective using a 532 nm laser excitation with a power of 35 mW for 10 seconds. 
The baseline corrected and scaled spectra are plotted with ±1 SD in Figure 3.17A and Figure 
3.17B. The mean spectra for the HeLa EVs and UVHeLa EVs do not show any visible 
differences at any location in the spectrum, even before the SD is plotted. This is not entirely 
unexpected, as the EVs released from the irradiated and non-irradiated HeLa cells did not 
display the same divergence of size profile seen in the EVs from the irradiated BL2 and BL2-
bcl2 cells. This may be due to the exchange of the cells into serum-free medium before the 
EV separation procedure, which could have resulted in the activation of starvation-induced 
stress responses in both the irradiated and non-irradiated cells. This is evident in the plot of 
the SD, shown in Figure 3.17C, where the SDs of the spectra are very similar. For most peaks 
the deviation is actually higher in the control HeLa EVs than the irradiated UVHeLa EVs, which 
should not be the case if the HeLa EVs are all released as the result of a constitutive process 
as anticipated. The fact that the control HeLa EVs show a similar, if not greater amount, of 
heterogeneity than the UVHeLa EVs is indicative of the alteration of the cell state after being 
placed in the serum free medium, despite this being a common method for the separation 




Figure 3.17: Baseline-corrected mean spectrum of HeLa EVs and UVHeLa EVs plotted with ±1 
SD shaded. (A) shows the mean spectrum for each EV type offset for clarity. The spectra are 
overlaid in (B), showing that there is no difference in the Raman spectra of the two EV types 
and the SD overlaps at all points. (C) shows the plotted SD for each condition. The SD of both 
EV spectra are reasonably high, with the SD of the HeLa EVs having a higher intensity at 
almost all points. Raman spectra were acquired in PBS with a 60x water immersion objective 







Figure 3.18: PCA plot of PC1 scores vs PC2 scores for HeLa EVs and UVHeLa EVs. PCA did not 
reveal any further differences between the two groups of EVs which were not discernible 
from the spectra alone. 
PCA of the HeLa EVs and UVHeLa EVs spectra also shows that there is no observable 
difference between the two groups of EVs. The plot of PC1 vs PC2 scores is shown in Figure 
3.18, where each point on the plot represents a single EV spectrum. Both groups have an 
even distribution of positive and negative scores for PC1 and PC2, clustering about the origin. 
This is observed for plots of the first 4 PC scores against each other (PC1 accounts for 35.9% 
of the variation, PC2 7.7%, PC3 6.2%, and PC4 1.8%). Therefore, the low levels of cellular 
apoptosis in the HeLa cells were likely not high enough to produce a population of apoEVs 
from these cells in sufficient numbers for this population to be observed in this small sample 
size of Raman spectra. 
3.5.3 Comparison of Raman spectra for BL2 EVs, BL2-bcl2 EVs, HeLa EVs, and UVHeLa EVs 
The Raman spectra of the BL2 EVs and BL2-bcl2 EVs, and the spectra of the HeLa EVs and 
UVHeLa EVs, were each compared pairwise using PCA, which showed that the BL2 EVs have 
a different composition to the BL2-bcl2 EVs (Figure 3.15), and there is no observable 
difference between the HeLa EVs and the UVHeLa EVs (Figure 3.18). Since different cell types 
can be discriminated by Raman spectroscopy,224,230,232,233 the spectra of the EVs from the UV-
irradiated BL2 and BL2-bcl2 cells were analysed together with the EVs separated from the 
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HeLa and UVHeLa cells in order to determine whether EVs deriving from different cell types 
can also be distinguished from each other. The mean spectra are plotted together in Figure 
3.19A, which shows a striking similarity between the spectra of EVs separated from the two 
different cell types. The SD is plotted in Figure 3.19B, showing that the BL2-bcl2 EVs have the 
lowest SD of the four groups of EVs. The SD for the BL2 EVs is quite similar to that of the HeLa 
EVs and the UVHeLa EVs. 
PCA was carried out on the four groups of EVs, shown in Figure 3.20A. Although there is not 
a distinct separation between the EVs from the two cell types, there is a very slight separation 
of the EVs derived from the HeLa cells along the axis of PC3, which accounts for 7% of the 
variance between the spectra. The majority of the HeLa EVs and UVHeLa EVs have a positive 
score for PC3, while the BL2-bcl2 EVs all have a negative PC3 score. Many of the BL2 EVs have 
a negative PC3 score, but there are some with a positive score, so this alone cannot be used 




Figure 3.19: (A) Mean, baseline corrected spectra of BL2 EV, BL2-bcl2 EV, HeLa EV, and 
UVHeLa EV plotted with ±1 SD shaded. The spectra are offset for clarity, but the SD of the 
spectra overlap for the two groups at almost all points. (B) The SD for each mean spectrum 
is plotted, offset for clarity. Raman spectra were acquired in PBS with a 60x water immersion 






Figure 3.20: PCA of the first derivative Raman spectrum of BL2 EVs, BL2-bcl2 EVs, HeLa EVs, 
and UVHeLa EVs. (A) Plot of PC1 scores against PC3 scores, showing that the HeLa EVs and 
UVHeLa EVs show some separation from the BL2 EVs and BL2-bcl2 EVs along the PC3 axis. (B) 
Plot of the loading on PC3, showing contributions from peaks at 660 cm−1, 917 cm−1, 990 cm−1, 
1381 cm−1, and 1738 cm−1. 
The PC3 loading is shown in Figure 3.20B, with peaks assigned in Table 3.4. These peaks 
correspond to functional groups found in nucleic acids, such as cytosine at 660 cm−1 and 
ribose at 917 cm−1 and 990 cm−1; proteins, with the amide I band at 1643 cm−1; and lipids are 
represented by the peak at 1738 cm−1. This shows that, while the spectra look very similar, 
there are slight differences in the composition of EVs from the two different cell types 
corresponding to a variety of biomolecules. These are minor differences however, as the 
loading of PC3 explains just 7% of the variance of the spectra, while PC1 and PC2 explain 
51.2% and 18.2%, respectively. This distinction between EVs of different cell types by PCA of 











cancer cell-derived and non-cancer cell derived EVs,296,298,299 so it is not surprising that EVs 
from cancer cells of two different cell lineages may also be distinguished using this technique. 
Table 3.4: Assignment of peaks in PC3 loading comparing BL2 EVs and BL2-bcl2 EVs with HeLa 
EVs and UVHeLa EVs 
Raman shift (cm−1) Assignment 
660 Cytosine 
917 Ribose (RNA) 
990 Ribose 
1381 CH3 




Raman spectroscopy combined with multivariate analysis is a powerful tool for the analysis 
of biological systems. As shown in this work, Raman maps of cells can be used to distinguish 
between viable and apoptotic BL2 cells, without any observable difference between the 
viable BL2 cells and both untreated and UV-irradiated BL2-bcl2 cells. Comparing this BL cell 
line with viable and apoptotic HeLa cells under the same apoptotic stimulus again shows both 
that the UV-irradiated HeLa cells can be distinguished from the untreated cells, and that the 
HeLa cells of epithelial origin can be distinguished from the lymphocytes. Within this large 
dataset, the apoptotic cells do not clearly separate from their viable counterparts, showing 
that the variation between cells of different lineages overrides the distinguishing features of 
early cell death. 
Similarly, EVs released from different cell types and states can also be distinguished by Raman 
spectroscopy. The spectra of the EVs are quite different to those of their parental cells, 
showing that the EVs have different relative biomolecular constituents to the cells from 
which they derive. The BL2 EVs are relatively heterogeneous whereas the BL2-bcl2 EVs are 
quite homogeneous, as seen from the SD of their spectra. This population variability is to be 
expected due to the different status of these cells, where the apoptotic BL2 cells will be 
releasing both apoEVs and constitutive EVs but the BL2-bcl2 cells will be releasing only 
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constitutive EVs. These two groups of EVs can be distinguished from one another using PCA, 
showing that the apoEVs released from dying cells are fundamentally different from the EVs 
released constitutively from cells which are viable. This is mainly due to an increase in the 
nucleic acid bands in the BL2 apoEVs, showing that the fragmentation of the nucleus during 
apoptosis results in nuclear fragments which can be transported in EVs released from the 
cells. Although no discernible difference could be detected in the EVs released from HeLa 
cells which had been exposed to UVB irradiation and those which were untreated, the EVs 
released from HeLa cells could be distinguished from the EVs released from BL2 cells. This 
potentially has a great significance in the characterisation of EVs from clinical samples. If EVs 
from different cell types and different viability states can be distinguished from each other 
using Raman spectroscopy, it is possible that EVs from healthy and cancer cells are also 
distinguishable using this technique. This could be used to monitor cancer EVs in the 
peripheral blood of patients. A drawback of this is that Raman spectroscopy is currently not 





4 Bioinformatics and proteomics to identify plasma membrane proteins 
present on extracellular vesicles 
4.1 Introduction 
Gene expression profiling is a technique used to determine which genes are active in a 
particular sample by measuring the amount of mRNA present for each gene sequence. This 
analysis is both qualitative and quantitative, giving not only information on which particular 
mRNAs are present, but also how many copies of these nucleic acid sequences are detected. 
In this way, a global picture of the gene expression in a sample can be investigated, rather 
than techniques such as quantitative reverse-transcriptase polymerase chain reaction, where 
only a single gene can be investigated at one time. This picture can then be used to compare 
the genes being expressed in different environmental conditions, or between healthy and 
diseased tissue, in order to establish a genetic hypothesis for the changes occurring between 
samples. 
4.1.1 Affymetrix gene expression microarrays and BioLayout Express3D 
4.1.1.1 Affymetrix GeneChip 
Affymetrix GeneChip microarrays are gene expression platforms composed of perfect match 
probes for nucleic acid analysis. Each probe is 25 bp long, designed to match a particular gene 
sequence. Each gene is represented on the microarray by many different probes, typically 11 
probes per gene, making up a probe set for that gene. Each chip contains tens of thousands 
of these probe sets in order to investigate gene expression in a sample. The nucleic acid 
sample is labelled with biotinylated nucleotides during an amplification process, which is 
incubated with the array, washed, and then stained in order to detect the nucleic acids which 
have hybridised with the probe arrays. The array is then scanned, and each scan location 
corresponds to a particular known probe sequence, so that the staining intensity can be then 
used as a readout for the expression level of that nucleic acid sequence in the sample.303 
4.1.1.2 Microarray data pre-processing 
The gene expression data must be quality controlled and normalised before input into a 
network graph for visualisation. This pre-processing is carried out using a frozen robust 
multiarray analysis (fRMA) algorithm. Each array undergoes background correction, then 
normalisation. A quantile normalisation algorithm is used, where each quantile across all of 
the arrays are normalised, which gives a more equalised distribution of probe intensities.288 
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The normalised data are then summarised as gene expression, often represented by a mean 
of probe set intensities. fRMA has been developed to allow for analysis of multiple batches 
of array data together, which was not possible using the original RMA algorithm due to the 
inter-batch variability observed with microarrays.288 
4.1.1.3 BioLayout Express3D  
The software BioLayout Express3D was used to interrogate the gene expression microarray 
data obtained from the online repository Gene Expression Omnibus. This software is an 
open-source application designed to display a large amount of data as a 3D network, which 
has been extremely useful for the display of the large data outputs of microarray gene 
expression analysis.  
The 3D graph generated by BioLayout follows classical graph theory in that it is made up of 
nodes which are connected by edges (Figure 4.1A). In biological systems, the nodes represent 
genes, transcripts, or proteins, and the edges represent similarities or functional linkages 
between nodes.290 The network is constructed using a modified Fuchterman and Rheingold 
graph layout algorithm, in which the nodes of the graph experience a repulsive force, and the 
edges exert an attractive force on the nodes which they connect.304 The graph undergoes 
successive iterations of node and edge repulsion and attraction, initially with a high 
temperature function allowing the nodes to move more freely. Successive rounds are carried 
out with slowly lowering temperatures to limit the movement of the nodes, until the final 
rounds of iteration at a set low temperature refine the final positions of the nodes, 
generating a stable and ‘aesthetically pleasing’ graph.304 
 
Figure 4.1: Representative example of BioLayout Express3D graphical output. A) Close-up of 
the network graph, showing the nodes, which represent genes, connected by edges, 
representing a functional linkage between genes. B) An example of a cluster, where each of 
the nodes is given the same colour to distinguish from other clusters. 
For analysis of gene expression profiles, the similarity between the gene expression in 




minimum correlation value is a Pearson coefficient of 0.7, as a lower coefficient would 
generate a graph with a very high number of edges and would be difficult to interpret. Nodes 
with no connections above the selected threshold are removed from the graph. Increasing 
the Pearson threshold even further removes more edges, and large networks fragment into 
smaller graphs.290 Smaller graphical components commonly form; due to redundancy in gene 
representation in the microarray chips, multiple probes for a single gene may be present, and 
these may only correlate with each other. A clustering algorithm (Markov cluster, MCL) is 
used to partition the structured graph into clusters of nodes expected to be biologically 
significant, used to identify genes which may be coexpressed and likely to share regulatory 
mechanisms and functional relationships (Figure 4.1B). MCL discovers clusters by the 
identification of nodes which share higher-order connectivity rather than pairwise linkages, 
avoiding false positive clustering in the presence of spurious edges. Typically, an MCL 
inflation value of 2.2 is used in analysis. 
Each cluster has an associated graph showing the mRNA expression level in each sample 
across the cluster for the genes represented in the cluster. In order to identify the proteins 
which were upregulated in the B cell cancer samples, these graphs were inspected for each 
cluster, and the clusters which showed a higher expression level of the genes in the cancer 
samples were taken for further analysis. The genes in these clusters were researched in order 
to determine which of these gene products were known to localise to the plasma membrane. 
4.1.2 Aims of the chapter 
The aim of this chapter is to use bioinformatic techniques to identify proteins which could be 
transferred onto the EVs which can be used as targets for EV detection. As EVs are released 
from all types of cells, both lymphoma cells and the healthy B cell counterparts will be 
releasing EVs, and both of these EV populations could be found in the blood. Thus, in order 
to preferentially detect EVs from lymphoma cells in the blood of a patient, identifying 
proteins which are upregulated in lymphoma cells compared to healthy B cells would suggest 
that these upregulated proteins are found in greater abundance in the lymphoma EVs. The 
hypothesis is that the larger size of EVs being studied are the MV type, and thus derive from 
the plasma membrane, so these EVs should have plasma membrane markers on their 
surface. Upregulated plasma membrane proteins will be present in greater numbers on the 
lymphoma EVs, thus preferentially detecting these EVs in a blood sample from a patient. The 
first method investigated was to use public gene microarray databases in order to identify 
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plasma membrane proteins which are upregulated in B-cell cancers compared to healthy B 
cell samples.  
The BioLayout Express3D software was used to compare the gene expression profiles of 
healthy B cells at various stages of maturity to gene expression profiles of lymphoma biopsy 
samples and lymphoma cell lines. In this way, plasma membrane proteins which are 
overexpressed in the lymphoma samples compared to healthy B cells can be identified and 
investigated as potential B cell lymphoma EV detection targets. 
Proteomic analysis of the apoEVs from BL2 cells and the EVs from UV-irradiated BL2-bcl2 cells 
was also carried out. The results of this analysis were searched for proteins localised to the 
plasma membrane. This analysis is beneficial because proteins which are found only on the 
apoEVs can be identified and used to selectively detect apoEVs in the presence of 
constitutively released EVs. 
4.2 Datasets chosen 
The gene expression datasets chosen for analysis were obtained from the GEO database. A 
number of healthy B cell datasets were available, isolated from blood or tonsillar B cells. 
Some samples consisted of peripheral blood mononuclear cells analysed without further 
purification, some were B cells isolated based on specific surface markers such as CD19, 
CD20, CD10, or immunoglobulins. 135 healthy B cells samples were chosen for analysis. Brief 
descriptions of the sample types and accession numbers for the healthy B cell samples used 
are given in Table 4.1. 
Lymphoma samples were also available, isolated from patient biopsy tissue or from 
established non-Hodgkin’s lymphoma (NHL) cell lines. The cell line being used is the Burkitt’s 
lymphoma (BL) cell line BL2. A number of BL datasets were available on GEO, from both cell 
lines and from biopsies of sporadic, endemic, and HIV-associated tissue. However, BL is not 
common and only 43 gene expression datasets were available. In order to balance the 
number of healthy and oncological datasets, samples from other types of NHL were included. 
Diffuse large B cell lymphoma (DLBCL) is the most common form of NHL, and can present 
with a morphology that is similar to BL with some cases intermediary between BL and DLBCL. 
9 samples were available on GEO of biopsy tissue that was classified as BL-like DLBCL, along 
with 49 DLBCL biopsy samples. Combined with 24 NHL cell line datasets, this brought the 
number of lymphoma samples in the dataset to 126 to be compared to the 135 healthy B cell 
samples. The GEO accession numbers and brief descriptions of the lymphoma gene 
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expression array data are given in Table 4.2. A full description of all of the samples used 
including GSE accession number and GSM sample names is included as an appendix 
(Appendix 1). 
Table 4.1: GEO accession number and brief sample description for healthy B cell gene 
expression array data used for BioLayout Express3D analysis 
Accession number Cell type (source) 
GSE46062 PBMC 
GSE58208 PBMC 
GSE64028 B cell (PBMC) 
GSE10831 GC B cell (tonsil) 
GSE12366 GC B cell (tonsil) 
Naïve GC B cell (tonsil) 
Naïve B cell (PBMC) 
Memory B cell (PBMC) 
GSE17186 Naïve B cell (PBMC) 
Memory B cell (PBMC) 
Transitional B cell (PBMC) 
Transitional B cell (Cord blood) 
GSE17269 Naïve B cell (PBMC) 
GSE19599 Immature B cell (Bone marrow) 
Pre-B cell (Bone marrow) 
Pro-B cell (Bone marrow) 
GSE26725 B cell (PBMC) 
GSE28491 B cell (PBMC) 
GSE36907 Mature B cell (PBMC) 
Class switched B cell (PBMC) 
B cell (PBMC) 
Splenic B cell (PBMC) 
Naïve B cell (PBMC) 
GSE38697 GC B cell (Tonsil light zone) 
GC B cell (Tonsil dark zone) 




Table 4.2: GEO accession number and brief sample description for the lymphoma gene 
expression array data used for analysis using BioLayout Express3D  
Accession number Sample type 
GSE20011 Namalwa (BL cell line) 
SU-DHL-4 (NHL B cell line) 
GSE26673 BL biopsies 
GSE36133 BL cell lines (various) 
DLBCL cell lines (various) 
B cell lymphoma (unspecified) 
GSE38885 BL biopsies 
DLBCL (BL-like) biopsies 
DLBCL biopsies 
GSE64085 BL biopsies 
 
4.3 Evaluation of gene expression in datasets 
The combined B cell and lymphoma gene expression array table was annotated with the 
probe ID, Entrez gene ID, the HGNC gene symbol, and the gene name using the annotation 
library from Bioconductor. A gene signature was also applied, using data indicating any 
known function that is associated with a particular gene, which was obtained from 
collaborators on the project. The annotated expression table was imported into BioLayout 
Express3D Version 3.3. The Pearson correlation was set to 0.85, increased from the minimum 
value of 0.7 in order to reduce the size of the graph while maintaining some of the smaller 
clusters which contained only redundant probes on the array measuring the same gene, 
which could still identify upregulated genes. MCL clustering analysis was used with the 
default inflation value of 2.2. 
This generated a 3D network graph consisting of over 1200 clusters, shown in Figure 4.2. The 
mean expression pattern for each cluster was viewed, with the sample information available 
as coloured blocks underneath each sample. The expression levels of the genes in the healthy 
B cell data, which were grouped together on one side of the cluster samples, was visually 
compared to the expression level in the lymphoma samples. When the mean expression 
levels of the genes were considered to be higher in the lymphoma samples than in the 
healthy B cell samples, the genes involved in that cluster were investigated to determine the 
cellular localisation of the gene products. Proteins which showed localisation to the plasma 
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membrane were investigated further, cross-referencing against gene expression profile data 
for the BL2 cell line which had been generated previously in the group (unpublished data), 
and a brief literature review of the protein function was carried out to determine whether 
the protein localised to the cortical membrane or had an external portion which could be 
used as an imaging target. The results of this analysis are given in Table 4.3, giving the gene 
name, level of expression of the gene found in gene expression profile array data carried out 
on the BL cell line BL2, and function of the gene product. The expression profiles of each of 
these genes from the BioLayout cluster analysis are given in Figure 4.3. 
 
Figure 4.2: Full network graph generated by BioLayout. Due to the Pearson correlation value 
chosen, many small graphical components form which consist of clusters of redundant probe 




Table 4.3: Final results of BioLayout analysis to identify plasma membrane proteins which 
have higher expression levels in lymphoma samples than in healthy B cell samples. Genes 
which showed increased expression were evaluated for cellular localisation of the gene 
product, and then cross referenced with gene expression profile data of the BL2 cell line, 
which is shown in the table along with a brief description of the protein function. 
Gene name BL2 expression Function 
CD59 132.07-289 Regulator of complement-mediated cell lysis 
MCAM 595.94 Cellular adhesion 
LDLR 131.36/394.45 Endocytosis of LDL 
BEST3 309.7 Cl- channel 
CD46 366.97-1219.52 Regulator of complement-mediated cell lysis 
TMEM165 130.81-626.77 Unknown 
SLC16A1 100.85-553.27 Monocarboxylate transporter 
 
Seven genes were identified as plasma membrane locating proteins which showed greater 
expression in the lymphoma samples than in the healthy B cell samples. CD59 and CD46 were 
among the genes identified as upregulated. Both are membrane-bound complement 
regulatory proteins (mCRPs), ubiquitously expressed on human cells to prevent damage of 
cells by the complement system. CD46 acts as a cofactor in the inactivation of C3b and C4b 
complement components.305 CD59 inhibits pore formation by the membrane attack complex, 
blocking the insertion of C9 into the plasma membrane by inhibiting the C5b-8 complex.306 
The expression of mCRPs in lymphoma is associated with treatment response to the anti-
CD20 antibody rituximab combined with CHOP.307 Exosomes derived from antigen presenting 
cells have been shown to have CD59 on the surface, which acts to protect the EVs from lysis 
by complement.308 CD46 and CD59 have also been observed on exosomes derived from B 
cells analysed by proteomics.309 
MCAM was also identified in these results, showing one of the highest level of gene 
expression in the BL2 data amongst the identified plasma membrane proteins. MCAM, 
melanoma cellular adhesion molecule, so called because it was first identified as a poor 
prognostic indicator in melanoma,310 is also known as CD146. Although this protein has 
mainly been associated with epithelial cells, particularly having a role in the metastatic 
progression of tumours of the prostate311 and ovary,312 it has also been shown to have 
expression in certain lymphocyte subsets313,314 and also in some leukaemias.315 CD146 has 




































































Figure 4.3: Gene expression profiles of BioLayout clusters identified as having increased 
expression in lymphoma datasets compared to healthy B cell datasets. The row along the 
bottom of each profile displays colour-coded disease state characteristics of each sample 
with the legend given at the bottom of the figure, where BL is Burkitt’s lymphoma, DLBCL is 
diffuse large B cell lymphoma, and N/S is not specified NHL. A) Cluster 374, expression profile 
of CD59 B) Cluster 461, expression profile of MCAM C) Cluster 680, expression profile of LDLR 
D) Cluster 852, expression profile of CD46 E) Cluster 882, expression profile of TMEM165 F) 
Cluster 1236, expression profile of SLC16A1 
Therefore, based on the literature search results CD59, CD46, and CD146 were initially 
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4.4 Validation of protein targets 
In order to use the results of the gene expression analysis, the proteins first had to be 
experimentally validated for expression on the BL line BL2. If the proteins were confirmed to 
be present on the surface of the BL2 cells, then the EVs derived from the cells can be analysed 
to determine whether the proteins are transferred to the surface of the EVs. 
4.4.1 Detection of proteins on cells 
BL2 cells were analysed by flow cytometry in cold PBS with 5% goat serum at a density of 1 x 
106 mL−1. 100 µL of this cell suspension was incubated with the appropriate monoclonal 
antibody, or isotype control for 40 minutes at 4°C. The washed cells were then resuspended 
in 500 µL of 5% goat serum in PBS and run on the flow cytometer with a stop point of 10,000 
events recorded in the cell gate. The results of this analysis are shown in Figure 4.4. BL2 cells 
are almost all positive for CD46, showing 99.9% of cell events in the positive gate (Figure 
4.4A), and are overwhelmingly positive for the presence of CD59, with 99.6% of cell events 
in the positive gate (Figure 4.4B). However, despite showing a reasonably high level of 
expression in the BL2 gene expression profile analysis (Table 4.3), BL2 cells did not stain 
positively for CD146, as only 0.8% of cell events were over the threshold set by the isotype 
control to enter the positive event gate (Figure 4.4C).  
Thus, although identified by bioinformatic analysis, CD146 was not analysed further and 
dropped from the potential panel of markers for the detection of EVs derived from BL cells. 
CD46 and CD59 showed strong expression levels on the BL2 cells, which is expected as these 
proteins are ubiquitously expressed on all tissue types, so these were brought forward to 




Figure 4.4: Flow cytometry of BL2 cells. A) BL2 stained with anti-CD46 antibody and the 
corresponding isotype control, showing 99.9% CD46-positive cells B) BL2 stained with anti-
CD59 antibody and the corresponding isotype control, showing 99.6% CD59-positive cells C) 
BL2 stained with anti-CD146 antibody and the corresponding isotype control, showing 0.84% 
CD146-positive cells 
4.4.2 Detection of proteins on EVs 
As BL2 cells showed strong staining with antibodies against CD46 and CD59, the presence of 
these proteins on the surface of EVs was investigated. EVs were separated from BL2 and BL2-
bcl2 cells as described in Section 2.3. The 1.2 µm filtrate from the EV separation procedure 
was used in flow cytometry analysis, diluted 4 in 5 with 0.1 µm filtered 5% goat serum in PBS, 
giving a final concentration of 1% goat serum. After 30 minutes incubation with the 
appropriate monoclonal antibody or isotype control, a 1 in 100 dilution of 10 µM ATTO390-
maleimide membrane dye was added and incubated with the sample for 15 minutes in order 
to non-specifically fluorescently label the EVs membrane proteins. The stained samples were 










avoid swarm detection, and events were recorded for 2 minutes. A fluorescent threshold was 
set based on the ATTO390-maleimide membrane dye, and thus only events positive for 
ATTO390-maleimide were detected. This removes any events due to electronic noise, or lipid 
particles, from the analysis, as only particles with a lipid membrane are fluorescent using this 
dye. A typical plot for this detection is shown in Figure 4.5E. The ATTO390-maleimide is 
measured on the VL1-H (440/50 nm) channel, and any events registered by the instrument 
which are not positive in this channel are removed. The SSC-H axis gives a rough indicator of 
particle size. Two gates were used in this detection strategy; the R2 gate shown in Figure 4.5E 
contained the majority of the EVs of interest to this study (63.9% of total ATTO390-maleimide 
positive events reside in this gate), the R1 gate is thought to contain a minority of larger 
particles which may be some debris which passed through the 1.2 µm filter during separation, 
so the events in this gate are not included in the analysis. 
Detection of proteins on the surface of the EVs was done using both monoclonal antibodies 
and the appropriate isotype control which was conjugated with the same fluorophore that 
was conjugated to the monoclonal. A gate is drawn on the histogram for the isotype control 
sample so that approximately 2% of events from the R2 ATTO390-maleimide gate are 
‘positive’ for the isotype control. This gate is then applied to the monoclonal antibody sample 
to gauge the number of events which stain positively for the protein under investigation. 
Separated BL2 EVs were analysed for the presence of both CD46 and CD59, shown in Figure 
4.5. Figure 4.5B and Figure 4.5D show the isotype control samples for the anti-CD46 antibody 
and the anti-CD59 antibody, respectively, giving less than 2% positive events from the R2 
scatter gate. Approximately 5% of the BL2 EVs stained positively with anti-CD46 monoclonal 
antibody (Figure 4.5A), which is not detectable over isotype control. Similarly, only 12% of 
BL2 EVs are stained positively with anti-CD59 monoclonal antibody (Figure 4.5C), which does 




Figure 4.5: Investigation of the presence of CD46 or CD59 on the surface of EVs derived from 
BL2 cells A) Histogram of BL2 EVs stained with anti-CD46 mAb showing 4.9% positive events 
B) Histogram of BL2 EVs stained with IgG2a isotype control for anti-CD46 mAb showing 1.5% 
positive events C) Histogram of BL2 EVs stained with anti-CD59 mAb showing 11.6% positive 
events D) Histogram of BL2 EVs stained with IgG2a isotype control for anti-CD59 mAb 
showing 1.7% positive events E) Scatter plot showing the events positive for ATTO-390 










Figure 4.6: Investigation of the presence of CD46 or CD59 on the surface of EVs derived from 
BL2-bcl2 cells A) Histogram of BL2-bcl2 EVs stained with anti-CD46 mAb showing 8.4% 
positive events B) Histogram of BL2-bcl2 EVs stained with IgG2a isotype control for anti-CD46 
mAb showing 1.6% positive events C) Histogram of BL2-bcl2 EVs stained with anti-CD59 mAb 
showing 48.2% positive events D) Histogram of BL2-bcl2 EVs stained with IgG2a isotype 
control for anti-CD59 mAb showing 2.0% positive events 
The same procedure was carried out using EVs separated from BL2-bcl2 cells, shown in Figure 
4.6. Figure 4.6B and Figure 4.6C shows the isotype control samples for the anti-CD46 
antibody and the anti-CD59 antibody, where the number of positive events are 
approximately 2% in each case. 8.5% of BL2-bcl2 EVs stain positively with anti-CD46 
monoclonal antibody (Figure 4.6A), which again is not much of a shift from the isotype control 
level. However, the number of BL2-bcl2 EVs which are positive for staining with anti-CD59 
monoclonal antibody is 48%, which is a reasonable increase above the isotype control. 
These data suggest that the CD46 membrane protein is not transferred onto the surface of 
either BL2 EVs or BL2-bcl2 EVs during their formation under these conditions. CD59 also does 
not appear to transfer to the surface of BL2 EVs. However, a larger proportion of BL2-bcl2 







well separated from the isotype control, meaning that it is likely that a large population of 
EVs contain a low copy number of these proteins. This may make detection using this protein 
difficult in other assays such as a SERS assay, thus neither CD46 nor CD59 were taken forward 
as proteins to use for the EV detection assay. 
4.5 Proteomics analysis of BL2 and BL2-bcl2 EVs 
Samples of BL2 EVs and BL2-bcl2 EVs were prepared for proteomics analysis by Margaret 
Paterson, and carried out in collaboration with the research group of Prof Tony Whetton at 
the University of Manchester. 
As proteomics data were available within the group, these were used to try to identify plasma 
membrane proteins present on the EVs surface. 
The data received were split into three categories: BL2 EVs only, BL2-bcl2 EVs only, and 
proteins which were found in both BL2 EVs and BL2-bcl2 EVs. This categorisation was useful, 
as proteins which were found on both BL2 EVs and BL2-bcl2 EVs could prove useful in the 
detection of BL EVs generally, whereas proteins which were found on the surface of only the 
BL2 derived EVs could be useful in the detection of apoEVs specifically. In total, 995 unique 
proteins were identified across both the BL2 EVs and BL2-bcl2 EVs; 864 proteins were 
detected in the BL2 EVs sample and 531 proteins detected in the BL2-bcl2 EVs sample. 400 
(40%) of these proteins were common to both the BL2 and BL2-bcl2 EVs, 464 proteins (47%) 
were found in the BL2 EVs only, and 131 proteins were unique to the BL2-bcl2 EVs (13%). 
In order to identify which of these proteins were located in the plasma membrane, the list of 
proteins was annotated with the gene ontology (GO) data using the biomaRt package for R.318 
There are three GO domains; ‘molecular function’ and ‘biological process’ describe the 
function of the gene, while ‘cellular component’ gives information on the cellular localisation 
of the gene product. Many cellular component labels describe locations which are associated 
with membranes, for example ‘plasma membrane’, ‘cell surface’, or ‘receptor complex’. 
Other terms of interest included those associated with EVs, such as ‘extracellular vesicle’, or 
‘extracellular exosome’. Other labels specifically describe locations which are associated with 
the cytosolic side of a membrane, such as ‘cell cortex’. These labels were used to rule out 
proteins which only associate with the internal structures of the plasma membrane, as these 
would not be useful as imaging targets. The full list of GO components used to identify 
potential plasma membrane proteins from the proteomics results is given as an appendix 
(Appendix 2).  
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Using the GO annotated proteomics data, a number of plasma membrane associated 
proteins were identified. The proteins common to both BL2 and BL2-bcl2 EVs are given in 
Table 4.4, alongside the expression in BL2 identified by gene expression profile array. Many 
of these common proteins are associated with B cell function, such as the pan-B cell marker 
CD20, CD79B, and CD45. CD10 is also present, which is a B cell marker known to be associated 
with BL. 
Table 4.4: Plasma membrane proteins which are common to both BL2 EVs and BL2-bcl2 EVs 
identified from proteomics data using GO components  
HGNC symbol Protein name BL2 expression 
(arbitrary units) 
Origin 
RPSA ribosomal protein SA (67 kD laminin 
receptor) 
10476 Common 
HSPA8 heat shock protein family A (Hsp70) 
member 8 
7784.323 Common 
MS4A1 membrane spanning 4-domains A1 (CD20) 2230.575 Common 
CD37 CD37 2168.75 Common 
CD48 CD48 2126.93 Common 
CD79B CD79B 1893.41 Common 
ATP1B3 ATPase Na+/K+ transporting subunit beta 
3 
1528.83 Common 
SLC7A5 solute carrier family 7 member 5 1031.58 Common 
ATP1A1 ATPase Na+/K+ transporting subunit alpha 
1 
676.29 Common 
PTPRCAP protein tyrosine phosphatase, receptor 
type C associated protein 
502.72 Common 
BSG Basigin (CD147) 502.42 Common 
PTPRC protein tyrosine phosphatase, receptor 
type C (CD45) 
498.6 Common 
SLC3A2 solute carrier family 3 member 2 (CD98) 479.87 Common 
CD38 CD38 422.295 Common 
BST2 bone marrow stromal cell antigen 2 333.72 Common 
F11R F11 receptor (Junctional adhesion 
molecule-A) 
310.0867 Common 
SLC1A5 solute carrier family 1 member 5 298.76 Common 
MME membrane metalloendopeptidase (CD10) 289.695 Common 
SLC16A1 solute carrier family 16 member 1 252.445 Common 




As CD20 is a pan-B cell marker which has been observed on EVs,319 this was chosen for initial 
studies to detect BL EVs using a SERS assay. 
The plasma membrane proteins detected in only the BL2 EVs is given in Table 4.5. Fewer of 
these proteins were identified as plasma membrane localising compared to the common 
proteins; only 10 BL2 EV proteins were found to be plasma membrane bound compared to 
20 for the group common to BL2 and BL2-bcl2 EVs, indicating that most of the changes 
observed in the apoEVs only are due to cytosolic proteins rather than those on the surface. 
Nucleolin is included in Table 4.5, despite this protein being ordinarily found in the nucleolus. 
However, nucleolin has been shown to localise to the plasma membrane, where it can 
interact with Fas to inhibit apoptosis.320 Nucleolin has a very high expression level in the gene 
expression profile data, however this is likely due to the nucleolar fraction, so nucleolin was 
not considered for detection of apoEVs. CD46 is also shown in Table 4.5, however as shown 
earlier this protein was not detectable above isotype control in a flow cytometry assay (Figure 
4.5). 
Table 4.5: Plasma membrane proteins which are unique to BL2 EVs identified from 
proteomics data using GO components  
HGNC symbol Protein name BL2 expression 
(arbitrary units) 
Origin 
NCL nucleolin 3749.45 BL2 
CD53 CD53 760.37 BL2 
CD46 CD46 675.4 BL2 
ST14 suppression of tumorigenicity 14 
(matriptase) 
602.445 BL2 
ITGB1 integrin subunit beta 1 338.5633333 BL2 
MPZL1 myelin protein zero like 1 298.395 BL2 
SLAMF6 signaling lymphocytic activation molecule 
family member 6 
296.32 BL2 
IGSF8 immunoglobulin superfamily member 8 152.08 BL2 
ROR1 receptor tyrosine kinase like orphan 
receptor 1 
120.91 BL2 
EMB embigin 58.19 BL2 
 
The protein CD53 is also shown in Table 4.5. CD53 is a tetraspanin protein associated with 
signal transduction in monocytes and B cells. Tetraspanins are well-known to be associated 
with EVs and CD53 has also been documented on EVs derived from B cells.321 CD53 has also 
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been shown to play a role in apoptosis, as CD53 is upregulated in a murine B cell lymphoma 
with increased resistance to radiation therapy,322 and cleavage of CD53 on a rat B cell 
lymphoma line protected the cells from apoptosis due to serum starvation.323 Therefore, 
CD53 appears to be a good candidate for use in detecting apoEVs. 
4.6 Discussion 
Open access gene expression profile data were used in order to identify plasma membrane 
proteins which could be useful in detecting BL EVs in a SERS assay. The gene expression data 
were analysed in the programme BioLayout Express3D. This software was designed to analyse 
functional linkages between genes in array data, not to identify upregulated genes. In order 
to identify genes which appeared to have higher expression in samples from lymphoma cases 
compare to healthy B cell samples, the expression profile of every cluster in the network 
graph had to be analysed and a judgement call was made on whether the expression pattern 
seemed higher for the lymphoma samples. This method may have introduced some user bias, 
as a large number of clusters had to be analysed, and the decision as to what constituted 
higher expression was arbitrary. 
Three candidate proteins were selected from this analysis: CD46, CD59, and CD146. Although 
there were data to suggest that CD146 was expressed in BL2 cells, flow cytometric analysis 
showed that CD146 was not detectable on the surface of the cells. Flow cytometry showed 
that CD46 and CD59 were abundant on the BL2 cell surface, so the presence of these proteins 
on the EVs surface was then investigated. A specific EV flow cytometric detection method 
was used, whereby the EV membrane was stained with a fluorescent membrane dye, 
ATTO390-maleimide, and the fluorescence of this compound was used as a detection 
threshold to record events. This strategy is common in the analysis of EVs in order to reduce 
instrument noise and non-EV sample contaminants. However, using this strategy neither 
CD46 nor CD59 appeared to be present on the EVs surface with enough abundance for use 
in a detection assay. It may be that the flow cytometry assay was not sensitive enough to 
detect all of the EVs present in the samples, and many positive events could have been 
missed. For this reason, flow cytometry is not always the best technique for the analysis of 
proteins on EVs, unless the instrument is specifically adapted and dedicated for the detection 
of small particles. 
Proteomics data for the BL2 EVs and BL2-bcl2 EVs became available for analysis, generated 
by another researcher in the group as part of a collaboration. Analysing these data for the 
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presence of plasma membrane-localising proteins gave a number of promising candidates 
for use in a BL EV detection assay. Thus, CD20 was brought forward as a target for the 
detection of both BL2 EVs and BL2-bcl2 EVs, and CD53 was identified as a potential target for 




5 Detection of extracellular vesicles by surface enhanced Raman 
spectroscopy 
5.1 Introduction 
Traditional methods of EV analysis include ELISA, flow cytometry, and Western blotting. 
Many of these are bulk analysis techniques which require large amounts of purified sample 
and cannot distinguish subpopulations of EVs. One method which overcomes some of the 
limitations of EV analysis is surface enhanced Raman spectroscopy (SERS). A small sample 
volume can be used, the signal enhancement results in sensitive assays, and using 
multiplexed analysis allows EV subpopulations to be investigated. 
5.1.1 EV characterisation using SERS 
Fabrication of nanostructures to enhance the Raman signal of a sample has been previously 
successful in characterising EVs. In one study, Si micropillars coated with nanograins of Ag 
formed super-hydrophobic surfaces to detect EVs by SERS. This device was used to compare 
spectra obtained from colon cancer and colon epithelial exosomes, and differences in protein 
and lipid composition were observed.324 However, a commercial reagent called ExoQuick was 
used to separate the EVs, which is a polymer solution that causes precipitation of exosomes 
from solution allowing separation using a much lower speed of centrifugation. Although the 
manufacturers state that the polymers do not bind or interact with the exosomes, Lee et al. 
showed in their study of EVs by SERS that a similar reagent, total exosome isolation reagent, 
(TEIR) did contaminate the EV sample.325 In this work, hexagonal wells of 800 nm diameter 
and 300 nm depth were fabricated on dimethylpolysiloxane and sputter coated with Ag to 
create plasmonic nanobowls big enough to fit only a single exosome. With an enhancement 
distance of only 5 nm, this generated signal only from the exosome surface. Comparing the 
signal obtained from the EV sample in solution with the spectrum of TEIR, all of the observed 
peaks in the EV sample can be attributed to the polymer. However, the authors then left the 
device to dry completely, causing lysis of the exosomes and disappearance of the TEIR signals 
from the spectra. Exosomes derived from ovarian cancer cells were used to compare the TEIR 
isolation with ultracentrifugation, the most commonly used separation technique. The 
exosomes separated by ultracentrifugation were not contaminated by the separation 
procedure and therefore had a more consistent SERS signal between the samples in solution 
and dried. However, they were found to have a more heterogeneous size distribution, and 
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larger standard deviation (SD) of SERS spectra than the corresponding TEIR-isolated 
exosomes.325  
Another device fabricated to characterise EVs using SERS contained gold nanopyramids (200 
x 200 nm2) covered with a layer of graphene. The graphene was chosen to act as an internal 
standard which allowed the normalisation of signal in order to overcome the variability of 
signal enhancement due to non-uniform hotspots. This device required only 2 µL of sample 
and could distinguish between exosomes separated from foetal bovine serum (FBS) and 
human serum using PCA, as well as exosomes from two different lung cancer cell lines, with 
an overall sensitivity of 84%.326 
By non-specifically binding EVs with roughened metal surfaces, their Raman spectral 
signature can be greatly enhanced for sensitive characterisation of the EVs. Stremersch et al. 
took advantage of the negative surface charge of EVs by incubating with positively charged 
4-dimethylaminopyridine capped 10 nm AuNPs. These small AuNPs coated the outside of the 
EVs, allowing for the sensitive characterisation of individual EVs by SERS while remaining in 
solution. This analysis technique showed differentiation of EVs derived from B16F10 
melanoma cells and red blood cells with a discrimination specificity of 95% and 98%, 
respectively.327 Another group used 10 nm gold nanoparticles (AuNPs) with positively-
charged branched polyethyleneimine as a capping agent to electrostatically adsorb the 
EVs.328 The sample was then dried onto a gold slide to further enhance the Raman signals. 
Using a principal component analysis-discriminant function analysis (PCA-DFA) algorithm, 
exosomes from pancreatic epithelial cells and two pancreatic cancer cell lines were 
distinguished with an overall classification accuracy of 90%. 
One study used targeted capture of exosomes onto silver nanoparticles (AgNPs) for 
characterisation using SERS. A thiolated peptide against α3β1 integrin (LXY30-SH) was 
incubated with exosomes from α3β1-expressing SCOV-3 cells or exosomes from Jurkat cells, 
which do not express α3β1 integrin. AgNPs were then added, which bound to the exposed 
thiol of LXY30 and were separated by centrifugation. The SERS spectrum of AgNP-LXY30-
SCOV-3 exosomes had peaks which were not present in the AgNPs, AgNP-LXY30, or AgNP-
LXY30-Jurkat spectra, showing that targeted binding of exosome subsets can be used for 
characterisation by SERS.329 
Other groups have brought the EVs into contact with signal enhancing material by drying. By 
drying a solution of AuNPs onto a glass coverslip, and drying EVs on top, exosomes from lung 
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epithelial cells were distinguished from two non-small cell lung cancer cells lines using PCA.330 
The same group then went on to alter this method, by drying AuNPs onto a coverslip and 
then coating the particles with cysteamine to give a positive charge. The negatively charged 
exosomes could then associate with the AuNPs and spectra of the EVs in solution were 
obtained.331 The aim of this study was to identify surface proteins present on pancreatic 
cancer exosomes by first comparing the spectra of cancer exosomes to those derived from 
non-cancerous epithelial cells by PCA. The loadings which separated the cancer exosomes 
were then compared to SERS spectra of possible surface markers (CD9, CD81, epithelial cell 
adhesion molecule (EpCAM), and epidermal growth factor receptor (EGFR)), obtained by 
labelling the AuNPs with a capture antibody for each protein. EGFR was found to contribute 
most to the cancer exosome identification and was validated by western blot.331 Exosomes 
derived from ovarian cancer cells grown either in normoxia (21% O2) or hypoxia (1% O2) were 
characterised using SERS by incubating the exosome solutions with citrate-capped AuNPs in 
PBS and drying onto CaF2.332 However, only 20 spectra from each exosome type were 
acquired and half of these had evidence of thermal damage, so although spectral differences 
were observed between hypoxic and normoxic EVs the results are not reliable. 
5.1.2 EV detection using SERS 
In order to create sensitive biosensors to detect the presence of EVs, surfaces can be labelled 
with antibodies and the captured EVs detected using SERS active nanoparticles coated with 
specific antibodies and Raman reporter molecules. In this way, non-target EVs can be 
removed from the system, allowing the analysis of a specific subpopulation. Using large or 
paramagnetic beads as a capture method, the EV sample can be concentrated for population 
analysis, or using a functionalised chip can yield information from individual EVs. 
5.1.2.1 Capture with magnetic beads 
One facile method for the detection of EVs by SERS is using magnetic beads to separate the 
desired subpopulation from a sample. Antibody-functionalisation of magnetic beads causes 
specific EVs to be pulled from solution, which then can be incubated with SERS-active 
nanoprobes to form a sandwich-type immunocomplex for detection. 
One group used a depletion assay in order to detect subpopulations of EVs. Using anti-CD63 
functionalised magnetic beads to capture all exosomes, SERS probes against cell-specific 
proteins were incubated with the sample. The decrease in signal for a specific probe indicated 
the presence of exosomes from that cell type, and the assay was successful with pure and 
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mixed samples of both different SERS probes and exosome types.333 Using only 2 µL of 
exosome solutions from both cell culture and patient blood samples, exosomes from breast 
cancer cells could be detected using anti-HER2 probes, prostate cancer exosomes using anti-
prostate-specific membrane antigen probes, and colorectal cancer exosomes using anti-
carcinoembryonic antigen SERS NPs, with limits of detection (LOD) of 32 exosomes/µL, 203 
exosomes/µL, and 73 exosomes/µL, respectively.333 Another study also used anti-CD63 
functionalised magnetic beads to capture exosomes and anti-HER2 labelled SERS 
nanoparticles for specific detection of breast cancer derived exosomes, but with positive 
detection rather than depletion. Only 1 µL of purified exosome solution was needed, or 100 
µL of unpurified cell culture supernatant, and the LOD was calculated to be 1200 
exosomes.334 Although this LOD is much higher than that achieved in the depletion study, in 
this work the EVs concentration was determined by labelling with a fluorescent cytoplasmic 
dye and counting on a total internal reflection fluorescence microscope, which is by no means 
a standard technique to determine EV concentration. Anti-CD9 functionalised magnetic 
beads have also been used to capture exosomes, with detection using gold nanostars with 
cholesterol-labelled DNA strands on their surface. The cholesterol is incorporated into the EV 
membrane, allowing detection of all captured exosomes. 200 µL of exosome sample was 
used, and the LOD of this system was found to be 27 exosomes/µL.335 This system was also 
tested using serum samples, from three healthy controls and three patients with liver cancer. 
The SERS quantification of exosome number correlated well with the concentration found by 
TRPS, although the SERS assay required a long incubation (10 hours) of the EVs with the 
magnetic beads. 
5.1.2.2 Capture on functionalised surface 
Rather than using magnetic beads for capture, one study used the self-assembly of 
polydopamine (PDA) on glass slides to encapsulate antibodies against proteins known to have 
increased expression in pancreatic cancer for detection of pancreatic cancer exosomes.336 
The SERS probes were composed of an AuNP core with a silver shell and also used PDA 
encapsulation to functionalise the probes with antibodies. Only 2 µL of exosome solution and 
3 µL of SERS probes were required, making this a very sensitive and effective assay. Two 
exosome markers, CD9 and CD63, were used for detection of exosomes from pancreatic 
cancer and epithelial cell lines, as well as two pancreatic cancer markers, glypican 1 (GPC-1) 
and migration inhibitory factor (MIF). Using the same antibodies for both capture and 
detection, pancreatic exosomes and pancreatic epithelial exosomes were found to have 
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similar levels of CD9 and CD63, but GPC-1 and MIF were preferentially detected on cancer 
exosomes with a LOD equivalent to 1 exosome in the 2 µL test sample. The assay was also 
used on serum from patients with pancreatic cancer and healthy controls. Not only could the 
anti-MIF immunosensor differentiate between exosomes from patient and healthy samples, 
when the pancreatic patients were divided into subgroups, the results were also significant 
in detecting early vs late stage disease and metastatic vs non-metastatic disease.336 
Another study reports the fabrication of an antibody-coated gold chip microarray for the 
capture of exosomes from different breast cancer cell lines.337 Using a 3D-printed plastic 
array template, wells of 2 mm diameter and 15 µL capacity were created on a gold chip and 
functionalised with HS-PEG-antibody. Antibodies were chosen based on breast cancer 
surface markers (EpCAM, CD44, EGFR, IGFR) and exosome markers (CD81, CD63, CD9). 
Binding of exosomes to the antibodies was validated by staining with a fluorescent 
membrane dye visualised by microscopy. The presence of exosomes in the wells was 
detected using gold nanorods (AuNRs) with QSY21 Raman reporter molecule. The capping 
agent (CTAB) is positively charged and could electrostatically adsorb to the exosomes for 
detection. The protein markers detected on the exosome surface by SERS were found to 
reflect the expression of those proteins on the parental cell, indicating that plasma 
membrane proteins can be transferred to the exosome surface. The SERS results were 
validated by ELISA, with a 0.97 correlation coefficient between the SERS and ELISA signals. 
The SERS assay was also carried out on plasma samples from HER2-positive breast cancer 
patients, which were found to have significantly higher levels of EpCAM and HER2 compared 
to healthy controls.337 
5.1.3 SERS on nitrocellulose 
Nitrocellulose is a commonly used material to non-specifically bind proteins. Proteins are 
adsorbed onto the surface by hydrophobic interactions and can be bound either by 
transferral using an electric current, as in Western blotting, or by simply placing a drop of 
protein solution on the membrane. Nitrocellulose is extremely useful for immunodetection 
of specific proteins and has been combined with SERS to yield sensitive detection assays. 
5.1.3.1 Protein detection on nitrocellulose 
SERS immunoblots have been used as an alternative to fluorescence or enzyme detection 
such as ELISA due to a higher sensitivity and ability to multiplex. SERS immunoblots have 
been used for the detection of purified samples of IL-6 and duplexed detection of IL-6 and  
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IL-8.338 IgG was detected using a SERS assay on nitrocellulose, but the LOD was calculated to 
be greater than the highest concentration of protein tested (20 ng in 2 µL) due to non-
uniform distribution of the protein on the membrane.339 The same study also detected 
bovine β-lactoglobulin, and CACNA1F retinal membrane protein in cell lysate. IgG has also 
been detected using small (2-5 nm) AuNPs using a silver enhancement step after nanoparticle 
binding to increase the scattering cross-section for sensitive detection by SERS.340 
5.1.3.2 Cells binding on nitrocellulose 
Circulating tumour cells (CTCs) are rare events which can be found in the blood of cancer 
patients. Much like EVs, they are being investigated as a liquid biopsy method of cancer 
diagnosis or prognosis. One study has used nitrocellulose to capture lung cancer cells by 
adsorbing anti-EpCAM antibody to the nitrocellulose and detecting the captured cells using 
anti-EpCAM functionalised SERS nanoparticles.341 The membrane had been made 
transparent prior to the adsorption of antibody, so the detection of cells was verified by 
brightfield microscopy. Capture efficiency increased with an increase in the number of cells 
applied to the membrane. Cells were also detected which had been spiked into blood as a 
proof-of-concept for the detection of CTCs, but the detection efficiency was only 34%. 
In a microfluidic device for the detection of glucose in blood, a nitrocellulose channel was 
included in the design to bind the protein and cells in the whole blood samples to allow on-
chip separation of blood components before detection with SERS nanoparticles.342 This study 
shows that whole cells can be adsorbed onto the nitrocellulose surface as well as proteins 
and smaller molecules. 
5.2 Aims of chapter 
The aim of this work was to develop a SERS-based assay for the detection of EVs. The 
proteomics results discussed previously in Section 4.5 were used to identify proteins that 
could be used as targets for a SERS probe. Due to the high centrifugation speeds required to 
pellet EVs, separation of the unbound reporter-labelled nanoparticles could not be easily 
achieved by a centrifugation method. In order to get efficient washing of unbound AuNPs 
from EVs, a capture method was used. Published literature of SERS detection of EVs have all 
studied exosomes, which have known protein markers enriched on the surface to non-
specifically capture all exosomes in the sample. Due to the differences in biogenesis of the 
EVs studied here and exosome-type vesicles in the literature, and a lack of knowledge of 
surface markers present on EVs in this study, another approach was required.  
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A nitrocellulose membrane was used in order to non-specifically bind the EV membrane 
proteins. This was chosen as a capture method as it would non-specifically capture all EVs 
present in the sample. The SERS nanoparticles functionalised with antibodies against the 
chosen plasma membrane proteins were then applied, and the unbound nanoparticles could 
be washed off the membrane. 
5.3 Synthesis of SERS nanoparticles 
5.3.1 Synthesis of gold nanoparticle colloid 
A colloid of gold nanoparticles was synthesised using the citrate reduction method.294 Gold 
tetrachloroaurate was dissolved in boiling deionised water, and sodium citrate was added in 
order to form gold nanoparticles. The nanoparticles were characterised using UV-vis to 
measure the local surface plasmon resonance (LSPR) and to determine the concentration of 
nanoparticles in the colloidal suspension. The surface charge and hydrodynamic radius were 
analysed by dynamic light scattering (DLS) using Zetasizer Nano ZS (Malvern). 
UV-vis analysis of the citrate-capped AuNPs show that the LSPR reaches a maximum at 530 
nm (Figure 5.1), which is expected for gold nanoparticles of this size. The concentration of 
AuNPs, calculated using the Beer-Lambert law with an extinction coefficient343 of 7.66 x 109 
M−1 cm−1 and a path length of 1 cm, was found to be 0.2 nM.  
The DLS results, given in Table 5.1, show that the particles are approximately 22 nm in 
diameter, with a zeta potential of -40 mV indicating that they are stable against aggregation. 
However, the polydispersity index (PdI) of the nanoparticles was reasonably high at 0.66, 






Figure 5.1: Extinction spectrum of citrate-capped gold nanoparticles 
Table 5.1: Zavg and zeta potential of citrate-capped gold nanoparticles with standard 
deviation (SD) of three replicates measured by DLS 
Size  ZAvg (nm) ± SD PdI 
 21.69 ± 0.15 0.66 
Zeta potential mV ± SD  
 -40.1 ± 1.1  
 
5.3.2 Functionalisation of gold nanoparticles 
5.3.2.1 Raman reporter concentration 
A Raman reporter molecule was used in order to increase the sensitivity of analyte detection. 
Malachite green isothiocyanate (MGITC) was chosen as the reporter, as it has low 
background fluorescence and a Raman enhancement factor on AuNPs of approximately 3 x 
106.344 MGITC also exhibits strong absorbance at 621 nm, and would therefore be in 
resonance  with 633 nm laser excitation to give surface enhanced resonance Raman (SERRS). 
MGITC binds to gold surfaces via the sulfur of the isothiocyanate, which can be seen by the 
presence of an Au-S band in the SERS spectrum at 218 cm−1, and the presence of -N(CH3)2 
bending and rocking bands at 1433 cm−1 and 1475 cm−1 indicates that the positively charged 
dimethylamino group is also in contact with the metal surface.344 
In order to determine the optimal concentration of MGITC on the AuNP surface to yield good 
SERS signal, both in solution and on nitrocellulose, a dilution series of different 
concentrations of MGITC were added to the AuNPs. A stock solution of 100 µM MGITC was 
made up and the appropriate volume added to 1 mL of AuNPs to yield final concentrations 


























centrifugation and the MGITC AuNPs were resuspended in 1 mL water for characterisation. 
The LSPR, size, and SERS spectra of each MGITC concentration was then measured. 
The sizes of the MGITC coated AuNPs, acquired by DLS, are given in Table 5.2. There is a slight 
increase in the size of the MGITC AuNPs compared to unfunctionalised nanoparticles, which 
is to be expected as DLS measures the hydrodynamic radius, which will be changed by the 
addition of a charged molecule such as MGITC to the surface of the nanoparticles. The 0.5 
µM MGITC AuNP suspension had obvious aggregation, which can be seen as this sample had 
the highest measured diameter of 108 nm. For 0.1-0.3 µM MGITC, the size increased to 
approximately 25 nm, compared to 22 nm measured for the unfunctionalised particles. 0.4 
µM and 0.6 µM MGITC were 28 nm diameter, and 0.8-1 µM were approximately 29 nm. The 
increase in average diameter seen with increasing MGITC concentration could be due to the 
formation of small aggregates. It has been reported that the addition of a small volume of 
highly concentrated MGITC stock solution to an AuNP colloid can form stable multimeric 
aggregates, due to the high local concentration of MGITC displacing citrate molecules from 
the surface of a small number of particles, and the higher positive charge on these 
nanoparticles attract the more negatively charged citrate-capped AuNPs to irreversibly form 
aggregates.344 However, the largest diameter was not observed for the AuNPs with the 
highest concentration of MGITC as would be expected, as the 0.7 µM MGITC AuNPs were 
measured to have a diameter of 33 ± 1.07 nm. This sample also had the lowest PdI value of 
0.56 
Table 5.2: Zavg of different concentrations of MGITC added to AuNPs with SD of three 
replicates and PdI to indicate monodispersity. Data acquired by DLS. 
 Zavg (nm) ± SD PdI 
AuNP citrate 21.69 ± 0.15 0.66 
AuNP MGITC 0.1 µM 25.55 ± 0.28 0.60 
AuNP MGITC 0.2 µM 24.95 ± 0.13 0.59 
AuNP MGITC 0.3 µM 25.9 ± 0.14 0.61 
AuNP MGITC 0.4 µM 28.1 ± 0.99 0.58 
AuNP MGITC 0.5 µM 108 ± 3.13 0.22 
AuNP MGITC 0.6 µM 28.05 ± 1.37 0.61 
AuNP MGITC 0.7 µM 33.66 ± 1.07 0.56 
AuNP MGITC 0.8 µM 29.19 ± 0.94 0.59 
AuNP MGITC 0.9 µM 29.04 ± 0.29 0.56 
AuNP MGITC 1 µM 29.92 ± 0.21 0.57 
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When the AuNPs are functionalised with MGITC, the LSPR red-shifts to 535 nm (Figure 5.2). 
This is in line with the increase in size seen by DLS, as the LSPR increases with an increase in 
particle size. 
 
Figure 5.2: Extinction spectra (normalised to extinction at 450 nm) of MGITC-functionalised 
AuNPs over a range of MGITC concentrations. 
The SERS spectra of the MGITC AuNPs in water were acquired using a Snowy Range 
spectrometer using 785 nm excitation wavelength with 45 mW power and an integration 
time of 1 second (Figure 5.3A). The aggregation of the 0.5 µM MGITC AuNPs can be seen in 
the SERS spectrum of these particles, as some of the peaks have shifted. The intensities of 
the spectra for the lowest concentrations of MGITC (0.1 and 0.2 µM MGITC AuNPs) are 
noticeably reduced when compared to the spectrum of 1 µM MGITC AuNP, by 4-fold and 2.5-
fold, respectively. The concentration that gives the highest intensity spectrum is 0.6 µM 
MGITC AuNPs, but the intensities in this spectrum are not greatly increased over either the 
1 µM MGITC AuNP or 0.8 µM. The results of this dilution study show that MGITC is easily 
adsorbed onto the surface of the AuNPs and gives a good SERS signal over a range of 
concentrations. 
As the aim of this experiment was to preform SERS of EVs captured onto nitrocellulose, it was 
necessary to obtain SERS spectra of the MGITC AuNPs dried onto this substrate to ensure 
that a robust signal was also seen when the particles were not in solution and analysed under 
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dried onto raw nitrocellulose. Raman maps of three areas of the AuNP spot were acquired 
using the streamline beam configuration of a Renishaw InVia spectrometer, using 785 nm 
laser excitation at 9 mW power with a 2 second integration time. The mean signal of the 
three maps of each spot were calculated, to reduce the variation in intensity due to the 
coffee-ring drying effect or heterogeneity in density of the MGITC AuNPs on the 
nitrocellulose. The mean spectra are shown in Figure 5.3B. The overall signal intensity is 
greatly reduced when comparing the spectra acquired on the nitrocellulose to the MGTIC 
AuNPs in solution. A reduced laser power must be used for the samples on nitrocellulose, as 
if the laser power and integration time are too high then the substrate will heat up and burn. 
There will also be less MGITC AuNPs present within the laser irradiation spot on the 
nitrocellulose than are present within the laser volume when examined in solution. However, 
although the SERS signal of the MGITC AuNPs is reduced on nitrocellulose, the MGITC peaks 
can still be clearly seen. The concentration of MGITC which gave the highest SERS signal is 
0.7 µM MGITC AuNPs, so this concentration was used for all future experiments. 
There are some peaks present in the spectra of the MGITC AuNPs on nitrocellulose which are 
background signal from the substrate, such as the shoulder at 850 cm−1 and the 1374 cm−1 
peak which causes the lack of resolution between the 1363 cm−1 and 1430 cm−1 peaks of 
MGTIC (Figure 5.4). A comparison of the peaks observed in the SERS spectrum of MGITC 
AuNPs in solution and the intrinsic Raman spectrum of the nitrocellulose substrate are listed 
in Table 5.3. Some MGITC distinguishing peaks, such as those at 1169 cm−1 and 1581 cm−1, do 
not contain significant overlap with peaks produced by the nitrocellulose. Since the 1169 
cm−1 peak has the highest intensity of the MGITC peaks, and no contributing noise from the 
capture substrate, the intensity of this peak can be used as the marker of MGITC AuNP 
presence in the EV detection assay. On nitrocellulose, this peak is shifted to 1171 cm−1, which 
could be due to the influence of the nitrocellulose on the MGITC signal or could possibly be 




Figure 5.3: SERS spectra of various concentrations of MGITC adsorbed onto the surface of 
AuNPs. A) MGITC AuNPs in solution. Spectra were acquired on a Snowy spectrometer using 
785 nm excitation with integration time of 1 second at 45 mW. B) MGITC AuNPs spotted and 
dried onto raw nitrocellulose. Spectra represent the mean of three areas of the AuNP spot 
mapped using the streamline configuration of a Renishaw InVia with 785 nm laser excitation, 






Figure 5.4: Comparison of SERS spectra of MGITC AuNPs in solution and adsorbed onto 
nitrocellulose, with the intrinsic Raman spectrum of nitrocellulose acquired under the same 
conditions as the MGITC AuNP maps. All spectra were acquired using 785 nm laser excitation. 
Spectra were scaled to unity in order for the spectral intensities to be comparable. The main 
nitrocellulose peaks observed at 850 cm−1 , 1284 cm−1, and 1374 cm−1 can be observed in the 
0.3 µM MGITC AuNP nitrocellulose spectrum, and the two most prominent MGITC peaks 
which do not overlap with nitrocellulose peaks are those at 1169 cm−1  and 1581 cm−1. 
Nitrocellulose samples were acquired with a Renishaw inVia spectrometer with 9 mW laser 
power and 2 second acquisition time and the sample in solution was acquired using a Snowy 







Table 5.3: SERS peaks observed in the spectrum for MGITC AuNPs in solution and the intrinsic 
Raman peaks of nitrocellulose 
MGITC 
Raman shift (cm−1) 
Nitrocellulose 




















5.3.2.2 Antibody conjugation to AuNPs 
Based on the results of the proteomics analysis of the BL2 and BL2-bcl2 EVs, CD20 and CD53 
were chosen as biomarker targets for binding to SERS AuNPs. CD20 is a pan-B cell marker and 
was found to be present on both BL2 apoEVs and BL2-bcl2 EVs. CD53 is a tetraspanin protein 
found predominantly on leucocytes. Proteomics results indicated that CD53 is present only 
on the apoEVs and was not detected in the BL2-bcl2 EVs. These two proteins were chosen as 
targets for detection by SERS as the anti-CD20 SERS AuNPs should bind to both types of EVs 
but the anti-CD53 should be specific for apoEVs. 
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Monoclonal antibodies against both of these proteins were conjugated to MGITC-
functionalised AuNPs using polyethylene glycol (PEG), giving two different SERS probes 
consisting of AuNPs functionalised with MGITC Raman reporter and the appropriate 
antibody. For initial studies, the same reporter was used for both SERS probes, however once 
the assay is optimised a different reporter molecule could be used for each SERS probe so 
that both proteins could be detected in the same assay. Two different carboxy-PEG-thiol 
molecules, carboxy-PEG12-thiol with a molecular weight of 635 g/mole (PEG635) and PEG 
with a molecular weight of 5000 g/mole (PEG5000), were used in order to determine whether 
the length of the polymer had an effect on the stability of the AuNPs and the SERS signal. The 
thiol group of the PEG moiety has an affinity for the gold surface of the nanoparticle, and the 
carboxy group on the other end of the linker allows coupling of NH2 groups of the antibody 
via EDC/NHS coupling. The spectra of anti-CD20 monoclonal antibody conjugated to MGITC-
functionalised AuNPs using both PEG635 and PEG5000 is shown in Figure 5.5A. The PEG635-
conjugated AuNPs give a much weaker SERS signal than the AuNPs which had been 
conjugated using PEG5000. PEG5000 was therefore used to conjugate both antibodies to the 
AuNPs surface. The SERS spectra of anti-CD20 monoclonal antibody conjugated to MGITC-
functionalised AuNPs using PEG5000 and anti-CD53 monoclonal antibody conjugated to 
MGITC-functionalised AuNPs using PEG5000 are shown in Figure 5.5B. The spectrum of 
MGITC-functionalised AuNPs is also shown for reference, to show that the conjugation of 
antibodies to the nanoparticle surface does not change the spectrum of MGITC. 
The antibody-conjugated SERS nanoparticles were also characterised by extinction 
spectroscopy and DLS. The extinction spectrum of anti-CD20 and anti-CD53 functionalised 
AuNP are shown in Figure 5.6. The LSPR of citrate-capped AuNP is 530 nm, whereas the 
functionalised AuNPs have a slightly red-shifted LSPR at 535 nm. The concentration of AuNPs 
in the antibody conjugated samples was calculated to be 8.2 x 10−11 M for anti-CD53 SERS 
AuNP and 8.4 x 10−11 M for anti-CD20 SERS AuNP when resuspended in 1 mL of water. The 
sizes of the different conjugates are given in Table 5.4. The anti-CD53 conjugates are larger 
than the anti-CD20 AuNPs, with the PEG635 AuNPs measuring 47.44 ± 0.39 nm and 37.98 ± 
0.33 nm, respectively. The PEG5000 anti-CD20 conjugated AuNPs are larger than the PEG635 
counterpart, at 40.44 ± 0.14 nm in diameter. The anti-CD53 antibody conjugated with 
PEG5000 are slightly smaller than the PEG635 equivalent AuNPs however, at 45.57 ± 0.15 
nm. These are increased from the unfunctionalized citrate-capped AuNP, which were 21.69 





Figure 5.5: Conjugation of monoclonal antibodies to AuNPs using PEG. A) anti-CD20 
monoclonal antibody was conjugated to MGITC-functionalised AuNPs with both PEG635 and 
PEG5000. The PEG5000 conjugated SERS nanoparticles give a stronger SERS signal than the 
nanoparticles conjugated using PEG635. B) The SERS spectra of anti-CD20 conjugated with 
PEG5000 to MGITC-functionalised AuNPs and anti-CD53 conjugated with PEG5000 to MGITC-
functionalised AuNPs. The spectra of MGITC-functionalised AuNPs is also shown as a 
comparison to show that the antibody conjugation does not affect the MGITC spectrum. All 
spectra were acquired with 785 nm laser excitation on a Snowy Sierra spectrometer using 45 






Figure 5.6: Extinction spectroscopy of functionalised gold nanoparticles. The LSPR of the 
antibody-conjugated AuNPs is 535 nm.  
Table 5.4: Size of antibody-conjugated AuNPs measured by DLS 
 
Size mean ± SD 
AuNP MGITC anti-CD53 PEG635 47.44 ± 0.39 
AuNP MGITC anti-CD53 PEG5000 45.58 ± 0.15 
AuNP MGITC anti-CD20 PEG635 37.98 ± 0.33 
AuNP MGITC anti-CD20 PEG5000 40.44 ± 0.14 
 
5.4 Detection of BL2 cells using SERS nanoparticles 
In order to test the SERS detection method on nitrocellulose and optimise the data 
acquisition and processing, the anti-CD20 SERS AuNPs were first used on BL2 cells adsorbed 
to nitrocellulose. 
Unfixed viable BL2 cells from culture were diluted in PBS to give cell solutions with 
concentrations varying from 10 x 106 mL−1 to 5 x 106 mL−1. 1 µL of each of these cell 
suspensions was dropped onto a 1 cm x 1 cm square of nitrocellulose, the edges of the spot 
were marked, and the nitrocellulose was allowed to dry. Care was taken not to allow the tip 
of the pipette to touch the nitrocellulose when applying the cells, as this would create a 
groove in the nitrocellulose in which AuNPs could accumulate. When the nitrocellulose was 
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for 1 hour at room temperature. 20 µL of anti-CD20 conjugated MGITC AuNPs (0.84 nM) was 
then added with 150 µL of 0.1% BSA/0.05% Tween 20 in 10 mM phosphate buffer (BSA/PBT) 
and placed on a shaker at room temperature for one hour. The nitrocellulose squares were 
then washed with 0.05% Tween 20 in 10 mM phosphate buffer (PBT) to remove any SERS 
AuNPs which had bound non-specifically. For the samples with higher cell concentrations, a 
visible red spot of AuNPs was observed. 
Raman maps of control untreated nitrocellulose, nitrocellulose blocked with BSA, and 
nitrocellulose blocked and incubated with BSA/PBT were taken, in order to ensure that these 
molecules do not interfere with the signal obtained. The spectra are shown in Figure 5.7. The 
untreated nitrocellulose has a relatively high Raman background, which is greatly reduced 
when the samples are blocked and exposed to BSA/PBT. No additional Raman peaks were 
observed due to these agents, therefor no additional background peaks should be observed 
and the MGITC signal will not be masked further. 
 
Figure 5.7: Raman spectra of control nitrocellulose samples. The untreated nitrocellulose has 
a high background, which is reduced when blocked with BSA and incubated with Tween 20 
in phosphate buffer. No additional peaks were observed in these samples. All spectra were 
acquired with 785 nm laser excitation in streamline beam configuration on a Renishaw inVia 
spectrometer with 9 mW laser power and a 2 second acquisition time. 
Raman maps were then taken of the cell samples on nitrocellulose which had been incubated 
with the anti-CD20 SERS AuNPs. An area of 500 x 500 steps in both the x and y was mapped, 
with a step size of 3.5 µm, which covered the area of the visible AuNP spot. For samples 
without a visible nanoparticle spot, the centre of the marked droplet was mapped. The 
cosmic ray removal tool on the WiRE 4.4 software was used to remove any spurious peaks 
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which may interfere with the data processing. The intensity of the MGITC peak at 1171 cm−1 
was measured and a false colour map of intensity was plotted. However, some areas of the 
maps were giving an intensity value which seemed anomalously high. Upon investigating the 
original data, it was found that the samples had some regions of very high background, 
despite the observed effect of the nitrocellulose blocking. Therefore, in order to remove the 
areas of high background from the results the intensity at the base of the nitrocellulose peak 
1140 cm−1, was subtracted from the intensity at 1171 cm−1, and this value was then used in 
the data processing. A minimum threshold of 100 was set, and a mask was created to remove 
any areas of the map which had a relative intensity of below 100 (Figure 5.8). The BL2 cell 
concentrations where the AuNP spots were visible, 8 x 106 mL−1 (Figure 5.8D), 9 x 106 mL−1 
(Figure 5.8E), and 10 x 106 mL−1 (Figure 5.8F), have clear round spots in the mask where the 
AuNPs have bound to the BL2 cells. The lower concentrations which did not have visible 
spots, 5 x 106 mL−1 (Figure 5.8A), 6 x 106 mL−1 (Figure 5.8B), and 7 x 106 mL−1 (Figure 5.8C), still 
have areas of SERS signal in the mask, demonstrating that NPs had bound but the 
concentration was so low that it was not visible to the eye. The PBS no cell control has no 
visible signal from the MGITC anti-CD20 SERS AuNPs (Figure 5.8G). It appears that most of 
the signal comes from the edge of the spot, indicating that there may be a slight coffee-ring 
effect occurring when the cell solutions dry on the nitrocellulose, leading to the majority of 
cells drying in the outside of the spot which yields an uneven SERS signal distribution. In 
Figure 5.8E, an area on the bottom-right edge of the AuNP spot was found to have burned 
after the Raman map had completed, which may have been due to a high concentration of 
AuNPs becoming hot when in the path of the laser and causing the underlying nitrocellulose 
to burn. This coffee-ring effect can be concentration dependent and can be reduced by 
reducing the volume of the droplet.345 However, only 1 µL of each cell suspension was applied 
to the nitrocellulose and if this were to be reduced further the droplet would not easily 
detach from the pipette tip without the tip touching the surface of the nitrocellulose. The 
coffee-ring effect can also be supressed by the addition of molecules such as PEG or sugar to 
increase the viscosity of the droplet.346,347 
The number of pixels in the mask showing relative intensity of >100 was used as a measure 
of the number of MGITC-functionalised AuNPs detected. This is shown in Figure 5.9. The PBS 
no cell control has negligible detected signal. The number of pixels in the mask of the BL2 cell 
samples generally increased with an increasing number of cells applied to the nitrocellulose. 
The highest concentration of cells, 10 x 106 mL−1, was measured to have 9814 AuNP pixels, 9 
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x 106 BL2 cells mL−1 had 9334 pixels, and the 7 x 106 mL−1 sample had 5470 pixels above the 
threshold. The highest number of pixels was detected in the 8 x 106 mL−1 sample, with 16490. 
The two lowest concentrations, 5 x 106 mL−1 and 6 x 106 mL−1, had a very low level of detected 
signal, at 738 and 1242 pixels, respectively. The 5 x 106 mL−1 sample has less than 10% of the 
detected signal of the 10 x 106 mL−1 sample, indicating that the number of pixels is not directly 
proportional to the number of cells. It may be that the addition of more cells causes the 
AuNPs to form larger hot spots on the nitrocellulose, increasing the signal intensity and 
therefore the number of pixels detected above the threshold value of 100. Therefore, 
although the AuNPs are binding to the cells, the SERS signal intensity relationship with the 




Figure 5.8: MGITC peak intensity mask of 
1170 cm−1 – 1140 cm−1 with threshold level of 
100, for varying dilutions of BL2 cells on 
nitrocellulose incubated with anti-CD20 
conjugated SERS nanoparticles. The white 
pixels are those with a signal of less than 100 
arbitrary units. A) 5 x 106 mL−1 BL2 cells B) 6 x 
106 mL−1 BL2 cells C) 7 x 106 mL−1 BL2 cells D) 
8 x 106 mL−1 BL2 cells E) 9 x 106 mL−1 BL2 cells 
F) 10 x 106 mL−1 BL2 cells G) PBS no cell 
control. Raman data were acquired using 785 
nm laser excitation in streamline beam 









Figure 5.9: The quantification of the number of pixels in the MGITC peak intensity mask of 
1170 cm−1 – 1140 cm−1 with a threshold level of 100 for varying concentration of BL2 cells. 
The number of pixels in the mask is roughly dependent on the concentration of cells applied 
to the nitrocellulose. 
5.5 Detection of BL2 and BL2-bcl2 EVs with SERS nanoparticles 
As the preliminary SERS assay using the BL2 cells appeared successful, the assay was then 
attempted for the detection of EVs captured on the nitrocellulose. The EVs were prepared 
from UV-irradiated BL2 and BL2-bcl2 cells and separated by dual filtration through a 5 µm 
mesh filter and 1.2 µm syringe filter as described in Section 2.3. In order to increase the 
concentration of EVs in the suspension, and to remove the proteins present in the media 
which would bind to the surface of the nitrocellulose, the EV suspensions were centrifuged 
at 20,000 g for 1 hour at 4°C. Two separate 500 µL aliquots of each EV suspension were 
pelleted. One pellet was resuspended in 1 mL of 0.1 µm filtered PBS and used to quantify the 
number of EVs in the pellet using a NanoSight. The other pellet was resuspended in 100 µL 
of 0.1 µm filtered PBS and assumed to have a concentration of 10x that of the 1 mL EV 
suspension. Based on reports of EV concentrations in the blood of cancer patients and 
healthy controls of approximately 50x108 mL−1,158 and the concentrations of EVs found in the 
in vitro preparations, a serial dilution with concentrations ranging from 40 x 108 mL−1 to 5 x 
108 mL−1 was used.  
The samples were spotted onto the nitrocellulose and incubated with anti-CD20 SERS 
nanoparticles or anti-CD53 SERS nanoparticles, as described in Section 5.4. Three 
independent EV preparations were carried out. For two of these three, the 20,000 g pellet 
had a concentration of less than 40 x 108 mL−1. In one of these instances, the sample was 
diluted with 0.1 µm filtered PBS to yield a concentration of 20 x 108 mL−1, and so for the 40 x 
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108 mL−1 sample two 1 µL spots were applied to the nitrocellulose, allowing the drop to dry 
in between applications. In the other instance, the 20,000 g pellet had a concentration of 
only 10 x 108 mL−1, so two and four 1 µL drops were applied for the 20 x 108 mL−1 and 40 x 
108 mL−1 samples, respectively.  
The data were acquired and analysed as described in Section 5.4, where the peak height of 
the 1171 cm−1 peak was found by subtracting the peak intensity at 1140 cm−1 from the 1171 
cm−1 intensity and using this to generate a mask of MGITC signal with a threshold level of 
100. The mean number of pixels in the masks of the three replicate experiments was 
calculated along with the SD and is shown in Figure 5.10. The No EV control was found for 
each type of SERS nanoparticle. The PBS control used in the cell detection described in 
Section 5.4 was used, together with a second PBS control carried out alongside the EV 
samples and a region outside of the sample droplet area was mapped as a third control. The 
number of pixels in the anti-CD20 SERS nanoparticle no EV control samples was 69 ± 72, 
which is low when compared to the signals achieved for the cell samples in Figure 5.9, 
although the SD is high. However, the signals achieved for the BL2 EV samples with anti-CD20 
SERS nanoparticles are comparable to this control (Figure 5.10A). The 40 x 108 mL−1 droplet 
had a pixel area of 170 ± 111, the 20 x 108 mL−1 sample gave a pixel area of 103 ± 68, 10 x 108 
mL−1 yielded an area of 83 ± 51 pixels and the sample with the lowest concentration of 5 x 
108 BL2 EVs mL−1 actually generated the highest MGITC pixel area, of 239 ± 425 pixels.  
The results for the BL2-bcl2 EVs incubated with anti-CD20 SERS nanoparticles are similarly 
unreliable (Figure 5.10B). Only the 40 x 108 mL−1 sample had a pixel number greater than that 
of the no EV control, at 74 ± 50 pixels. For the 20 x 108 mL−1, 10 x 108 mL−1, and 5 x 108 mL−1 
samples the areas were 22 ± 19 pixels, 21 ± 13 pixels, and 51 ± 50 pixels, respectively. Again, 
the lowest concentration of BL2-bcl2 EVs sees an increase in the MGITC signal detected when 
compared to some of the higher EV concentrations analysed.  
For the anti-CD53 SERS nanoparticles, the no EV control samples had a mean area of 130 ± 
170 pixels. This large SD indicates the high variability in SERS AuNP detection by this method. 
Based on the proteomic results, CD53 should only be found on BL2 EV and should not be 
present on BL2-bcl2 EVs. The BL2 EV samples incubated with anti-CD53 SERS nanoparticles 
each had similar values for the MGITC pixel area (Figure 5.10C). 40 x 108 EV mL−1 had 80 ± 31 
pixels above the threshold, and 20 x 108 mL−1 yielded 84 ± 54 pixels. The pixel area found for 
10 x 108 mL−1 was 65 ± 69, and the 5 x 108 mL−1 sample was found to have 67 ± 100 pixels. All 
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of the BL2 EV samples incubated with the anti-CD53 SERS nanoparticles had a fewer pixels 
above the threshold than the control. The same was found of the BL2-bcl2 EV samples 
incubated with anti-CD53 SERS nanoparticles (Figure 5.10D). The number of pixels was found 
to be 45 ± 30, 31 ± 14, 30 ± 36, and 138 ± 261 for the 40 x 108 mL−1, 20 x 108 mL−1, 10 x 108 
mL−1, and 5 x 108 mL−1 samples, respectively. 
 
Figure 5.10: Quantification of MGITC signal from SERS EV detection assay. Each pixel area 
represents the mean of three independent experiments with ±1 SD A) BL2 EVs at various 
concentrations on nitrocellulose incubated with anti-CD20 conjugated MGITC AuNPs. B) BL2-
bcl2 EVs at various concentrations on nitrocellulose incubated with anti-CD20 conjugated 
MGITC AuNPs. C) BL2 EVs at various concentrations on nitrocellulose incubated with anti-
CD53 conjugated MGITC AuNPs. D) BL2-bcl2 EVs at various concentrations on nitrocellulose 
incubated with anti-CD53 conjugated MGITC AuNPs. 
These results indicate that the detection of EVs using SERS nanoparticles is not effective at 
the concentrations examined. It could be that, unlike the cells from which they came, the EVs 
are too small to be detected in this manner. The majority of the EVs population are less than 
300 nm in diameter, and the SERS AuNPs were found to be approximately 45 nm by DLS, thus 
a limited number of AuNPs can bind to each EV. The number of CD20 and CD53 protein 
molecules on their surface may be very low, and as half of the EV surface is bound to the 





cell surface there may be several protein molecules in close proximity, allowing the formation 
of AuNP hotspots, the EVs are too small with too low protein copy number for this to occur. 
5.6 Western blot analysis of EVs 
In order to determine whether the lack of detectable signal in the SERS assay was due to the 
sensitivity of the assay or due to the amount of protein found in the EVs, a Western blot was 
carried on both BL2 and BL2-bcl2 EVs for CD20 and CD53. Western blotting has been 
successfully carried out on EV preparations,107,113,132 so this was chosen as a validated 
technique for the detection of specific proteins in EVs. 
EVs were quantified by NTA, and 50 x 108 EVs were pelleted by centrifugation at 20,000 g for 
1 hour. The pellets were frozen at -80°C until ready to use. Three pellets of BL2 EVs and BL2-
bcl2 EVs were used in each blot. The Western blot results are shown in Figure 5.11A and 
Figure 5.11B probing for CD20 and CD53, respectively. The expected molecular weight of 
CD20 protein is 33-37 kDa, and CD53 protein is expected at 32-40 kDa. As can be seen from 
the blots, neither CD20 nor CD53 was detected in the BL2 or BL2-bcl2 EV lysates. However, 
the same band was present at a much higher molecular weight present in both blots. To test 
whether this band was due to non-specific binding of the secondary antibody to a protein 
present in the lysates, a blot was performed where the secondary antibody was added 
directly to the blocked membrane without the addition of the primary antibody. This analysis 




Figure 5.11: Western blots of BL2 (1) and BL2-bcl2 (2) EV lysates. A) Blot probed with anti-
CD20, 1 minute exposure to x-ray film. The arrow indicates where CD20 should appear. B) 
Blot probed with anti-CD53, 5 minutes exposure to x-ray film. The arrow indicates where 
CD53 should appear. C) Secondary only control. 
The unexpected bands observed in the Western blot are present in both the blot probed with 
anti-CD20 antibody and anti-CD53 antibody, indicating that they are not likely to be caused 
by dimerization of the target proteins. It may be that the antibodies are both recognising an 
epitope in a third protein, as both antibodies were raised against B cells (anti-CD20 against 
human tonsil B cells, and CD53 against leucocytes from a leukaemia patient). The fact that 
there are no bands visible at the expected molecular weights for CD20 and CD53 indicates 
that neither protein is present in sufficient quantities to be detectable by Western blot, and 
therefore SERS, despite being identified by proteomics. 
5.7 Discussion 
In order to detect the BL2 and BL2-bcl2 EVs by SERS, the EVs were captured on nitrocellulose 
and then incubated with antibody-conjugated SERS reporter AuNPs. Two different antibodies 
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and the other against CD53 which was shown by proteomics to be present only on the BL2 
apoEVs. 
The assay was first tested using BL2 cells captured on nitrocellulose and detected using anti-
CD20 SERS AuNPs. The system showed a good response, with the signal decreasing with a 
decrease in the number of cells applied to the nitrocellulose. The signal obtained from the 6 
x 106 mL−1 and 5 x 106 mL−1 samples were much lower than the higher cell concentrations, 
potentially indicating that the assay was reaching its limit of detection at these 
concentrations. However, signal was still observed above the PBS control, so the assay and 
data processing technique were deemed suitable for use with the EV samples. 
When the SERS signals of EV dilutions on nitrocellulose was compared to those of no EV 
controls, no difference in the number of pixels above the intensity threshold was observed. 
In fact, for most EV samples the signal was actually lower than the corresponding control. 
This result was unexpected. It could be due to an inherent issue with the AuNP signal 
enhancement. Although it was sufficient for cells, the cell surface would have many copies 
of CD20 on the surface, and proteins in close proximity to each other with bound SERS AuNPs 
could form hotspots in order to further enhance the signal. EVs are much smaller than cells, 
and may therefore only have a few, or one, copy of each protein on their surface. The EVs 
binding to the nitrocellulose will also block up to half of the EVs surface area, and therefore 
further limit the number of target proteins available for binding. If there are insufficient 
numbers of proteins in close proximity to form hotspots, the signal generated by a single 
SERS AuNP may not be enough to detect above the chosen threshold. SERS particles with 
stronger enhancement, such as core-reporter-shell nanoparticles, or signal amplification 
using silver enhancement after AuNP binding, may enhance the signal sufficiently for single 
particle detection. 
In order to determine why the assay was unsuccessful, Western blot analysis was carried out 
on the EV lysates to ensure that CD20 and CD53 protein were present in sufficient quantities. 
No CD20 or CD53 was detected on either the BL2 EVs or BL2-bcl2 EVs, despite these proteins 
being detected in proteomics analysis. As there was no detectable protein by Western blot, 
it is likely that this is the reason that the EVs were not detected by SERS. 
Therefore, although the SERS assay carried out here was unsuccessful, the assay may work if 
the proteins chosen are expressed at a high enough level to be detected by Western blot. 
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6 Conclusion and perspectives 
6.1 Conclusions 
Current methods used in the biochemical characterisation of EVs typically involve bulk 
analysis techniques, such as Western blot,113,328 ELISA,348 or proteomics.87,112 Flow cytometry, 
well established for the investigation of individual cells, is not reliable in the study of EVs due 
to the inability of the instrumentation to detect small particles.138 High-resolution 
fluorescence microscopy techniques may be used to study EVs, however the number of 
different analytes which can be detected simultaneously is limited by the broad emission 
spectra of the fluorophores used. Raman spectroscopy, however, is a label-free method 
which can be used to semi-quantitatively identify biochemical functional groups present in a 
sample due to the narrow peaks produced, and when used in conjunction with multivariate 
analysis can distinguish between biological samples treated under different 
conditions.211,225,230 
The aim of this work was to use Raman spectroscopy and surface enhanced Raman 
spectroscopy (SERS), in conjunction with some bioinformatics techniques, in order to 
characterise and detect extracellular vesicles (EVs) derived from aggressive tumour cells, in 
an attempt to distinguish EVs released from apoptotic cells (apoEVs) and EVs released from 
non-apoptotic cells. The cells predominantly used in this work were the Burkitt’s lymphoma 
(BL) cell line BL2, and a line of BL2 which had been transfected with the anti-apoptosis gene 
BCL-2. 
Raman spectroscopic analysis of BL2 EVs and BL2-bcl2 EVs revealed features that indicate 
apoEVs are a distinct population from their non-apoptotic counterparts. The BL2 apoEVs 
signals indicated the presence of higher levels of nucleic acids as cargo within these particles 
compared to the BL2-bcl2 EVs, potentially derived from the nuclear fragmentation occurring 
as a result of the apoptotic process. As well as distinguishing between the apoEVs and non-
apoEVs, some differences were also observed when the BL EVs Raman data were compared 
with HeLa EVs spectral data. The distinction between EVs derived from cells of different 
lineages and between different EV populations released from cells of the same type show 
that Raman spectroscopy has great potential for the label-free classification of EVs. 
Despite the benefits of Raman spectroscopy for the analysis of EVs in a label-free manner, 
there are also limitations to this method. The Raman microscope instrumentation used in 
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this study require the EVs to be observed on the surface of the CaF2 window. The majority of 
the particles measured are less than 300 nm in diameter, and thus may not be distinguished 
easily due to the diffraction limit of light. A way of overcoming this would be to use an optical 
trapping system, where the particles in suspension are trapped by the electromagnetic field 
of a laser in order to interrogate the spectrum of the EV. This strategy has been used to study 
exosome-type EVs, which are typically defined as having a diameter below 100 nm.296,299,302 
The analysis of EVs by Raman spectroscopy is also not very high throughput. Raman 
cytometry, whereby flow cytometer instrumentation is used to acquire Raman spectra, has 
been proposed to increase the throughput of Raman spectroscopic analysis.208 However, the 
same limitations of flow cytometry would likely apply to the analysis of EVs by this technique. 
As well as these drawbacks, Raman signals are inherently weak. SERS analysis is better suited 
for the analysis of biological specimens such as EVs. The metal nanoparticles can enhance 
the Raman signals by many orders of magnitude, acquisition times are reduced, and by using 
different Raman reporter dye molecules to identify particular biomarkers, sensitive, 
multiplexed detection of complex samples can be achieved. 
Publicly available gene expression microarray datasets were used in order to identify plasma 
membrane proteins which showed higher levels of expression in aggressive non-Hodgkin 
lymphoma samples when compared with healthy B cell data, in order to identify biomarkers 
that would preferentially be found on cancer-derived EVs over the constitutively released B-
cell derived EVs. Three candidate proteins were identified, CD46, CD59, and CD146. 
Validation of these markers showed that CD146 was not present on the surface of the 
parental BL2 cells, and CD46 and CD59 were not detected on the surface of the EVs by flow 
cytometry. However, flow cytometric analysis of EVs is sometimes disputed. Many flow 
cytometers are not set up to analyse such small particles, and the limit of detection in terms 
of particles size can often be larger than the size range of EVs to be analysed. Dedicated flow 
cytometers, which have altered settings and specialised filters, may be more relevant for the 
analysis of EVs, but these are not widely available. Therefore, a negative result of EVs 
analysed by flow cytometry may indicate that the protein of interest is not expressed in the 
sample, but it may also indicate that the EVs which do carry that particular biomarker are 
below the limits of detection of that particular instrument. Further methods of validation, 
such as Western blot or ELISA, could be carried out in conjunction with flow cytometry to 
give more confident results. 
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Proteomics data for samples of BL2 EVs and BL2-bcl2 EVs was available, generated by Maggie 
Paterson in collaboration with a Prof Tony Whetton at the University of Manchester. These 
data generated more candidate biomarkers which could be used for the detection of BL2 EVs. 
CD20 and CD53, which had been identified by proteomics in BL2 EVs and BL2-bcl2 EVs, and 
BL2 EVs only, respectively, were used in the development of a SERS-based assay for the 
detection of these EV subsets. 
Gold nanoparticles (AuNPs), functionalised with the Raman reporter molecule malachite 
green isothiocyanate (MGITC) and either anti-CD20 or anti-CD53 antibodies, were generated. 
Due to the presence of a reporter molecule on the AuNPs, a washing step was necessary in 
order to only detect those AuNPs which had bound to their respective target. Nitrocellulose 
was chosen as a substrate to capture the EVs due to the property of non-specifically binding 
proteins on the nitrocellulose surface via hydrophobic interactions. This substrate could then 
be exposed to the SERS AuNPs and subsequently washed to remove any unbound AuNPs 
without losing any of the EVs in the sample. Preliminary testing of the assay using BL2 cells 
showed binding of the anti-CD20 MGITC AuNPs with encouraging signal intensities. However, 
when the BL2 EVs and BL2-bcl2 EVs were used in the assay the SERS signals obtained from 
both anti-CD20 MGITC AuNPs and anti-CD53 MGITC AuNPs samples was no different to no 
EV controls. Western blot analysis of the BL2 EVs and BL2-bcl2 EVs showed that neither 
protein was detectable, despite being identified in the proteomics analysis. 
In future, better care must be taken to correctly validate the presence of biomarkers 
identified through bioinformatics analyses such as gene expression microarrays and 
proteomics. A number of promising candidates remain on the list of potential biomarkers, 
including proteins known to be associated with B cells or lymphoma such as CD10, or CD79b. 
Interestingly, CD46, which was identified as potentially upregulated in lymphoma samples by 
gene expression analysis, also appears on the list of proteins found on the BL2 apoEVs by 
proteomics. Thorough investigation using multiple complementary assays should be used to 
ascertain whether these markers are actually present in the sample in order to be used as 
targets for detection with SERS nanoparticles. 
The nitrocellulose-based capture assay may not be the most suitable method for the 
characterisation of EVs by SERS. The results show that many of the EV samples analysed in 
this assay had a lower SERS signal intensity than the control samples containing no biological 
sample of any kind. The pore size of the nitrocellulose was 450 nm, so it may be that case 
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that the EVs were becoming trapped within the pore of the nitrocellulose membrane, 
thereby reducing the area available for the binding and detection of the SERS AuNPs to the 
EV targets. Published works have used magnetic beads to capture EVs for phenotype analysis 
and detection by SERS in a sandwich type assay, where an antibody against a general EV 
marker is placed on the magnetic bead to capture the majority of the EVs in the sample, and 
then SERS NPs targeted against markers of interest are added.333–335 By applying a magnetic 
field, the unbound SERS NPs can be removed from the sample of captured EVs. These studies 
have all been looking at the exosome-type EVs, which are the most well-studied of the 
different subtypes of EVs, and have a number of proteins which are considered to be 
‘exosome markers’ commonly displayed on their surface, such as tetraspanins CD9, CD63, 
and CD81. Thus, there are known proteins which could be used to capture all exosomes, 
which were then investigated for the presence of other markers. However, there are no well-
characterised proteins known to be present on the surface of MV-type EVs or apoEVs. These 
EVs do tend to have markers of the cells from which they derive, but preliminary work by to 
capture BL EVs on magnetic beads using B-cell markers CD19 and CD20 for detection with 
fluorescence by flow cytometry were not proving successful, so the more general method of 
non-specific capture by using nitrocellulose was chosen. EVs tend to have a negative charge, 
so the assay may be improved by using magnetic beads coated with a positively-charged 
polymer, such as 4-dimethylaminopyridine (DMAP)327 or cysteamine,331 in order to non-
specifically capture EVs via electrostatic interactions. Cholesterol could also be used as a 
targeting molecule for EV-binding, as it can incorporate into the lipid bilayer of the EVs.335 
6.2 Perspectives 
Since the first studies into the shedding of ‘membrane fragments’ in the 1970s, the field of 
EV research has rapidly grown and matured. In fact, the wide range of topics to which EV 
research has been applied has led to a persistent lack of consensus around EV definitions and 
nomenclature, as each field of interest appears to have developed separate terminology to 
describe the particles. For example, those studying EVs derived from cancer cells coined the 
term ‘oncosome’, prostate epithelia were designated as producing ‘prostosomes’, and EVs 
shed from platelets are generally termed ‘microparticles’. In 2013, when the International 
Society for Extracellular Vesicles (ISEV) held a meeting attempting to create standardised 
definitions and nomenclature, no consensus could be reached.104 Concomitant with the lack 
of consensus on nomenclature is wide variation in EV separation and analysis techniques. 
The creation by ISEV of guidelines for the definition, separation, and analysis of EVs,105 as well 
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as the development of tools for transparent reporting of EV studies,106 should go a long way 
to advance the field of EV research by creating concordance between the different research 
areas. 
Due to the small size of EVs, advances in technology have been necessary in order to 
characterise these particles. Nanoparticle tracking analysis and tunable resistive pulse 
sensing have been developed as high-throughput methods of characterising the size 
distribution of EVs, however biochemical analysis still relies heavily on lengthy bulk analysis 
techniques such as Western blot and ELISA. Many groups are developing methods and 
instrumentation to make flow cytometry more sensitive for small particles, suitable for the 
analysis of EVs; this would be an enormously beneficial tool in the EV research arsenal. 
As the myriad functions of EVs are revealed, there is clear potential for their use as treatment 
agents. It has been shown that, for example, EVs released by tumour cells can prime the pre-
metastatic niche182,183 or block the action of targeted anti-tumour antibodies,171,172 thus 
preventing the release or function of these EVs could provide a novel therapeutic avenue. 
EVs derived from mesenchymal stem cells show clinical benefits, having been purported to 
increase the speed of tissue recovery after injury.151 EVs are present in all biological fluids, 
and could potentially be used as non-invasive disease biomarkers. One study has shown that 
the detection of EVs in urine can be more successful in screening for prostate cancer than 
the current prostate specific antigen test.349 This hypothesis could be applied to any number 
of diseases in which EVs have been shown to have pathological activity. 
The field of EV research still has many obstacles to overcome. However, due to the diverse 
array of functions and applications of these particles, the interest in the field continues to 
grow. With this increased attention will come technological advances over the coming years 
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46062 GSM1122702_1_Bcells WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
 
GSM1122703_2_Bcells WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
 
GSM1122704_3_Bcells WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
 
GSM1122705_4_Bcells WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
  GSM1122706_5_Bcells WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
58208 GSM1403331_NOR-PBMC-01 WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
 
GSM1403333_NOR-PBMC-03 WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
 
GSM1403334_NOR-PBMC-04 WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
  GSM1403335_NOR-PBMC-05 WHOLE BLOOD PBMC PBMC - HEALTHY IC NEG 
64028 GSM1563084_IgMIgDCD27_1 WHOLE BLOOD PBMC B CELL IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM1563085_IgMIgDCD27_2 WHOLE BLOOD PBMC B CELL IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM1563086_IgMIgDCD27_3 WHOLE BLOOD PBMC B CELL IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM1563087_IgMIgDCD27_4 WHOLE BLOOD PBMC B CELL IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM1563088_IgMIgDCD27_5 WHOLE BLOOD PBMC B CELL IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM1563089_CSW1 WHOLE BLOOD PBMC B CELL CLASS SWITCHED HEALTHY IC NEG 
 
GSM1563090_CSW2 WHOLE BLOOD PBMC B CELL CLASS SWITCHED HEALTHY IC NEG 
 
GSM1563091_CSW3 WHOLE BLOOD PBMC B CELL CLASS SWITCHED HEALTHY IC NEG 
 
GSM1563092_CSW4 WHOLE BLOOD PBMC B CELL CLASS SWITCHED HEALTHY IC NEG 
 
GSM1563093_CSW5 WHOLE BLOOD PBMC B CELL CLASS SWITCHED HEALTHY IC NEG 
 
GSM1563094_IgMonly1 WHOLE BLOOD PBMC B CELL IgM+ IgD- CD27+ HEALTHY IC NEG 
 




GSM1563096_IgMonly3 WHOLE BLOOD PBMC B CELL IgM+ IgD- CD27+ HEALTHY IC NEG 
 
GSM1563098_IgMonly5 WHOLE BLOOD PBMC B CELL IgM+ IgD- CD27+ HEALTHY IC NEG 
 
GSM1563099_naive1 WHOLE BLOOD PBMC B CELL IgM+ IgD+ CD27- HEALTHY IC NEG 
  GSM1563100_naive2 WHOLE BLOOD PBMC B CELL IgM+ IgD+ CD27- HEALTHY IC NEG 
10831 GSM273221 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC) CD10+  HEALTHY IC NEG 
 
GSM273227 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC) CD10+  HEALTHY IC NEG 
  GSM273228 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC) CD10+  HEALTHY IC NEG 
12366 GSM310429 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC) CD19+ CD38++ IgD- HEALTHY IC NEG 
 
GSM310430 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC) CD19+ CD38++ IgD- HEALTHY IC NEG 
 
GSM310431 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC) CD19+ CD38++ IgD- HEALTHY IC NEG 
 
GSM310432 WHOLE BLOOD PBMC B CELL (NAIVE) CD19+ CD27+  HEALTHY IC NEG 
 
GSM310433 WHOLE BLOOD PBMC B CELL (NAIVE) CD19+ CD27+  HEALTHY IC NEG 
 
GSM310434 WHOLE BLOOD PBMC B CELL (NAIVE) CD19+ CD27+  HEALTHY IC NEG 
 
GSM310435 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC 
NAÏVE) 
CD19+ CD38- IgD+  HEALTHY IC NEG 
 
GSM310436 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC 
NAÏVE) 
CD19+ CD38- IgD+  HEALTHY IC NEG 
 
GSM310437 TONSIL MONONUCLEAR 
CELLS 
B CELL (GC 
NAÏVE) 
CD19+ CD38- IgD+  HEALTHY IC NEG 
 
GSM310438 WHOLE BLOOD PBMC B CELL 
(MEMORY) 
CD19+ CD27-  HEALTHY IC NEG 
 
GSM310439 WHOLE BLOOD PBMC B CELL 
(MEMORY) 
CD19+ CD27-  HEALTHY IC NEG 
  GSM310440 WHOLE BLOOD PBMC B CELL 
(MEMORY) 
CD19+ CD27-  HEALTHY IC NEG 
17186 GSM422305 WHOLE BLOOD PBMC B CELL (NAÏVE) CD20+ CD10- CD27-  HEALTHY IC NEG 
 
GSM422295 WHOLE BLOOD PBMC B CELL (NAÏVE) CD20+ CD10- CD27- HEALTHY IC NEG 
 




GSM422304 WHOLE BLOOD PBMC B CELL 
(MEMORY) 
CD20+ CD10- CD27+  HEALTHY IC NEG 
 
GSM422296 WHOLE BLOOD PBMC B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21LO  
HEALTHY IC NEG 
 
GSM422306 WHOLE BLOOD PBMC B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21LO  
HEALTHY IC NEG 
 
GSM422307 WHOLE BLOOD PBMC B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21HI  
HEALTHY IC NEG 
 
GSM422297 WHOLE BLOOD PBMC B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21HI  
HEALTHY IC NEG 
 
GSM422299 CORD BLOOD - B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21LO  
HEALTHY IC NEG 
 
GSM422302 CORD BLOOD - B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21LO  
HEALTHY IC NEG 
 
GSM422300 CORD BLOOD - B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21HI  
HEALTHY IC NEG 
 
GSM422303 CORD BLOOD - B CELL 
(TRANSITIONAL) 
CD20+ CD10+ CD27- 
CD21HI  
HEALTHY IC NEG 
  GSM422301 CORD BLOOD - B CELL (NAÏVE) CD20+ CD10- CD27-  HEALTHY IC NEG 
17269 GSM432521_HD-naive-1 WHOLE BLOOD PBMC B CELL (NAÏVE) CD19+ CD27- CD38+ 
CD21+ 
HEALTHY IC NEG 
 
GSM432522_HD-naive-2 WHOLE BLOOD PBMC B CELL (NAÏVE) CD19+ CD27- CD38+ 
CD21+ 
HEALTHY IC NEG 
  GSM432523_HD-naive-3 WHOLE BLOOD PBMC B CELL (NAÏVE) CD19+ CD27- CD38+ 
CD21+ 
HEALTHY IC NEG 
19599 GSM488973 BONE 
MARROW 








- B CELL (PRE-B) CD19+ CD34- CD10+ 
CD20LO 




- B CELL (PRE-B) CD19+ CD34- CD10+ 
CD20LO 




- B CELL (PRO-B) CD19+ CD34+ 
CD10+ 
HEALTHY IC NEG 
  GSM488981 BONE 
MARROW 
- B CELL (PRO-B) CD19+ CD34+ 
CD10+ 
HEALTHY IC NEG 




GSM658011_C103 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
 
GSM658012_C107 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
 
GSM658013_C105 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
  GSM658014_C104 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
28491 GSM705402_B_03_08_10 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
 
GSM705403_B_05_08_10 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
 
GSM705404_B_07_07_10 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
 
GSM705405_B_23_07_10 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
  GSM705406_B_27_07_10 WHOLE BLOOD PBMC B CELL CD19+ HEALTHY IC NEG 
36907 GSM905504_CD5_1 WHOLE BLOOD PBMC B CELL (MATURE) CD5+ HEALTHY IC NEG 
 
GSM905505_CD5_2 WHOLE BLOOD PBMC B CELL (MATURE) CD5+ HEALTHY IC NEG 
 
GSM905506_CD5_3 WHOLE BLOOD PBMC B CELL (MATURE) CD5+ HEALTHY IC NEG 
 
GSM905507_CD5_4 WHOLE BLOOD PBMC B CELL (MATURE) CD5+ HEALTHY IC NEG 
 
GSM905508_CD5_5 WHOLE BLOOD PBMC B CELL (MATURE) CD5+ HEALTHY IC NEG 
 
GSM905509_class_switched_1 WHOLE BLOOD PBMC B CELL (CLASS 
SWITCHED) 
IgG/A+ CD27+ HEALTHY IC NEG 
 
GSM905510_class_switched_2 WHOLE BLOOD PBMC B CELL (CLASS 
SWITCHED) 
IgG/A+ CD27+ HEALTHY IC NEG 
 
GSM905512_class_switched_3 WHOLE BLOOD PBMC B CELL (CLASS 
SWITCHED) 
IgG/A+ CD27+ HEALTHY IC NEG 
 
GSM905514_class_switched_5 WHOLE BLOOD PBMC B CELL (CLASS 
SWITCHED) 
IgG/A+ CD27+ HEALTHY IC NEG 
 
GSM905517_class_switched_6 WHOLE BLOOD PBMC B CELL (CLASS 
SWITCHED) 
IgG/A+ CD27+ HEALTHY IC NEG 
 
GSM905518_class_switched_7 WHOLE BLOOD PBMC B CELL (CLASS 
SWITCHED) 
IgG/A+ CD27+ HEALTHY IC NEG 
 
GSM905515_MD27_6 WHOLE BLOOD PBMC B CELL  IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM905516_MD27_7 WHOLE BLOOD PBMC B CELL  IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM905525_MD27_1 WHOLE BLOOD PBMC B CELL  IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM905526_MD27_2 WHOLE BLOOD PBMC B CELL  IgM+ IgD+ CD27+ HEALTHY IC NEG 
 




GSM905528_MD27_4 WHOLE BLOOD PBMC B CELL  IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM905529_MD27_5 WHOLE BLOOD PBMC B CELL  IgM+ IgD+ CD27+ HEALTHY IC NEG 
 
GSM905519_IgM-only_1 WHOLE BLOOD PBMC B CELL  IgM+ IgDLO CD27+ HEALTHY IC NEG 
 
GSM905520_IgM-only_2 WHOLE BLOOD PBMC B CELL  IgM+ IgDLO CD27+ HEALTHY IC NEG 
 
GSM905521_IgM-only_3 WHOLE BLOOD PBMC B CELL  IgM+ IgDLO CD27+ HEALTHY IC NEG 
 
GSM905523_IgM-only_4 WHOLE BLOOD PBMC B CELL  IgM+ IgDLO CD27+ HEALTHY IC NEG 
 
GSM905524_IgM-only_5 WHOLE BLOOD PBMC B CELL  IgM+ IgDLO CD27+ HEALTHY IC NEG 
 
GSM905530_MGZ_1 WHOLE BLOOD PBMC B CELL (SPLENIC) IgM+ CD27+ CD21HI HEALTHY IC NEG 
 
GSM905532_MGZ_3 WHOLE BLOOD PBMC B CELL (SPLENIC) IgM+ CD27+ CD21HI HEALTHY IC NEG 
 
GSM905534_MGZ_4 WHOLE BLOOD PBMC B CELL (SPLENIC) IgM+ CD27+ CD21HI HEALTHY IC NEG 
 
GSM905535_MGZ_5 WHOLE BLOOD PBMC B CELL (SPLENIC) IgM+ CD27+ CD21HI HEALTHY IC NEG 
 
GSM905537_naive_1 WHOLE BLOOD PBMC B CELL (NAÏVE) IgD+ CD27- HEALTHY IC NEG 
 
GSM905538_naive_2 WHOLE BLOOD PBMC B CELL (NAÏVE) IgD+ CD27- HEALTHY IC NEG 
 
GSM905539_naive_3 WHOLE BLOOD PBMC B CELL (NAÏVE) IgD+ CD27- HEALTHY IC NEG 
 
GSM905540_naive_7 WHOLE BLOOD PBMC B CELL (NAÏVE) IgD+ CD27- HEALTHY IC NEG 
 
GSM905541_naive_4 WHOLE BLOOD PBMC B CELL (NAÏVE) IgD+ CD27- HEALTHY IC NEG 
  GSM905542_naive_5 WHOLE BLOOD PBMC B CELL (NAÏVE) IgD+ CD27- HEALTHY IC NEG 
38697 GSM947665_HSLZ_1 TONSIL LIGHT ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4HI CD83LO 
HEALTHY IC NEG 
 
GSM947666_HSLZ_2 TONSIL LIGHT ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4HI CD83LO 
HEALTHY IC NEG 
 
GSM947667_HSLZ_3 TONSIL LIGHT ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4HI CD83LO 
HEALTHY IC NEG 
 
GSM947668_HSLZ_4 TONSIL LIGHT ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4HI CD83LO 
HEALTHY IC NEG 
 
GSM947669_HSDZ_1 TONSIL DARK ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4LO CD83HI 
HEALTHY IC NEG 
 
GSM947670_HSDZ_2 TONSIL DARK ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4LO CD83HI 
HEALTHY IC NEG 
 
GSM947671_HSDZ_3 TONSIL DARK ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4LO CD83HI 
HEALTHY IC NEG 
185 
 
  GSM947672_HSDZ_4 TONSIL DARK ZONE B CELL (GC) CD19+ CD38+ IgD- 
CXCR4LO CD83HI 
HEALTHY IC NEG 
39411 GSM967665_JG2004051901 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967666_JG2004051903 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967667_JG2004051905 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967668_JG2004051907 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967674_JG2004051911 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967675_JG2004051913 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967676_JG2004051915 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967681_JG2004060419 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967682_JG2004060421 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967683_JG2004060423 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967684_JG2004060425 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967689_JG2004070101 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967690_JG2004070103 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967691_JG2004070105 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967692_JG2004070107 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967697_JG2004070109 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967698_JG2004070111 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 





GSM967699_JG2004070113 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967700_JG2004070115 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967705_JG2004070117 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967706_JG2004070119 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
 
GSM967707_JG2004070121 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
  GSM967708_JG2004070123 WHOLE BLOOD PBMC B CELL CD5+ CD19+ HEALTHY (NUTRIENT 
STARVED 4 HR) 
IC NEG 
20011 GSM499734 CELL CULTURE - LYMPHOMA CELL 
LINE 
NAMALWA BURKITT - NEG 
 
GSM499735 CELL CULTURE - LYMPHOMA CELL 
LINE 
SU-DHL-4 B NON-HODGKIN - NEG 
36133 GSM886991 CELL CULTURE - LYMPHOMA CELL 
LINE 
EB1 BURKITT - NEG 
 
GSM886992 CELL CULTURE - LYMPHOMA CELL 
LINE 
EB2 BURKITT - NEG 
 
GSM887019 CELL CULTURE - LYMPHOMA CELL 
LINE 
GA-10 BURKITT - NEG 
 
GSM886889 CELL CULTURE - LYMPHOMA CELL 
LINE 
BL-41 BURKITT - NEG 
 
GSM886890 CELL CULTURE - LYMPHOMA CELL 
LINE 
BL-70 BURKITT - NEG 
 
GSM886900 CELL CULTURE - LYMPHOMA CELL 
LINE 
CA46 BURKITT - NEG 
 
GSM886973 CELL CULTURE - LYMPHOMA CELL 
LINE 
DAUDI BURKITT - NEG 
 
GSM887493 CELL CULTURE - LYMPHOMA CELL 
LINE 
P3HR-1 BURKITT - NEG 
 
GSM887523 CELL CULTURE - LYMPHOMA CELL 
LINE 
RAJI BURKITT - NEG 
  GSM887649 CELL CULTURE - LYMPHOMA CELL 
LINE 
ST486 BURKITT - NEG 
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64085 GSM1564128_case-1 HEART (PTLD) BIOPSY LYMPHOMA - BURKITT ID NEG 
 
GSM1564129_case-2 LIVER (PTLD) BIOPSY LYMPHOMA - BURKITT  ID NEG 
 
GSM1564130_case-3 KIDNEY (PTLD) BIOPSY LYMPHOMA - BURKITT  ID POS 
 
GSM1564131_case-4 LIVER (PTLD) BIOPSY LYMPHOMA - BURKITT  ID POS 
 
GSM1564132_case-5 HEART (PTLD) BIOPSY LYMPHOMA - BURKITT  ID NEG 
 
GSM1564133_case-6 LIVER (PTLD) BIOPSY LYMPHOMA - BURKITT  ID NEG 
 
GSM1564134_case-7 KIDNEY (PTLD) BIOPSY LYMPHOMA - BURKITT  ID NEG 
 
GSM1564135_case-8 - BIOPSY LYMPHOMA - BURKITT  IC NEG 
 
GSM1564136_case-9 - BIOPSY LYMPHOMA - BURKITT  IC NEG 
 
GSM1564137_case-10 - BIOPSY LYMPHOMA - BURKITT  IC NEG 
 
GSM1564138_case-11 - BIOPSY LYMPHOMA - BURKITT  IC NEG 
  GSM1564139_case-12 - BIOPSY LYMPHOMA - BURKITT  IC NEG 
38885 GSM951477_hyb10713 LYMPH NODE BIOPSY LYMPHOMA - BURKITT IC NEG 
 
GSM951478_hyb10677 LYMPH NODE BIOPSY LYMPHOMA - BURKITT IC NEG 
 
GSM951479_hyb10695 LYMPH NODE BIOPSY LYMPHOMA - BURKITT IC NEG 
 
GSM951480_hyb10731 LYMPH NODE BIOPSY LYMPHOMA - BURKITT IC POS 
  GSM951455_hyb10733 GUT BIOPSY LYMPHOMA - BURKITT ID POS 
26673 GSM656467 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (SPORADIC) IC - 
 
GSM656452 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656453 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656454 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656455 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656456 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656457 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656458 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656459 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656460 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 




GSM656462 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656463 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (ENDEMIC) IC - 
 
GSM656465 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (HIV 
ASSOCIATED) 
ID - 
  GSM656466 LYMPH NODE BIOPSY LYMPHOMA - BURKITT (HIV 
ASSOCIATED) 
ID - 
































GSM951476_hyb10686 GUT BIOPSY LYMPHOMA - DLBCL (BURKITT 
LIKE) 
IC NEG 
36133 GSM886855 CELL CULTURE - LYMPHOMA CELL 
LINE 
A3/KAW DLBCL - NEG 
 
GSM886857 CELL CULTURE - LYMPHOMA CELL 
LINE 
A4/FUK DLBCL - NEG 
 






GSM886931 CELL CULTURE - LYMPHOMA CELL 
LINE 
CI-1 B NON-HODGKIN - NEG 
 
GSM886975 CELL CULTURE - LYMPHOMA CELL 
LINE 
DB DLBCL - NEG 
 
GSM886987 CELL CULTURE - LYMPHOMA CELL 
LINE 




GSM887143 CELL CULTURE - LYMPHOMA CELL 
LINE 
HT - - NEG 
 
GSM887186 CELL CULTURE - LYMPHOMA CELL 
LINE 
JM1 - - NEG 
 
GSM887289 CELL CULTURE - LYMPHOMA CELL 
LINE 
MC116 - - NEG 
 
GSM887459 CELL CULTURE - LYMPHOMA CELL 
LINE 
NU-DHL-1 DLBCL - NEG 
 
GSM887460 CELL CULTURE - LYMPHOMA CELL 
LINE 
NU-DUL-1 - - NEG 
 
GSM887471 CELL CULTURE - LYMPHOMA CELL 
LINE 
OCI-LY-19 DLBCL - NEG 
 
GSM887472 CELL CULTURE - LYMPHOMA CELL 
LINE 
OCI-LY3 DLBCL - NEG 
 
GSM887514 CELL CULTURE - LYMPHOMA CELL 
LINE 
PFEIFFER DLBCL - NEG 
 
GSM887539 CELL CULTURE - LYMPHOMA CELL 
LINE 
RI-1 - - NEG 
 
GSM887543 CELL CULTURE - LYMPHOMA CELL 
LINE 
RL - - NEG 
 
GSM887651 CELL CULTURE - LYMPHOMA CELL 
LINE 
SU-DHL-10 DLBCL - NEG 
 
GSM887653 CELL CULTURE - LYMPHOMA CELL 
LINE 
SU-DHL-4 DLBCL - NEG 
 
GSM887654 CELL CULTURE - LYMPHOMA CELL 
LINE 
SU-DHL-5 DLBCL - NEG 
 
GSM887655 CELL CULTURE - LYMPHOMA CELL 
LINE 
SU-DHL-6 DLBCL - NEG 
 
GSM887656 CELL CULTURE - LYMPHOMA CELL 
LINE 
SU-DHL-8 DLBCL - NEG 
 
GSM887709 CELL CULTURE - LYMPHOMA CELL 
LINE 
TOLEDO DLBCL - NEG 
 
GSM887724 CELL CULTURE - LYMPHOMA CELL 
LINE 
U-937 DLBCL - NEG 
  GSM887741 CELL CULTURE - LYMPHOMA CELL 
LINE 
WSU-DLCL2 DLBCL - NEG 




GSM951417_hyb6597 GUT BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951418_hyb10676 TESTIS BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951419_hyb6554 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951420_hyb6566 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951421_hyb6569 GUT BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951423_hyb6606 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951424_hyb6556 GUT BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951425_hyb10730 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID NEG 
 
GSM951426_hyb10712 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951427_hyb10715 WALDEYER BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951428_hyb6580 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951429_hyb10681 GUT BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951430_hyb6568 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951431_hyb10675 WALDEYER BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951432_hyb10690 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951433_hyb10709 WALDEYER BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951434_hyb6593 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 




BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951437_hyb10703 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951438_hyb6599 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951439_hyb10697 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951440_hyb6562 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951441_hyb10727 GUT BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951442_hyb10685 BALT BIOPSY LYMPHOMA - DLBCL ID POS 
 








GSM951445_hyb6564 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951446_hyb10682 LYMPH NODE BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951448_hyb6579 GUT BIOPSY LYMPHOMA - DLBCL ID POS 
 
GSM951456_hyb6598 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951457_hyb6561 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951458_hyb10710 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951459_hyb6607 MEDIASTINUM BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951460_hyb10692 GUT BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951461_hyb6603 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951462_hyb6600 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951463_hyb6573 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951464_hyb6576 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 





BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951467_hyb10683 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951468_hyb6563 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951469_hyb10728 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951470_hyb6581 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951471_hyb6570 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 
 
GSM951472_hyb10719 LYMPH NODE BIOPSY LYMPHOMA - DLBCL IC NEG 




Appendix 2 Full list of GO components used to identify potential plasma 
membrane proteins from the proteomics results 
GO term name 
adherens junction 
anchored component of membrane 
anchored component of plasma membrane 
anchored component of synaptic vesicle membrane 
apical junction complex 
apical part of cell 
apical plasma membrane 
apicolateral plasma membrane 
astrocyte projection 
axolemma 
axonal growth cone 
azurophil granule membrane 
B cell receptor complex 
basal plasma membrane 
basement membrane 
basolateral plasma membrane 
bicellular tight junction 
bleb 
blood microparticle 
brush border membrane 




cell cortex region 
cell junction 




cell-cell adherens junction 
cell-cell contact zone 
cell-cell junction 
cell-substrate junction 
chloride channel complex 
chromaffin granule membrane 
chylomicron 
ciliary membrane 
ciliary pocket membrane 
clathrin coat 




clathrin-coated vesicle membrane 





cytoplasmic ribonucleoprotein granule 
cytoplasmic side of apical plasma membrane 
cytoplasmic side of plasma membrane 
cytoplasmic vesicle membrane 
dendrite 
dendritic spine 
dendritic spine head 
dendritic spine neck 
desmosome 
discoidal high-density lipoprotein particle 










extrinsic component of cytoplasmic side of plasma membrane 
extrinsic component of external side of plasma membrane 





glial limiting end-foot 
growth cone 
hexameric IgM immunoglobulin complex 
HFE-transferrin receptor complex 
hydrogen:potassium-exchanging ATPase complex 
immunoglobulin complex, circulating 
immunological synapse 
integral component of plasma membrane 
integrin alpha10-beta1 complex 
integrin alpha11-beta1 complex 
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integrin alpha1-beta1 complex 
integrin alpha2-beta1 complex 
integrin alpha3-beta1 complex 
integrin alpha7-beta1 complex 
integrin alpha8-beta1 complex 
integrin complex 
intercalated disc 
intermediate-density lipoprotein particle 




lateral plasma membrane 
lipopolysaccharide receptor complex 
low-density lipoprotein particle 
membrane coat 
membrane raft 
MHC class I peptide loading complex 
MHC class I protein complex 
MHC class Ib protein complex 
MHC class II protein complex 
microspike 
microvillus membrane 
monomeric IgA immunoglobulin complex 
multivesicular body 
muscle cell projection membrane 
neuromuscular junction 
neuron projection 
neuron projection terminus 
neuronal cell body membrane 
pentameric IgM immunoglobulin complex 
periciliary membrane compartment 
phagocytic cup 
photoreceptor disc membrane 
photoreceptor outer segment membrane 
plasma lipoprotein particle 
plasma membrane 













Schwann cell microvillus 
secretory dimeric IgA immunoglobulin complex 
secretory IgA immunoglobulin complex 
slit diaphragm 
SNARE complex 
sodium:potassium-exchanging ATPase complex 
specific granule membrane 
sperm head plasma membrane 




synaptic vesicle membrane 
synaptobrevin 2-SNAP-25-syntaxin-1a complex 
tertiary granule membrane 
T-tubule 
uropod 
very-low-density lipoprotein particle 
zonula adherens 
 
